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CHAPTER 1
GENERAL INTRODUCTION
Sanne Duinkerken, R.J. Eveline Li, Floor J. van Haften, Jesper van Eck van der Sluijs, Tanja D. de 
Gruijl, Fabrizio Chiodo, Sjoerd T.T. Schetters, Juan J. Garcia-Vallejo and Yvette van Kooyk
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Chapter 1
The Immune System & Anti-Cancer Vaccination
The immune system
The immune system is a powerful system that protects us against dangers from 
outside encompassing pathogens such as bacteria and viruses, but also from danger 
coming from within like tumor cells. It comprises the rapidly responding non-specific 
innate immune response and the slower responding but antigen-specific adaptive 
immune response. Both the innate and adaptive immune response have unique 
properties but can only induce full-blown immunity when working together [1].
 Innate immune cells are the first responders to invading pathogens by recognition 
of pathogen-associated molecular patterns (PAMPs) which bind pattern recognition 
receptors (PRRs) (Table 1) [1, 2]. Innate immune cells include macrophages, natural 
killer (NK) cells and granulocytes which react to pathogen invasion within minutes 
and can either engulf the pathogens for clearance or secrete soluble factors thereby 
inducing killing or neutralization. However, without involvement of the adaptive 
immune response this reaction remains antigen non-specific, and no long-term 
memory will be generated. In order to enable specific clearance of danger both 
from outside (pathogens) and within (tumor cells), the adaptive immune response 
is activated via a specialized innate antigen-presenting cell (APC), the dendritic cell 
(DC) [1, 3]. DC reside in blood and tissues such as the skin and mucosa and, upon 
exposure to pathogens and activation, are able to activate T lymphocytes (T cells).
Table 1. Human innate pattern recognition receptors and their ligands
Pattern recognition receptor Ligands (PAMP)
Toll-like receptor (TLR) Bacterial lipopeptides and flagellin, LPS, single- and 
double-stranded RNA, hypomethylated DNA
NOD Peptidoglycans
NOD-like receptor (NLR) MDP, peptidoglycans, bacterial flagellin and secretion 
factors, double-stranded RNA
C-type lectin receptor (CLR) Carbohydrates/glycans
RIG-like receptors (RLR) Viral RNA, cGAS/STING, DNA resulting from double-
stranded breaks, cyclic dinucleotides




T cells mediate the specific defense of the adaptive immune system. Naïve T cells 
recirculate through blood and secondary lymphoid organs, until they are activated by 
recognition of specific antigen-derived peptides presented by DC in the paracortical 
areas of lymph nodes (LN). T cell activation can lead to both a type-1 cellular response 
and a type-2 humoral response by subsequent activation of B cells. An important 
feature of the adaptive immune response is the induction of immunological memory. 
This property of the adaptive immune system enables antigen-specific T or B cells to 
rapidly respond to previously encountered antigens (e.g. microbe derived), thereby 
diverting disease. This feature is of great importance for the efficacy of vaccines.
Vaccination
Classic vaccines induce adaptive immunity against infectious agents. Altered parts 
of infectious agents are added within the vaccine to elicit antigen-specific adaptive 
immune responses, without causing disease. Important for the working mechanism 
of vaccines is recognition by DC via PRR, which elicits vaccine uptake and some 
phenotypic changes. Amongst these phenotypic changes is the migration of DC to 
draining lymph nodes (LN) and the reprogramming of DC towards antigen-specific T 
cell activation. T cells can subsequently help inducing cellular and humoral responses 
via activation of B cells for antibody production. Here, immunological memory is built 
to ensure continued protection.
DC are key players in the initiation of immunity and hence vaccine efficacy and 
there are various DC subsets. Main subsets comprise plasmacytoid DC (pDC) and 
myeloid/conventional DC 1 (cDC1), and DC 2 (cDC2) [4]. They are present throughout 
the body in the blood, lymphoid and non-lymphoid tissues such as mucosal tissues 
and the skin (Figure 1). pDC are migratory and reside in secondary lymphoid organs 
which they home to via the blood circulation. cDC are often residential and remain 
within tissues until activation, followed by migration to the LN for priming of naïve 
T cells. Of note, dedicated blood-derived cDC1/cDC2 subsets also reside in the LN 
[5, 6]. The different DC subsets are specialized in the induction of tailored adaptive 
immune responses [4, 7].
The site of vaccination can dictate vaccine efficacy and should be selected carefully. 
Furthermore, vaccine application should be relatively easy to ensure proper delivery 
of the vaccine and applicability for large cohorts. Although vaccines are often applied 
intramuscularly there are no resident DC in the muscle, relying on DC influx and 
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vaccine drainage. In contrast, the skin is easily accessible and harbors different DC 
subsets making it a potent vaccination site. Four main subtypes of DC have been 
characterized [8]. In the dermis, three DC subsets are distinguished based on the 
expression of the membrane markers CD1a, CD14 and CD141, while Langerhans 
cells (LC) reside in the upper layer, the epidermis (Figure 1) [8]. Interestingly, studies 
show intradermal vaccination of the flu vaccine decreases the necessary dose, while 
inducing similar levels of immunity as compared to intramuscular vaccination [9]. 
This shows the potential of the skin as prime vaccination site.
Figure 1. Human DC subsets and their localization DC are classified in the three main categories 
pDC, cDC1 and cDC2. pDC are migratory and circulate the lymphatics through the blood circu-
lation. cDC are tissue resident and present within the LNs and non-lymphoid tissues such as the 
skin, gut and lung. Within the human skin four different DC subsets are described with the LC in 
the epidermis and three dermal DC subsets distinguished based on expression of the membrane 
molecules CD1a, CD14 and CD141
Cancer immunotherapy
Over the past decade modulation of the immune system to fight cancer, also known 
as cancer immunotherapy, has become a promising treatment modality for patients. 
Among different strategies is the design of cancer vaccines that are aimed to instruct 
DC to induce long-lasting immunity towards tumors. Its principle is to achieve 
anti-tumor immunity by facilitating processing and presentation of tumor specific 
antigens by DC to enhance anti-tumor immunity [10]. DC can be activated either ex 
vivo or targeted in vivo in their natural environment. The latter is preferable as it can, 
amongst others, considerably lower the costs and labor intensiveness by providing 
an off-the-shelf product [11].




For cancer immunotherapy in vivo DC targeting strategies can instruct antigen uptake 
by skin resident DC that present tumor antigens to T cells [8, 12, 13], using the skin as 
prime vaccination site. For vaccination purposes tumor-associated antigens (TAA) or 
neoantigens [10], in the form of peptides, can be synthesized to provide the vaccine 
with “tumor specificity” for T cell responses to attack or help attack the tumor [12]. 
Efficient induction of CD8+ cytotoxic T lymphocytes (CTL) with an ability to home to 
the tumor effector site is essential for antitumor efficacy.
To develop anti-tumor intradermal vaccination strategies, multiple aspects need 
to be taken into consideration. The presence of different DC subsets which vary in 
phenotype and function to take up tumor antigens, process and present these when 
migrating to the draining LNs. The vaccine can be designed to specifically target 
to one DC subset, but also to target more subsets simultaneously. Furthermore, 
DC play an important role in programming effector T cells, since the signals DC 
give will determine whether T cells become pro-inflammatory effector cells, or so-
called regulatory T cells (Tregs), or will even become anergic. Moreover, the skin is 
highly vascularized, which facilitates the recruitment of other immune cells to the 
vaccination site to further reinforce and amplify the immune response. In addition, 
besides vaccine delivery to LN by migrating skin DC, the vaccine itself may drain to 
LNs where LN resident DC can respond (Figure 2).
Vaccine development for DC induced adaptive immunity
T cell activation signals
 For proper activation of naïve T cells three signals given by APC are necessary: (1) 
T cell receptor (TCR) triggering by recognition of major histocompatibility complex 
(MHC) bound epitopes (i.e. processed peptide derived from antigens), (2) co-
stimulatory molecule signals for proliferation and (3) cytokine induced phenotypic 
skewing [14].
In their resting state DC have an immature phenotype and are well equipped to 
capture antigens while receptive for activation signals through PRR stimulation. As 
such, upon interaction with pathogens via PRRs, DC not only engulf them for antigen 
processing and retrieval, but also become activated and change their transcriptional 
profile to become mature DC. In the mature state, DC upregulate the expression of 
co-stimulatory molecules and chemokine receptors which will guide their migration 
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towards the LNs and mediate the subsequent induction of effector T cells. Once 
arrived here they are now fully equipped to activate naïve T cells to become effector 
cells by giving the three necessary stimulatory signals.
DC antigen processing for T cell activation
DC are professional APC capable to process and present antigens on their cell surface 
in a MHC dependent fashion. Recognition of the epitope-MHC complex is essential 
for triggering of the TCR. T cells can be divided into two main subclasses, namely CD4+ 
helper T cells and cytotoxic CD8+ T cells. There are multiple CD4+ T helper subsets 
and depending on the type of infection specific helper T cells will be activated to 
induce effector cell types for efficient pathogen clearance [15]. In contrast to CD4+ T 
helper cells, CD8+ T cells, or cytotoxic T lymphocytes (CTL), have cytotoxic capacities 
and can effectively kill virus-infected or tumor cells. Triggering of the TCR differs 
between the two subsets as they recognize different MHC molecules loaded with 
epitopes of different lengths. CD4+ T cells are activated by recognition of 12-17mer 
epitopes loaded in MHC class II, whereas CD8+ T cells recognize 8-11mer epitopes in 
an MHC class I dependent manner.
Before antigens can be presented on the respective MHC molecules they must be 
processed for which DC use two classical routes. Endogenous proteins are degraded 
to peptides by the proteasome and transported via the transporter associated with 
antigen processing (TAP) to the endoplasmic reticulum (ER). In the ER peptides are 
loaded on MHC class I molecules and the peptide-loaded complex is then transported 
and presented on the cell surface. When DC encounter exogenous antigens, they are 
taken up and degraded in the endosomal compartment followed by loading on MHC 
class II molecules and transported to the cell surface of the DC for presentation [16, 
17]. However, two shuttle routes allow for the alternative presentation of exogenous 
and endogenous antigens on MHC-I and - II molecules, respectively. Autophagy 
induces presentation of endogenous antigens by MHC II [18] and DC use cross-
presentation for the loading of exogenous antigen-derived epitopes in MHC I [19]. 
The latter mechanism is used by DC for the activation of cytotoxic CD8+ T cells 
following vaccination with whole protein antigens or long peptides.
DC antigen cross-presentation
There are two cross-presentation routes known that shuttle exogenous antigens for 
MHC I loading: the vacuolar and the cytosolic pathway [20]. Antigens that enter the 




vacuolar pathway stay within their endocytic compartment (endosomes), followed by 
lysosomal degradation and subsequent loading on MHC I molecules present within 
endosomes. In contrast, antigens entering the cytosolic pathway are translocated 
from the endosome into the cytosol and degraded by the proteasome prior to loading 
on MHC I according to the classical process for endogenous antigens. Different DC 
subsets have varying cross-presenting efficiency and the migratory CD141+ cDC1 
is described to be the prime cross-presenting DC present in human tissues [21] 
[22]. Interestingly, there are ways to influence cross-presentation ability and tweak 
vaccines to enhance cross-presentation via specific DC receptor stimulation and 
targeting [23]. This can enhance cross-presentation by DC subsets which are not 
described to be as efficient, but are interesting targets for vaccination.
DC targeting for antigen uptake
For vaccination purposes we rely on the capacity of DC to take up exogenous 
antigens followed by activation of both CD4+ and CD8+ T cells via regular- and cross-
presentation, respectively. For active engulfment of molecules DC use endocytosis, 
a process which induces membrane invaginations and intracellular cleaving from the 
membrane for further intracellular trafficking and processing. Endocytosis can occur 
in various ways and depends on cell type, size and possible binding of molecules to 
membrane expressed receptors. Uptake of large particles (>0,5µm) or even cells is 
known as phagocytosis, whereas smaller particles are taken up via pinocytosis [24].
A form of endocytosis relevant for vaccination strategies is receptor-mediated 
endocytosis, in which membrane expressed receptors bind (pathogen) specific 
ligands for internalization. Making use of this property allows for the specific 
targeting of DC subsets via receptors by coupling their respective ligands to tumor 
specific particles. Furthermore, a diversity of receptors induce differential antigen 
processing and routing, thereby giving the ability to skew processing towards the 
cross-presentation route for subsequent CTL activation. The prime cross-presenting 
CD141+ DC are also located in the human skin [21]. Though, they represent a small 
minority of the total dermal DC pool and targeting other DC subsets might benefit 
vaccine efficacy. Using specific targeting can facilitate cross-presentation by DC 
subsets with inherent lower cross-presentation capacity, such as the CD1a+ and 
CD14+ dermal DC [25]. Therefore these targeting strategies hold promise for anti-
tumor immunotherapies.
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C-type lectin receptors for specific DC targeting
The most used DC receptors for targeting are C-type lectin receptors (CLR), which 
mediate antigen uptake and routing to facilitate antigen (cross)-presentation for 
DC (signal 1) [26]. CLR are a family of calcium-dependent receptors each having a 
highly conserved carbohydrate recognition domain (CRD) [27]. The CRD is able to 
recognize glycans thereby allowing binding of DC to pathogens or induction of cell-
cell interactions. Two types of CLR can be distinguished; type I CLR contain 8 to 10 
CRDs each able to recognize a multitude of glycans, whereas type II CLR only have 
one CRD and bind fewer glycan conformations [26, 28]. There are two strategies for 
CLR targeting: (1) targeting via antibodies directed against the receptor or (2) using 
their natural glycan ligand to bind to the receptor [28].
Although antibodies are a useful tool for specific, single receptor targeting and elucidating 
e.g. CLR routing, glycans may serve as a more versatile approach. Glycans are naturally 
occurring entities with both cellular and immunological properties, such as cell-cell 
interaction and pathogen recognition and uptake [29]. The use of glycans for targeting 
purposes instead of antibodies has several advantages. Glycans are relatively small and 
can be conjugated to a diversity of tumor specific peptide constructs without interfering 
with the conformation. In contrast, antibodies are large and have a maximum in efficient 
peptide coupling. Furthermore, glycans offer multiple possibilities for functionalization 
of vaccines through changing their density, amount and spatial orientation [30, 31]. 
This allows for the specific design of CLR targeting compounds, in contrast to the rigid 
conformation of antibodies. Production of glycans is easier on a large scale, which can 
considerably lower costs. Besides the conformational ease of glycans as targeting tool, 
also the possibility to use a single glycan for multiple CLR targeting make glycans a more 
versatile targeting moiety compared to antibodies (Figure 2, step 1).
Many different CLR are used for in vivo vaccination approaches including Langerin, 
DEC-205, DC-SIGN, macrophage galactose lectin (MGL), CLEC9A, macrophage mannose 
receptor (MMR) and dectin-1, as reviewed by van Dinther et al [27]. There are some 
interesting CLR candidates of which the glycan ligands are known. MMR, Langerin and 
DC-SIGN recognize high mannose containing glycans. Furthermore, Langerin and DC-SIGN 
bind (part of) the fucose containing Lewis type antigens [32]. This enables development 
of glycan-modified vaccines for specific targeting to these CLR. The conformation in 
which the glycans are presented can dictate CLR binding efficiency and facilitation of DC 
antigen cross-presentation [32].




Figure 2. Schematic overview of (considerations in) vaccine design for immunotherapy. The 
design of a novel glycan-based immunotherapeutic vaccine consists of multiple steps. First, the 
carbohydrate moiety must be selected (1), taking the CLR to target into mind and its affinity to 
the receptor (or receptors). Covalent binding to the peptide antigen or conjugation as separate 
moieties to the carrier is also dependent on the carrier platform (2). Compliant to the targeted 
receptor, multivalent presentation with optimal density, spacing, and flexibility of the carbohy-
drates must be sought out. The overall carrier size, charge, and stability on incorporation of the 
glycopeptides must additionally be considered. Supplemental cargo can be added to boost the 
immunization process through DC maturation and enhanced antigen (cross)-presentation (3), 
provided there are no negative CLR-binding effects or alterations in processing via receptor cross 
talk. DC-SIGN, dendritic cell specific ICAM grabbing non-integrin; CLR, C-type lectin receptor; dDC, 
dermal dendritic cell; LC, Langerhans cell; TLR, Toll-like receptor.
Multivalent delivery systems
When aiming for CLR targeting, the design of the tumor antigen containing particle 
is very important [31]. Glycan-mediated interactions are generally weak and this low 
affinity is compensated through avidity [31]. Avidity ensures that the frail binding 
between individual ligand and receptor accumulates, thereby strengthening the 
interaction. In contrast to glycans, antibodies generally rely on their high binding 
affinity. Where an antibody or a glycan monomer can only bind one CRD with set 
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affinity, a glycan polymer can bind multiple CRD and CLR molecules thereby inducing 
receptor multimerization which enhances glycan-receptor avidity [31].
Binding of glycans by the CRD of CLR is influenced by their spatial orientation 
and conformation within the cellular membrane [33]. The most straightforward 
manner of introducing a CLR-targeting moiety is the covalent attachment of a 
specific glycan onto a specific amino acid in an antigenic peptide [32]. However, 
effective CLR receptor-glycan interactions require both affinity and avidity, through 
multimerization of the receptors.
The (multi)valency of a glyco-peptide can be increased by incorporation into carrier 
systems (Figure 2, step 2). Gold nanoparticles (AuNP) are widely used as carrier 
system due to their easy changeability in size, shape, surface- and other chemical 
properties. The simultaneous functionalization of AuNP with thiol-containing 
antigenic peptides and with thiol-functionalized carbohydrates has been described 
with successful immunizing applications in vitro and in vivo [34]. Naturally occurring 
carrier systems in the nano-range are the outer membrane vesicles from pathogens 
[35], or small liposomes including glycans in the lipid bilayer, with antigen entrapped 
at the core [32]. Another effective system for glyco-peptide multimerization are poly 
aminoamide (PAMAM)-dendrimers, which have been applied successfully for DC 
targeting and immunization [30]. These defined nanostructures are repetitively and 
uniformly branched molecules, available in a large array of sizes and terminal groups, 
which double with each generation [36]. Next to the glycan moiety, the density, 
spacing and flexibility of the carrier system can contribute to the CLR targeting. 
This makes PAMAM-dendrimers an interesting carrier to develop and test multiple 
conformations of multivalent glyco-peptide systems for optimal CLR targeting. 
However, not always can high affinity CLR binding be directly translated to enhanced 
antigen presentation and T cell responses [21].
Adjuvants for DC maturation and antigen processing
Important for anti-tumor vaccines, besides the inclusion of tumor specific antigens, 
is the addition of adjuvants that enhance vaccine efficacy by inducing DC maturation. 
DC maturation entails the expression of co-stimulatory molecules which provide 
T cell stimulation (signal 2) and cytokine production for T cell skewing (signal 3). 
Furthermore, adjuvants can improve vaccine uptake and processing. Since PRR are 
naturally used by DC to sense pathogens for uptake and maturation, efforts have 




been made to find agonists, either naturally occurring or synthetic, to complement 
vaccines [37]. TLR, NOD-like receptors (NLR) and RIG-I-like receptors are PRR inducing 
DC maturation for T cell stimulation and skewing (signal 2 and 3).
The TLR family is commonly used for adjuvant purposes [38] and many agonists for 
the different TLR molecules have been described. Interestingly, cross-talk amongst 
TLR and CLR illustrate that the choice of adjuvant to be combined with CLR targeting 
may matter. Multiple CLR can react to concomitant TLR activation as described for 
DC immunoreceptor (DCIR) and TLR7/8 [39, 40], DC-specific ICAM-grabbing non-
integrin (DC-SIGN) and TLR3/4/5 [41], BDCA-2 and TLR9 [42] and Langerin and TLR3 
[43]. This can prompt immunomodulation of DC induced T cell responses, such as 
enhanced cross-presentation [40]. Interestingly, combinations of adjuvants for TLR 
and NLR stimulation can influence NLR induced signaling cascades and subsequent 
immunological processes including antigen uptake through autophagy [44] and 
presentation [45, 46]. Overall, the use of adjuvants is not only interesting for the 
proper induction of DC maturation to provide T cells with signal 2 and 3. Combining 
CLR targeting with TLR and/or NLR agonists may also enhance cross-presentation 
thereby further facilitating signal 1 (Figure 2, step 3).
Designing intradermal vaccine formulations for DC induced 
anti-tumor immunity
DC comprise a heterogeneous cell population that can be distinguished on many 
aspects. The classification of the different subsets is based on expression of cell 
surface molecules and localization throughout the body. Furthermore, transcription 
factor expression, transcriptional regulation and whether they are able to migrate 
or reside in tissue specific locations can distinguish these subsets from each other. 
All DC subsets can mediate peptide processing and presentation, but have varying 
ability in the type of T cells which are subsequently activated. [47] Moreover, the 
four different DC subsets in human skin may respond differently to vaccines as they 
express different CLR for glycan uptake of antigens, and different TLR for maturation 
purposes. Thus careful vaccine design is required (Figure 2) [48].
Langerhans cells
LC are distinguished from other DC subsets by the high expression of cell surface 
makers CD1a and the CLR Langerin that is specifically expressed on LC [49, 50]. Upon 
stimulation, they become potent APCs that preferentially induce CD4+ TH2 like and 
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CD8+ T-cell responses [51, 52]. Their cross-presenting capacity is largely dependent 
on the internalization pathway involved and the environmental cues they receive. 
Specific intracellular pathogens and viruses are able to elicit LC activation under 
inflammatory conditions, while LC are also able to distinguish between pathogens 
and commensals, inducing commensal tolerance [47]. Targeting LC for vaccination 
purposes is therefore dependent on signals that provide LC activation that tilts the 
balance toward anti-tumor inflammation rather than tolerance. The use of TLR 
agonists is a viable option to induce anti-tumor immunity. Since LC do not express 
TLR4, use of the clinically approved LPS derivative MPLA is not possible. However, 
they do express TLR3 and TLR7/8 providing opportunities to use Poly I:C [53] or 
imiquimod [54], respectively.
Dermal DC
Three other skin DC subsets are present in the dermal layer of the skin. These subsets 
are distinguished from each other based on cell surface molecules and the specific 
expression of CLRs.
CD1a+ dermal DC form the most abundant dermal DC subset. They specifically express 
the CLR MGL [55] and are the most mature dermal DC under steady state conditions. 
They have the capacity to activate both CD4+ and CD8+ T-cells [56] and are described 
to efficiently cross-present exogenous antigens. Expression of C-C motif receptor 
7 (CCR7) on CD1a+ dermal DC involved in DC migration suggests a high migratory 
potential to draining LN, making them interesting targets for DC vaccination therapies 
aiming to activate naïve T cells [56, 57].
CD14+ dermal DC are distinguished based on expression of the CLR DC-SIGN [55], 
though, also CD1a+ dermal DC express DC-SIGN albeit at lower levels [57]. Steady-
state, unstimulated CD14+ dermal DC have a more immature phenotype and induce 
Tregs and follicular T-helper cells (THF) [51, 58]. Furthermore, they have a low 
potential to activate allogeneic T-cell proliferation [59] and it has been shown that 
they are less efficient in cross-presenting antigens as compared to LC and CD1a+ 
dermal DC [51, 60]. However, recent studies showed that upon specific targeting 
CD14+ dermal DC can efficiently cross-present antigens for tumor specific T cell 
activation [25].




In addition to CD1a+ and CD14+ dermal DC, CD141+ dermal DC have been identified 
in the dermis of the skin and other peripheral tissues [61]. Although CD141 is highly 
expressed on this subset, CD141 is also expressed on all CD14+ dermal DC [62]. 
However, the CD141+ dermal DC can be further distinguished by the absence of CD14 
and low expression of CD11c [61]. Furthermore, CD141+ dermal DC are characterized 
by the specific expression of the CLR CLEC9A [55]. This subset has been described to 
efficiently cross-present antigens and highly express CCR7 that correlates with the 
spontaneous migration seen of these cells [61].
Induction of dermal DC maturation for proper T cell stimulation can be accomplished 
through activation of TLR, e.g. by use of the clinically approved TLR4 agonist MPLA 
or the TLR7/8 agonist imiquimod. Furthermore, the combination of TLR and NLR 
agonists which synergize holds promise for skin DC activation.
Cross-presentation via DC-SIGN and Langerin
Although CD141+ dermal DC are considered the prime cross-presenting DC residing 
in the skin, specific CLR targeting on the other dermal DC subsets can enhance 
and leverage their cross-presenting capacity. Two interesting CLRs expressed by 
human skin DC, of which the glycan ligands are known, are DC-SIGN and Langerin. 
As previously described, DC-SIGN is mainly expressed on CD14+ dermal DC, but also 
found on CD1a+ dermal DC, whereas Langerin expression is restricted to LCs [57, 
63]. Enhanced cross-presentation of melanoma specific antigens following targeting 
of CD14+ dermal DC and LCs via DC-SIGN and Langerin, respectively, confirms the 
potential for the targeting of these receptors for intradermal vaccination strategies 
[25, 43]. Interestingly, activation of DC via TLRs can alter the intracellular fate of 
antigens thereby favoring cross-presentation [64] and this feature can be combined 
with CLR targeting. Indeed, T cell activation following DC-SIGN targeting can be 
enhanced when combined with TLR stimulation using the TLR4 agonist MPLA [65]. 
Equally, Langerin targeting combined with the TLR3 agonist Poly I:C enhanced tumor 
specific CD8+ T cell activation [43]. Though, how DC-SIGN routing is affected by 
TLR4 signaling, and whether other TLR ligands can also affect DC-SIGN and Langerin 
antigen routing for enhanced cross-presentation, remains to be elucidated.
The expression of Langerin on LC and DC-SIGN on two of the dermal DC subsets 
and their cross-presentation induction potential, make them interesting targeted 
candidates for intradermal anti-tumor vaccines. To specifically target Langerin and 
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DC-SIGN their binding specificity to the Lewis type antigens can be used. DC-SIGN 
recognizes all Lewis type antigens, whereas Langerin recognizes Lewis (Le)b and LeY, 
but not Lea and LeX. Interestingly, both DC-SIGN and Langerin showed highest binding 
affinity for LeY, making this a suitable glycan for dual receptor targeting. However, the 
conformational presentation of glycan coated tumor specific compounds influences 
intracellular trafficking of the antigens targeted to Langerin and DC-SIGN [32]. Hence, 
careful evaluation of immune responses induced by LeY-conjugated tumor specific 
particles is imperative to ensure optimal CD8+ T cell activation, e.g. directed at cancer.
Intradermal delivery systems
Intradermal delivery of vaccines is often accomplished through needle injection. 
Though, this requires specific training and, hence, other delivery systems are 
being developed to simplify vaccination schemes such as delivery via microneedle-
patches or upon laser skin microporation [66]. The use of (epi)dermal laser ablation 
is especially interesting as it can enhance vaccine immunogenicity in combination 
with adjuvants [67] and even work as adjuvant itself [68], thereby enhancing vaccine 
efficiency. These kind of technical developments prompt investigation in use for 
anti-tumor immunotherapy, where indeed it was shown to improve in vivo anti-
tumor immune responses [69]. It would be very interesting to investigate the effect 
of laser treatment in combination with anti-tumor vaccines applied intradermally 
in human skin.
Future design of cancer vaccines
Tumor immunotherapy for treatment of cancer is a promising strategy as shown 
in the past decade. DC which bridge the non-specific innate and specific adaptive 
immune system can be used for induction of anti-tumor immune responses e.g. 
through vaccination. The human skin is easy accessible and harbors a vast number of 
DC subsets thereby making it a potent vaccination site. Nevertheless, vaccine design 
comes with several challenges. For induction of long lasting anti-tumor immunity the 
vaccine needs to contain both tumor specific antigens and adjuvant. Furthermore, 
the conformation in which the tumor specific antigens are delivered can dictate 
specific DC subset targeting and processing for antigen presentation. The use of 
glycan-induced CLR targeting by multivalent delivery systems may ensure endocytosis 
by multiple human skin DC subsets, and importantly, enhanced cross-presentation for 
CD8+ T cell activation. This can be further increased by careful selection of adjuvants, 
such as TLR and NLR agonists, which can influence CLR induced antigen processing. 




Besides, adjuvants can alter the skin microenvironment through induction of cytokine 
secretion thereby inducing innate immune cell influx.
Tumors develop to evade the immune system by creating an immune suppressive 
microenvironment [70]. This tumor microenvironment (TME) can use the naturally 
occurring brakes present on immune cells to avoid overstimulation and tissue 
damage, i.e. the so called immune checkpoints (IC). Furthermore, tumor reactive 
T cells cannot always penetrate into the tumor to clear tumor cells and are often 
“exhausted” (i.e. suppressed by coordinated expression of multiple IC) before proper 
tumor cell clearance. Multiple studies have shown promising results that lead to 
effective anti-tumor immunotherapy, either by removing the brakes through immune 
checkpoint inhibition [71] or by stimulating anti-tumor immunity [72-74]. Though 
there is still much room for vaccine improvement, ultimately combining it with IC 
blockade may be the way forward for effective cancer immunotherapy.
Thesis outline
In the studies described in this thesis we explored the potential of human skin DC 
to induce anti-tumor immunity. By the design of various vaccines we explored how 
the multiple human skin DC subsets responded for the induction of robust adaptive 
anti-tumor immunity. We used melanoma as a tumor model and synthesized a long 
peptide constituting both a CD4+ and CD8+ T cell specific epitope of the gp100 protein. 
As such, we can verify CD4+ T cell activation via classical antigen presentation, but 
also CD8+ T cell activation through cross-presentation.
For intradermally injected particulate vaccines, we need to ensure that the tumor 
antigen containing particle will reach the targeted DC subset to facilitate the 
induction of cytotoxic CD8+ T cells with tumor cell killing capacity. For this DC need 
to shuttle exogenously derived antigens into the endogenous presentation pathway, 
better known as cross-presentation. The expression of DC specific CLR gives us the 
opportunity to both specifically target skin DC whilst inducing cross-presentation, 
especially when combined with TLR stimulation. In chapter 2 we explored the 
possibility to specifically target epidermal LC through either Langerin or Dectin-
1 for induction of cross-presentation, using specific antibodies conjugated to the 
gp100 synthetic long peptide (SLP). We show Langerin to be superior in the activation 
of melanoma specific CD8+ T cells, compared to Dectin-1, due to differences in 
intracellular routing.
SanneDuinkerken-BNW.indd   21 20-11-2020   12:55:55
22
Chapter 1
In order to explore whether targeting dermal DC is beneficial in facilitating cross-
presentation, we used DC-SIGN as target candidate as it is expressed by CD14+ and 
CD1a+ DC in the dermis. In chapter 3 we elucidated the exact intracellular routing 
of DC-SIGN and its cargo by using an antibody specific for the CRD and one for the 
neck-region of DC-SIGN. Furthermore, we elucidated whether and how concomitant 
TLR4 stimulation could enhance DC-SIGN induced cross-presentation. We show that 
simultaneous triggering of DC-SIGN using an antibody conjugated to the melanoma 
specific gp100 SLP and TLR4 using LPS, efficiently enhances cross-presentation. This 
dual stimulation ensured SLP degradation by the proteasome and antigen processing 
for MHC I loading.
Many targeting strategies have focused on the targeting of a single DC subset through 
a single CLR. We wondered whether the simultaneous targeting of multiple DC 
subsets in the skin would enhance adaptive immunity. We therefore aimed to target 
multiple human skin DC subsets through both Langerin (LC) and DC-SIGN (dermal DC) 
using a single Langerin-DC-SIGN targeting vaccine formulation. Earlier work showed 
that Langerin and DC-SIGN require different sized formulations of antigenic particles 
for the induction of cross-presentation. In chapter 4, we used the overlapping glycan 
binding profiles for the Lewis Y type antigens of Langerin and DC-SIGN to target both 
receptors. Using Lewis Y (LeY) as targeting glycan we aimed to generate a single glyco-
vaccine targeting multiple human skin DC subsets simultaneously. As carrier system 
we used PAMAM-dendrimers, which are hyperbranched polymers with mirroring 
subunits containing reactive terminal sides to which e.g. peptides can be covalently 
conjugated and synthesized varied sizes, multivalent glyco-peptide vaccines. We used 
the generation 0 (containing 4 reactive groups) and the generation 3 (containing 
32 reactive groups) PAMAM-dendrimer cores to covalently link the gp100 SLP and 
create two differentially sized vaccines which fall between the peptide and liposome 
range. For specific targeting to both Langerin and DC-SIGN, LeY was added to the 
N-terminal side of the gp100 SLP. We show the generation 3 multivalent glyco-
dendrimers of approximately 50nm to efficiently target both Langerin and DC-SIGN, 
thereby reaching multiple human skin DC subsets when injected in situ. Furthermore, 
this enhanced activation of tumor specific CD4+ and CD8+ T cells compared to non-
targeting dendrimers. Cross-presentation was further enhanced by the addition of 
either the TLR4 agonist MPLA (DC) or TLR3 agonist Poly I:C (LC).




In order to investigate whether we could further optimize our cancer vaccine, we 
investigated whether we could improve DC maturation for cytokine skewing and 
co-stimulation and antigen processing, by combining various PRR agonists. TLR and 
NOD-like receptors (NLR) that are expressed by different human skin DC and can 
synergize for DC maturation and antigen handling. In chapter 5 we used the PAMAM-
dendrimer generation 0 core, to develop a multivalent antigenic vaccine containing 
both the gp100 SLP and the NOD2 agonist MDP. To this end a synthetic NOD2 agonist, 
M-TriLYS, was covalently linked at the N-terminal side of the multivalent antigenic 
dendrimer. We show that the combination of the NLR agonist-antigen complex 
with the soluble TLR4 agonist MPLA enhances cytokine secretion within the skin 
micromilieu. Furthermore, it enhances cross-presentation by human skin DC for 
CD8+ T cell activation.
Intradermal vaccine delivery is usually achieved through injection, though efforts 
are made to design systems that simplify intradermal vaccine delivery. One of those 
systems is the use of laser devices creating small pores at set depths within the 
skin. These devices haven been shown to not only simplify delivery, but also induce 
enhanced immunity. In chapter 6 we made use of an ablative fractional laser to 
verify whether it might benefit vaccination with our anti-tumor vaccine particles. 
We show that in our human skin explant model intradermal injection was more 
efficient for vaccine delivery to and uptake by skin DC, resulting in higher level CD8+ 
T cell activation.
This thesis aimed to develop a human skin DC targeting cancer vaccine, exploiting 
the expression by DC of the CLR Langerin and DC-SIGN. By the design of a multivalent 
glyco-vaccine incorporating melanoma specific gp100 epitopes and the targeting 
moiety LeY we could efficiently target multiple human skin DC for enhanced (cross)-
presentation using a single vaccine formulation. This dual targeting, multivalent 
vaccine can be used for inclusion of a multitude of epitopes and PRR agonists. 
Thereby we developed a flexible intradermal vaccine platform which has merit for 
clinical studies aiming to cure different types of cancer.
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LANGERIN-MEDIATED 
INTERNALIZATION OF MODIFIED 
PEPTIDES ROUTES ANTIGENS TO 
EARLY ENDOSOMES AND ENHANCES 
CROSS-PRESENTATION BY HUMAN 
LANGERHANS CELLS
Cynthia M. Fehres, Sanne Duinkerken, Sven C.M. Bruijns, Hakan Kalay, Sandra J. van Vliet, 
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The potential of the skin immune system to generate immune responses is well 
established and the skin is actively exploited as vaccination site. Human skin 
contains several antigen-presenting cell (APC) subsets with specialized functions. 
Especially the capacity to cross-present exogenous delivered antigens to CD8+ T 
cells is of interest for the design of effective immunotherapies against viruses or 
cancer. Here, we show that primary human LCs are able to cross-present synthetic 
long peptides (SLPs) to CD8+ T cells. In addition, modification of those SLPs using 
antibodies against the receptor Langerin, but not dectin-1, further enhanced the 
cross-presenting capacity of LCs through routing of internalized antigens to less 
proteolytic EEA-1+ early endosomes compared to dectin-1. The potency of LCs to 
enhance CD8+ T cell responses could be further increased through activation of 
LCs with the TLR3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data 
provide evidence that human LCs are able to cross-present antigens after Langerin-
mediated internalization. Furthermore, the potential of antigen modification to 
target LCs specifically provides a rationale to generate effective anti-tumor or anti-
viral CTL responses.
Key words: Antigen cross-presentation, dectin-1, early endosomes, human 
Langerhans cells, Langerin.





Antigen presenting cells (APCs) and, in particular, dendritic cells (DCs) induce adaptive 
immune responses through the presentation of endogenous peptides in the context 
of MHC class I and exogenous peptides in the context of MHC class II molecules 
to CD8+ and CD4+ T cells, respectively. In addition, DCs are able of capturing and 
presenting exogenously derived antigens in MHC class I molecules, a process known 
as cross-presentation [1]. Antigen cross-presentation plays an important role in 
the priming of cytotoxic T cells against viruses or tumors, but is also important in 
maintaining self-tolerance [2]. However, not all DC subsets have identical cross-
presentation capacities and some DC subsets appear better equipped for this task. 
Therefore, careful selection of the DC subset is of utmost importance in the design 
of anti-tumor or anti-viral DC targeting vaccination strategies.
Langerhans cells (LCs) are a subset of DCs present in mucosal tissues and stratified 
epithelium, like the epidermis of the skin. Human LCs are characterized by the 
expression of CD1a, the C-type lectin receptor (CLR) Langerin and the presence 
of Birbeck granules, which are associated with Langerin expression [3]. Langerin 
mediates recognition through the interaction with glycoconjugates such as high-
mannose structures, mannan or β-glucans expressed on the surface of pathogens 
[4]. Langerin mediates ligand internalization for antigen processing and presentation 
and, therefore, it has a potential to be used to specifically deliver antigens conjugated 
to glycans or α-Langerin antibodies to LCs. Although capture of exogenous antigens 
by human LCs resulted in the induction of CD4+ T cell responses [5, 6] it still remains 
under debate whether human LCs are able to cross-present exogenous antigens. In 
vitro derived LCs cultured from CD34+ progenitor cells efficiently promoted CD8+ T 
cell proliferation after internalization of soluble peptides [7]. Also, LCs pulsed with 
a short EBV peptide or a 39 amino-acid long peptide containing the EBV minimal 
epitope, were more efficient than pulsed dermal DCs in the cross-presentation of 
the EBV antigen to memory CD8+ T cells [8]. This enhanced CD8+ T cell activation 
by LCs was dependent on the interaction between CD70 and CD27 [8], but did not 
rely on specific, receptor-mediated uptake of antigens. On the other hand, others 
reported that isolated human LCs were unable to cross-present heat-inactivated 
measles virus, which was specifically recognized and internalized by Langerin [9]. 
In addition, studies performed in mice also suggest that LCs may have lower cross-
presenting capacity [10]. Using a murine model of Candida albicans skin infection, the 
authors showed that LCs were dispensable in the generation of cytotoxic T cells [10]. 
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Instead, Langerin+ dermal DCs (dDCs) were required for the generation of antigen 
specific CTL and Th1 cells against C. albicans. Other studies have recently suggested 
that cross-presentation is mainly an attribute of the Langerin+ dDC subpopulation 
and not of LCs in murine skin [11, 12]. However, the existence of an equivalent of 
this Langerin+ dDC subpopulation in human skin has been questioned [13], although 
very recently, a Langerin+ APC subpopulation has also been detected in the human 
dermis [14].
Because of their APC-restricted expression pattern and their function as antigen-
uptake receptors for processing and presentation, CLRs have often been studied 
as targeting receptors for vaccination [15, 16]. Antigen targeting to DEC-205, DCIR, 
CLEC9a, dectin-1 and DC-SIGN on DCs resulted in receptor internalization and 
enhanced antigen-specific CD4+ and CD8+ T cell responses [17-20]. Since CLRs are 
expressed by specific DC subsets, the choice of a CLR for targeting does not only 
determine the antigen internalization pathway, but also to which DC subset the 
antigen is targeted. Various pathways involved in cross-presentation after CLR-
mediated antigen internalization of antigens have been proposed. One mechanism 
involved the translocation of antigen into the cytoplasm for proteosomal degradation, 
followed by TAP-mediated peptide transport in the endoplasmatic reticulum (ER) 
and loading onto MHC class I molecules [21, 22]. Antigenic peptides can also be 
generated in the endocytic pathway in a proteosome-independent manner and 
subsequently bind to recycling MHC class I molecules present within endosomal 
compartments [23-25]. Recently, it was shown that antigen targeting to specific 
intracellular compartments, either to early endosomes via CD40 and mannose 
receptor antibody-conjugates or to late lysosomal compartments via DEC-205, 
resulted in antigen cross-presentation [26]. Targeting antigens to early endosomes 
has been shown to result in the most efficient antigen cross-presentation, suggesting 
that the endocytic compartments to which antigens are delivered determine the 
efficiency of cross-presentation.
In this study we set out to investigate the role of human LCs in cross-presentation of 
synthetic long peptides (SLPs) conjugated to antibodies specific for the CLRs Langerin 
and dectin-1, which gave us the opportunity to study the role of each receptor 
in processing and shuttling of antigens to MHC class I-loading compartments. To 
determine whether antigen uptake via Langerin or dectin-1 by human LCs results 
in a different intracellular routing and antigen cross-presentation, we analyzed 




co-localization of both receptors with the early endosomes marker EEA-1 and the 
lysosomal marker LAMP-1 in pulse-chase experiments. Here, we report that targeting 
Langerin either with antibodies, but not dectin-1, resulted in enhanced cross 
presentation. Altogether, these results support the rationale to develop vaccines that 
specifically target Langerin on human LCs to induce anti-tumor CD8+ T cell responses.
Materials and methods
Cells
Primary, human LCs were isolated from abdominal resections from healthy donors 
undergoing cosmetic surgery (Bergman Clinics, Bilthoven, The Netherlands) and were 
obtained with informed consent within 24 h after surgery as previously described 
[27]. Shortly, 5 mm thick slices of skin, containing the epidermis and dermis, were 
cut using a dermatome. The slices were incubated in dispase II (1 mg/ml, Roche 
Diagnostics) in IMDM (Invitrogen) supplemented with 10% FCS (BioWhittaker), 50 U/
ml penicillin (Lonza), 50 μg/ml streptomycin (Lonza) and 10 μg/ml gentamycin (Lonza) 
overnight at 4°C followed by mechanical separation of dermis and epidermis using 
tweezers. The epidermis was washed in PBS, cut into small pieces and incubated in 
PBS containing DNase I (200 U/ml, Roche Diagnostics) and trypsin (0.05%, Invitrogen) 
for 30 minutes at 37°C. After incubation, a single cell suspension was generated using 
100 μm nylon cell strainers (BD Falcon) and cells were layered on a Ficoll gradient. An 
average of 1x104 LCs per cm2 of tissue with a purity higher than 90% were obtained 
and characterized as CD1a+ Langerin+ cells by flow cytometry as described below. 
LCs were cultured in IMDM supplemented with 10% FCS, 50 U/ml penicillin, 50 μg/
ml streptomycin and 10 μg/ml gentamycin. When indicated, 5x104 LCs were cultured 
for 24 h in 200 ul medium supplemented with 20 μg/ml pI:C (Invivogen), 20 ng/ml LPS 
(derived from E. coli, Sigma), 5 μg/ml R837 (Invivogen) or 5 μg/ml R848 (Invivogen) 
to induce maturation. In indicated experiments, LCs were obtained by spontaneous 
migration. Shortly, epidermis and dermis were separated as described above. The 
epidermis was washed in PBS and cultured for 2 days in a 25 cm2 culture dish (Greiner) 
containing 40 ml of IMDM supplemented with 10% FCS, 50 U/ml penicillin, 50 μg/
ml streptomycin and 10 μg/ml gentamycin to allow spontaneous migration of LCs. 
After 2 days, cells present in the supernatant were harvested and layered on a Ficoll 
gradient and further cultured as described above.
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Tap-deficient T2 cell line
The TAP-negative BxT hybrid cell line 1.74xCEM (referred to as T2) was used for 
peptide stabilization assays [28]. T2 cells (1x105) were incubated overnight with 
peptides in RPMI at 37°C, washed twice in PBS and surface MHC class I expression 
assayed by flow cytometry (FACSCalibur, Becton Dickinson) using an HLA-A2 specific 
monoclonal antibody (Becton Dickinson).
Flow cytometry
Phenotypical analysis of isolated LCs was performed by flow cytometry. Cells were 
washed in PBS supplemented with 1% bovine serum albumin (BSA) and 0.02% 
NaN3 and incubated for 30 min at 4°C in the presence of appropriate dilutions of 
fluorescent-conjugated mAbs to CD1a (APC, clone HI149, Becton Dickinson), CD14 
(FITC, clone MoP9, Becton Dickinson), CD70 (PE, clone Ki-24, Becton Dickinson), CD86 
(PE, clone 2331, Becton Dickinson), HLA-DR (PerCP, clone L203, Becton Dickinson), 
HLA-ABC (FITC, clone W6/32, ImmunoTools) or CD83 (PE, clone HB15e, Beckman 
Coulter Immunotech), or corresponding isotype-matched control mAbs (Becton 
Dickinson). HLA-A2 status of the cells was determined using a specific mAb (Becton 
Dickinson). The cells were subsequently analyzed using the FACSCalibur and FlowJo 
software (Tree Star).
Imaging flow cytometry
Approximately 0.1x10 primary human LCs, which were migrated spontaneously from 
human skin, were incubated for 3 hours at 37°C in culture medium with or without 
20 μg/ml pI:C to induce maturation. Cells were then washed twice and incubated in 
ice-cold culture medium. As indicated, AF647-labeled anti-dectin-1 (AbD Serotec) 
and PE-labeled anti-Langerin (R&D Systems) were added and incubated for 15 min 
at 37°C in order to allow binding to cell surface expressed Langerin and dectin-1. 
Cells were then washed in ice-cold medium, transferred to a 37°C incubator and 
samples were obtained at the indicated time points. Cells were then washed in ice-
cold PBS and fixated in ice-cold 4% PFA in PBS for 20 minutes. To prevent cell loss 
during the staining procedure, LCs were mixed with monocyte-derived dendritic 
cells. Cells were then permeabilized in 0.1% saponin (Sigma) in PBS for 30 minutes 
at room temperature and subsequently blocked using PBS containing 0.1% saponin 
and 2% BSA for 30 minutes at room temperature. Stainings were performed at room 
temperature in PBS supplemented with 0.1% saponin and 2% BSA. After staining, cells 
were washed twice in PBS, resuspended in PBS containing 1% BSA and 0.02% NaN3 




and kept at 4°C until analysis. Cells were acquired on the ImageStream X (Amnis) 
imaging flow cytometer. A minimum of 15000 cells was acquired per sample at a 
flow rate ranging between 50 and 100 cells/second at 60x magnification. At least 
2000 cells were acquired from single stained samples to allow for compensation 
(Supporting Figure 1). Analysis was performed using the IDEAS v6.1 software (Amnis). 
Cells were gated based on the Gradient RMS (brightfield) feature, which was used to 
select for cells in focus (Supporting Figure 2A) and Langerin expression (Supporting 
Figure 2B). Co-localization (Supporting Figure 3) was calculated using the features 
bright detail similarity R3 (for 2-color co-localization) or bright detail co-localization 
3 (for 3-color co-localization).
Antibody degradation assay WB
LC were incubated in serum free IMDM for 30 minutes, incubated with 50µg/ml 
anti-Langerin (10E2) or anti-Dectin-1 (AbD Serotec) for 45 minutes on ice to ensure 
binding. Cells were washed twice in ice cold medium to remove unbound antibody 
and internalization was assessed after 0, 15 and 45 minutes incubation at 37˚C. 
Following indicated incubation times cells were lysed in NP40-lysisbuffer for 30 
minutes on ice. Nuclei were removed by spinning cells at 14000rpm for 10 minutes 
and supernatant containing cell lysate was used for WB. Cell lysates were denatured 
in SDS-sample buffer (Bio-rad) and reducing agent and boiled for 5 minutes. Samples 
were loaded and separated on a 10% SDS polyacrylamide gel in electrophoresis 
buffer (3g Tris, 14,4g Glycine, 1L MQ, 0,1% SDS) before transfer to a nitrocellulose 
membrane (Bio-rad) for 2 hours at 250mV for immunoblotting. The blot was blocked 
in blocking solution (Roht) for 1 hour at RT, followed by incubation with a polyclonal 
goat anti-mouse Ig HRP conjugate (Dako)for 1 hour at RT. After extensive washing 
with PBS plus 0,05% Tween antibody binding was visualized using ECL (Bio-rad). 
Antibody staining was removed by incubating the blot in stripping buffer for 1 hour at 
60˚C, followed by blocking for 1 hour at RT. Actin was stained using an goat polyclonal 
anti-actin IgG (Santa Cruz) and corresponding HRP-coupled secondary antibody.
Immunofluorescence microscopy
Human tissue sections (7 µm) were fixed in acetone and blocked with goat serum 
prior to staining. Antibodies directed against CD14, CD1a or Langerin were added 
at 10 µg/ml in PBS containing 1% BSA for 60 min. at 37°C followed by secondary 
Alexa 488-conjugated rabbit anti-mouse IgG2A, Alexa 546-conjugated rabbit anti-
mouse IgG2B or Alexa 647-conjugated rabbit anti-mouse IgG1 specific antibodies 
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(Molecular Probes) for 30 min. at room temperature. Sections were counterstained 
using hoechst and analyzed by fluorescence microscopy (Leica microsystems).
Modification of MART-1 peptides with glycans and antibodies
The synthetic long peptides MART-1 (CYTTAEELAGIGILTV) were produced by 
solid phase peptide synthesis using Fmoc-chemistry with a Symphony peptide 
synthesizer (Protein Tecnologies Inc., USA). Peptides were coniugated to glycans 
and antibodies on the N-terminal cysteine through a tiol-maleimide reaction. To 
this end, glycans were activated with the use of the bifunctional crosslinker MPBH 
(4-N-Maleimidophenyl butyric acid hydrazide, Thermo Scientific) and antibodies 
through reaction with SMCC (Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate, Thermo Scientific).
First, the hydrazide moiety of MPBH was covalently linked to the reducing end of 
the glycan via reductive amination. Shortly, a mixture of MPBH (3 eq.), glycan (1 
eq.) and picoline-borane (10 eq.) dissolved in Dimethyl-sulfoxide/Acetic acid (7:3, 
anhydrous and glacial respectively, Sigma) reacted for 2 h at 65°C. After cooling down 
to room temperature, 4 volumes of dichloromethane (Biosolve) were added and the 
mixture was vortexed thoroughly. Subsequently, 4 volumes of diethyl ether (Biosolve) 
were added and incubated until glycan-MPBH had completely precipitated. MPBH-
glycans were pelleted by centrifugation (2 min at 14000g), then the supernatant 
was discarded and the pelleted carbohydrate-MPBH was washed with cold diethyl 
ether 3 times. The obtained glycan-MPBH pellet was resuspended in aqueous 0.1% 
TFA (trifluoroacetic acid, Sigma) and lyophilized, followed by purification over a 22 
x 250 mm Vydac MS214 prep C18 column (Grace Alltech, elution water/acetonitrile, 
gradient 3% to 50% of acetonitrile in 40 min) on a Dionex prep 3000 HPLC system. 
The fractions containing the glycan-MPBH were pooled and lyophilized.
Peptides were glycosylated on their terminal cysteines with the activated glycan 
through a thiol-ene reaction. Briefly, the peptides (3 eq.) were dissolved in 0,05M 
phosphate buffer (pH 6.5) and added to the carbohydrate-MPBH (1 eq.). After 2 h 
of reaction at room temperature, the glycosylated peptides were purified using 
and Vydac MS214 prep C18 columns 10 x 250 mm (Grace Alltech, elution water/
acetonitrile, gradient 10% to 50% of acetonitrile in 40 min). The fractions containing 
the glycopeptide were pooled and lyophilized. The derivatization and purity of the 
glycosylated peptides was confirmed by HPLC (Vydac 218MS C18 5um 4.6 x 250 mm, 




Grace Alltech) and MS spectrometry (LCQ-Deca XP Iontrap Thermo Finnigan mass 
spectrometer in positive mode using nanospray capillary needle). Conjugation of the 
glycans to the glycopeptides was also confirmed by ELISA using antibodies specific 
for Leb, LeX and LeY, as previously described [18].
Peptides were conjugated to antibodies using the bifunctional crosslinker 
Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC, Thermo 
Scientific). Briefly, antibodies were activated with SMCC (8 eq.) in phosphate buffer 
pH 8.2 for 30 min at room temperature. After desalting over a G-25 10X100 mm 
single use desalting gel filtration column (Amersham), peptides were dissolved in 
DMSO and added to the vial containing the antibody. After performing the coupling 
reaction at room temperature for 2 h, the un-conjugated peptide was removed 
through size-exclusion chromatography using a superdex 75 column (30 x 100 mm, 
Amersham Biotech) eluting with 50 mM ammonium formate buffer, pH 6.8. The 
fractions containing the antibody-peptide constructs were pooled and lyophilized.
Generation of Langerin-Fc constructs
The binding capacity of Langerin to various Lewis-type glycans was determined using 
Langerin-Fc molecules. Langerin-Fc was generated by amplifying the extracellular 
domains of Langerin (aa 63–328) on RNA of LCs by PCR. The product was confirmed 
by sequence analysis and fused at the C-terminus to human IgG1-Fc in the Sig-
pIgG1-Fc vector. Langerin-Fc was produced by stable transfection of CHO cells and 
Langerin-Fc concentrations were determined by ELISA.
ELISA-based Langerin binding assay
The conjugation of the Leb, LeX and LeY glycans to the MART-1 peptides was 
confirmed by ELISA using anti-Leb, -LeX and -LeY antibodies (Calbiochem) [18]. 
Briefly, glycopeptides were dissolved in PBS containing 0.05% BSA and coated 
onto NUNC maxisorb plates (Roskilde) and incubated overnight at 4°C. Plates were 
blocked with 1% BSA in PBS to avoid non-specific binding. After extensive washing, 
the glycopeptides were incubated with Langerin-Fc for 90 min at RT. Binding was 
detected using a peroxidase-labeled F(ab′)2 goat anti-human IgG/Fcγ specific 
antibody. Signal detection was achieved by incubation with 1.3 mM H2O2 in the 
presence of TMB (3,3’,5,5’-tetramethylbenzidine) in 0.1M sodium acetate-citrate 
buffer until the development of the reaction. The reaction is then stopped using 1 
M H2SO4 and absorbance is measured at 450 nm using a colorimeter (BioRad). As a 
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positive control, biotin-labeled Leb, LeX and LeY conjugated to polyacrylamide (PAA; 
Lectinity) were used.
Quantitative real-time RT-PCR
Cells were lysed and mRNA was isolated using an mRNA Capture kit (Roche). cDNA 
was synthesized using the Reverse Transcription System kit (Promega) following 
manufacturer’s guidelines. Each experiment contained cells isolated from at least 
5 skin donors to obtain sufficient cells numbers for analysis. Oligonucleotides were 
designed using the Primer Express 2.0 software (Applied Biosystems) and synthesized 
by Invitrogen Life Technologies. Real-Time PCR analysis was performed as previously 
described using the SYBR Green method in an ABI 7900HT sequence detection system 
(Applied Biosystems) [29]. GAPDH was used as an endogenous reference gene.
Antigen presentation to human CD8+ T cell clones specific for MART-1
A CD8+ T cell clone specific for MART-126-35 was generated and cultured as described 
previously [30]. The modified 16 aa long MART-121-35 peptides (C-YTTAEELAGIGILTV) 
were added to 20 000 HLA-A2+ LCs, obtained after migration from the skin, per well 
at indicated concentrations together with poly I:C (20μg/ml) for 3 h at 37°C. After 
extensive washing, HLA-A2+ MART-1 specific CD8+ T cells (100 000/well) were added 
to the wells. After 24 h, supernatants were taken and IFN-γ levels were measured by 
sandwich ELISA using specific antibody pairs from Biosource and according to the 
manufacturer’s guidelines.
Statistical analysis
Results were analyzed using either a one-way ANOVA followed by Bonferrroni 
Multiple Comparison test or a two-way ANOVA followed by Bonferroni Multiple 
Comparison test using GraphPad Prism software (GraphPad Software, San Diego, 
CA). Results were considered to be statistically significant when p<0.05.
Results
LCs are the main Langerin+ cells in human skin
Although Langerin has been classically reported to be exclusively expressed on epidermal 
LCs in human skin [31, 32], recent publications have challenged this knowledge by reporting 
the existence of a Langerin+ CD1a+ dDC in human dermis, lung, liver and lymphoid tissue 
[14]. In order to analyze whether Langerin expression is restricted to epidermal LCs, human 




skin sections were stained for CD14, CD1a and Langerin. As shown in Figure 1A, the great 
majority of Langerin staining was observed in epidermal LCs, which were also positive for 
CD1a and only rare CD1a+ Langerin+ cells could be observed in the dermis in close proximity 
with the dermoepidermal junction (Figure 1A). These cells could simply represent activated 
LCs that migrate through the dermis to the lymph nodes [14]. In addition, it was recently 
demonstrated that these cells could also be dermal DCs that have been in contact with 
TGF-β leaked from the epidermis, resulting in upregulation of Langerin [33]. Nevertheless, 
the frequency of these cells is extremely low and it is questionable whether their presence 
in the dermis might have any functional relevance. Indeed, most of the dermal CD1a+ DCs 
observed were devoid of Langerin expression (Figure 1). 
Figure 1. Langerin is exclusively expressed by human LCs. A. Staining of a section of steady-state 
human skin for Langerin (blue), CD1a (green), CD14 (red) and Hoechst (yellow) and analyzed by 
fluorescence microscopy. B. Gating strategy of FACS-sorted LCs, CD14+, CD1a+ and double negative 
dermal DCs. C. Langerin mRNA is exclusively expressed in primary, FACS-sorted LCs and not by 
the other skin DC subsets. N=3, each experiment contains sorted cells of at least 5 skin donors. 
mRNA values are normalized to GAPDH levels.
Additionally, we confirmed the data by quantitative RT-PCR analysis for Langerin on 
FACS-sorted HLA-DR+ APCs isolated from the dermis and epidermis (Figure 1B). Figure 
1C confirms that Langerin is exclusively expressed by LCs and not by the dermal CD1a+ 
DCs, CD14+ DCs or the HLA-DR+CD1a-CD14- dermal DC subset, which may be constituted, 
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among others, by macrophages and BDCA3+ skin DCs. Thus, LCs are the main Langerin+ 
cells in the human skin.
Figure 2. Maturation of LCs in vitro upon stimulation with the TLR3 ligand pI:C A. Phenotypical 
characterization of human LCs after 16 h of culture in the presence of the indicated TLR ligands. 
The mean fluorescent intensity is depicted for MHC class I, CD86 and CD70. Data represent av-
erage ± SEM of 3 independent skin donors. B. Cytokines produced by human LCs cultured for 
16 h in the presence or absence of indicated TLR ligands. Data represent average ± SEM of 3 
independent skin donors.
Human LCs mature in vitro upon stimulation with pI:C, but are not affected 
upon stimulation with other TLR ligands
We wanted to investigate whether human LCs are able to cross-present antigens 
and induce CD8+ T cell responses. Since cross-presentation has been described to 
be dependent on the maturation status of DCs [34, 35], we investigated the effects 
of various TLR-specific compounds on the maturation of LCs and their cytokine 
responses. As shown in Figure 2A, only the TLR3 ligand pI:C induced an upregulation 
of the co-stimulatory molecules CD86 and CD70 and MHC class I, while the TLR4 
ligand LPS and the TLR7/8 ligands R837 and R848 had no effects (Figure 2A). In 




addition, only pI:C induced an enhanced production of the pro-inflammatory 
cytokines TNF-α, IL-6 and IL-8 (Figure 2B). LCs did not secrete the anti-inflammatory 
cytokine IL-10 either in the presence or absence of pI:C, LPS, R837 or R848 (levels 
below 10 pg/ml; data not shown). So, human LCs mature upon stimulation with the 
TLR3 ligand pI:C, which can be explained by the abundant expression of TLR3 by LCs 
as described in the literature [36, 37]
pI:C treatment enhances the cross-presentation capacity of LCs
In order to investigate the capacity of LCs to cross-present SLPs, we pulsed human 
LCs with a titration of a 16 aa long MART-1 peptide (C-YTTAEELAGIGILTV) containing 
an HLA-A2-restricted epitope (in italics) recognized by a MART-1 specific CD8+ T 
cell clone, in the presence of various TLR ligands. This clone responds to specific 
peptide-MHC-I complexes by the production of IFN-γ. To verify that the 16 aa SLP 
requires antigen processing before loading on MHC class I molecules, a T2 assay 
was performed. The data presented in Figure 3A excludes the possibility of direct 
external loading since the SLP did not stabilize HLA-A2 molecules on the surface 
of the TAP-deficient T2 cell line (Figure 3A). As a positive control, T2 cells were 
incubated with the minimal MART-1 epitope that can directly bind and stabilize 
HLA-A2 on the surface of the T2 cells (Figure 3A). In addition, HLA-A2+ human LCs 
were loaded with the 16 aa MART-1 SLP or the 10 aa minimal MART-1 epitope for 30 
minutes, washed and co-cultured with the MART-1 specific CD8+ T cell clone. Only 
when the LCs were loaded with the minimal epitope, the CD8+ T cells responded by 
secreting IFN-γ (Figure 3B). No T cell activation was observed when the LCs were 
incubated with the 16 aa SLP, indicating that this peptide requires processing before 
it can be presented on HLA-A2 molecules (Figure 3B).
As demonstrated in Figure 3C, human LCs were able to cross-present after 3 h of 
antigen internalization to the MART-1 specific CD8+ T cell clone as measured by the 
secretion of IFN-γ. Moreover, simultaneous administration of MART-1 peptide with 
pI:C resulted in a significant increased activation of the CD8+ T cells, whereas addition 
of LPS, R837 or R848 did not enhance cross-presentation (Figure 3C). Thus, human 
LCs are able to cross present soluble SLPs, which could be further enhanced in the 
presence of pI:C.
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Figure 3. pI:C stimulation of LCs results in superior antigen cross-presentation A. 1x105 T2 
cells were incubated with a 16 aa long MART-1 peptide, the minimal CD8 epitope or no peptide, 
where after the cells were analyzed for the expression of surface HLA-A2 by flow cytometry. Data 
represent average of three ± SD. **p <0.01. B. 2x104 HLA-A2+ LCs were incubated with a 16 aa 
long MART-1 peptide, the minimal CD8 epitope or no peptide for 30 min, washed and co-cultured 
with 1x105 MART-1 specific CD8+ T cells. After 24 h of co-culture, T cell activation was measured 
by IFN-γ ELISA on the supernatants. Data represent average of two experiments ± SD. **p <0.01. 
C. Human LCs were incubated with the synthetic long MART-1 peptide for 3 h and indicated TLR 
ligands, washed and co-cultured with a MART-1 specific CD8+ T cell clone. After 24 h of co-culture, 
T cell activation was measured by IFN-γ ELISA on the supernatants. Data of one representative 
experiment measured in triplicate is shown, n=3. *p<0.05.




Targeting Langerin, but not dectin-1, using SLP-antibody conjugates enhanced 
antigen cross-presentation in LCs
Since human LCs have the capacity to cross-present MART-1 SLPs, which were 
presumably internalized by pinocytosis, we next investigated whether receptor-
mediated internalization would enhance cross-presentation by altering the 
endocytic routing of the antigens. To investigate this, anti-Langerin or anti-dectin-1 
mouse monoclonal antibodies were conjugated to the MART-1 SLP via maleimide-
thiol coupling through the N-terminal Cys on the SLP. Both Langerin and dectin-1 
are expressed on human LCs (Figure 4A) and, as shown in Figure 1, Langerin is a 
specific marker of human LCs, making this receptor a suitable target for LC-targeting 
immunotherapy. Conjugation of the SLPs to anti-Langerin antibodies resulted in 
significantly higher activation of the CD8+ T cell clone (Figure 4B) as compared to 
the SLP alone or conjugated to the anti-dectin-1 antibody or an isotype control, 
indicating that Langerin-targeting enhances cross-presentation by human LCs. 
Furthermore, Langerin-specific responses were further increased when LCs were 
simultaneously exposed to pI:C (Figure 4C). Interestingly, although both dectin-1 
and Langerin were expressed on LCs (Figure 4A), we could not detect any dectin-
1-specific enhancement on cross-presentation as compared to the isotype control 
(Figure 4b and C), suggesting that antigens endocytosed via dectin-1 follow an 
intracellular routing that did not result in proper processing and/or loading to MHC 
class I. In addition, the effect of pI:C is not related to enhanced co-stimulation, as 
can be deduced from Figure 4D, where the no additional effect on IFNg production 
could be observed when MART-1 loaded LCs were stimulated with pI:C. Seemingly, 
dectin-1 or Langerin targeting did not have any co-stimulation-related effects on IFNg 
production (Figure 4D). Together, these data show that only Langerin targeting of 
MART-1 SLPs allowed antigen routing to a cross-presentation compartment, which 
could be enhanced by simultaneous triggering of TLR3.




Figure 4. SLPs conjugated to Langerin result in enhanced cross-presentation to antigen-spe-
cific CD8+ T cells. A. Dectin-1 and Langerin are highly expressed by human LCs as measured by 
flow cytometry. Open histograms: specific antibody; filled histograms: isotype control. Data are 
representative for 3 donors. B+C. MART-1 (CYTTAEELAGIGILTV) peptides were conjugated to an-
ti-Langerin and anti-dectin-1 or mIgG1 isotype control mAbs and incubated with human LCs for 3 
h in the presence (C) or absence (B) of 20 μg/ml pI:C, and co-cultured with a MART-1 specific CD8+ 
T cell clone. Activation of the T cells was measured by IFN-γ ELISA on the supernatants taken after 
24 h of co-culture. Data are representative of two independent experiments and depict average 
± SEM of triplicates. D. Human LCs were incubated with the MART-1 (CYTTAEELAGIGILTV) peptide 
in the presence or absence of anti-Langerin, anti-dectin-1 or 20 μg/ml pI:C for 3h, washed, and 
co-cultured with a MART-1 specific CD8+ T cell clone. Activation of the T cells was measured by 
IFN-γ ELISA on the supernatants taken after 24 h of co-culture.
Langerin routes antigens to specific early endosomes
To investigate the differences in antigen cross-presentation after Langerin and 
dectin-1 targeting, we pulsed LCs using fluorescently-labeled antibodies and followed 
their intracellular localization using the early endosomal marker EEA-1 and the 
lysosomal marker LAMP-1 by imaging flow cytometry. The fluorescence associated 
to the anti-Langerin antibody hardly decreased over time (Figure 5A), while that of 
the anti-dectin-1 antibody rapidly decreased (Figure 5B), suggesting that Langerin 
routes antigens to a less degradative compartment as compared to dectin-1. To 
further confirm this point, we investigated antibody degradation by western blot in 
LC lysates obtained at the abovementioned time-points. Data indeed confirmed a 




faster degradation of anti-dectin antibodies as compared to anti-Langerin (Figure 
5C).
We then investigated the co-localization of each of the CLR-specific antibodies 
with EEA-1+ compartments and observed that dectin-1 had a longer and stronger 
association with EEA-1+ compartments compared to Langerin based on the co-
localization score being close to 1 (Figure 5E and G). The co-localization between 
Langerin and LAMP-1+ compartments or dectin-1 and LAMP-1+ compartments was 
poor and did not differ in time and intensity (Figure 5E and G). Since there was a 
divergence in the degradation of the fluorescence signal and the localization to early 
endosomes, we speculated that dectin-1 and Langerin routed to different types of 
early endosomes with differing degradative capacities. To investigate this, we used 
a 3-color co-localization feature and addressed the co-localization of either EEA1 or 
LAMP1 with dectin-1 and Langerin simultaneously. In resting LCs, both dectin-1 and 
Langerin are expressed on the membrane of LCs, as shown in Figure 4A. However, 
there was a significant proportion of both receptors localized in an intracellular 
compartment, which appeared to be EEA1+ (Figure 5F and Supplementary Figure 4). 
Presumably, this compartment serves as an intracellular depot for quick up regulation 
of both receptors on the membrane of LCs. Interestingly, upon triggering of dectin-1 
and Langerin 3-color co-localization with EEA1 dramatically decreases, suggesting 
that although both receptors are internalized and routed to early endosomes (as 
shown in Figure 5E), they do not coincide in the same endosomes (Figure 5F and 
Supplementary Figure 4). These data indicate that Langerin routes to specific 
EEA-1+ early endosomes that, presumably, are better equipped to facilitate cross-
presentation than the early endosomes where dectin-1 routes to.
Discussion
Within the human skin, at least three main and distinct populations of DCs can be 
identified, namely LCs and CD14+ and CD1a+ dermal DCs. After activation, it has 
been shown that the Langerin+ LCs and dDC subsets are able to migrate to the skin-
draining lymph nodes, where they activate CD4+ and CD8+ T cell responses [38, 39]. 
The precise function of each subset is still under debate, especially with regard to 
antigen cross-presentation. Recently, a minor population of BDCA3+ myeloid DCs has 
been described as homologues of mouse CD8+ DCs and has shown to have superior 
cross-presentation capacity [40-42]. Antigen targeting to CLEC9a, a CLR expressed on 
BDCA3+ DCs, resulted in antigen uptake and (cross-)presentation [43]. However, it has 
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also been shown that human skin resident BDCA3+ DCs can produce IL-10 and induce 
regulatory T cells (Tregs) [44]. In addition, the low numbers of these cells also make 
them less favorable to target for the induction of anti-tumor immune responses.
In this study, we have investigated the cross-presentation capacity of human LCs 
when SLPs were targeted to distinct CLRs. Specific targeting of SLPs to the LC-
specific receptor Langerin, using either antibody- or glycan-modification, resulted 
in enhanced activation of effector CD8+ T cells. These results imply that human LCs 
are a suitable candidate for in vivo targeting of vaccines. Although LCs are located in 
the epidermis of the human skin, administration of a LC-targeting vaccine can also be 
applied intradermally, since intradermally deposited DEC-205 or Langerin antibodies 
have been shown to be rapidly captured by LCs [45].
In our studies, the targeting peptides to Langerin, as well as the targeting of proteins 
to Langerin [46], using monoclonal antibodies resulted in efficient antigen cross-
presentation. In contrast, antigens internalized via the CLR dectin-1 did not allow 
enhanced cross-presentation, showing that the intracellular routing of antigens 
internalized via dectin-1 is different from that of Langerin in LCs. This is supported 
by our imaging flow cytometry data, which demonstrates that dectin-1 routes to 
more degradative intracellular compartments which also did not co-localize with 
Langerin+EEA-1+ compartments. However, it has been shown for in vitro generated 
moDCs that dectin-1 allowed binding and internalization of CMV pp65 expressing 
apoptotic cells and this interaction resulted in cross-presentation to CMV pp65 
specific CD8+ T cells [19], showing the potential of dectin-1, when expressed on DC, 
to facilitate routing of antigen to MHC class I loading compartments. The discrepancy 
between these results and the findings presented in this paper concerning cross-
presentation after dectin-1 targeting, might be explained by the difference in cell 
types, primary LCs versus in vitro generated DCs. Alternatively, it may also be 
attributed to the mode of antigen delivery. In the experiments described here, 
dectin-1 was targeted using monoclonal antibodies conjugated to soluble MART-1 
peptides, whereas in the study of Weck et al. dectin-1 facilitated the uptake of total 
apoptotic cells [19].




Figure 5. Langerin routes to less degradative endosomal compartments in LCs after antigenic 
pulse compared to dectin-1 A+B. Remaining fluorescence of anti-Langerin (A) and anti-dectin-1 
antibodies (B) in a pulse-chase in the presence or absence of pI:C. C+D. Pulse-chase of anti-Lan-
gerin and anti-dectin-1 antibody degradation in LCs by western blotting using an anti-mouse Fc 
peroxidase-labeled antibody. Staining is shown in C, and band intensity quantification in D. E. 
Co-localization of Langerin and dectin-1 with the intracellular compartments EEA-1 and LAMP-1 
after receptor binding and internalization at the cell surface. F. Three color co-localization score 
of Langerin, dectin-1 and EEA-1 or LAMP-1 in resting conditions (left panel) or after receptor 
triggering at the cell surface (right panel) measured by imaging flow cytometry (representative 
images are shown in Supplementary Figure 4). G. Randomly selected LCs representing data 
depicted in E (time-point 15m).
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Dectin-1 is not the only CLR in which the capacity to cross-present is in part 
determined by the mode of antigen delivery. Van der Vlist et al. reported that 
human LCs were not able to cross-present antigens derived from whole measles 
virus (MV) or MV-infected apoptotic cells taken up via Langerin [9]. We have recently 
demonstrated that differences in size of the antigen influences Langerin-mediated 
antigen internalization and cross-presentation in LCs [47]. Bigger nanoparticles were 
less well internalized and cross-presented by LCs compared to small, soluble peptides 
[29]. These findings might explain the discrepancy found between the Van der Vlist 
study and the data presented here: in their study the authors used relatively big 
MV particles and MV-infected cells which were not cross-presented in a Langerin-
dependent fashion, whereas we do show Langerin-mediated internalization and 
cross-presentation of small SLPs in our studies.
This study also showed that cross-presentation by human LCs was enhanced in the 
presence of the TLR3 agonist pI:C. The combined administration of antigens and TLR 
agonists is reported to be necessary to prevent the induction of T cell tolerance. 
Recently the requirement of a potent activator to overcome the tolerogenic state 
of LCs to selectively and specifically induced the activation and proliferation of skin 
resident Tregs has been described [48]. Similar as DCs, in the presence of danger 
signal derived from pathogens, LCs become activated and induced the proliferation 
of effector memory T cells present in the skin and reduced the activity of Tregs [48]. 
It seems likely that the precise function of LCs in vivo might be determined by danger 
stimuli derived from the microenvironment [49].
Altogether, we have shown the capacity of human primary LCs to cross-present 
soluble synthetic long MART-1 peptides. Additionally, cross-presentation by LCs 
was enhanced when cells were concomitantly matured using the TLR3 agonist 
pI:C. Targeting of MART-1 SLPs to anti-Langerin antibodies resulted in further 
enhancement of the activation of MART-1 specific CD8+ T cells through the Langerin-
mediated routing of antigens to less proteolytic early endosomes compared to 
dectin-1-mediated antigen internalization. These results provide a rationale for the 
development of new in-vivo vaccines that target human LCs via Langerin for the 
induction of effective anti-tumor or anti-viral CTL responses.
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Figure S1. Compensation in imaging flow cytometry experiments. A critical step in the analysis 
of imaging flow cytometry data consists of the elimination of fluorescence leakage in neighbouring 
channels. This process is identical to compensation in classical flow cytometry and involves the 
acquisition of single stained samples and the processing of the data with a compensation wizard 
present in the software package IDEAS (Amnis-Millipore). Once a compensation table has been 
generated, it can be applied to the raw data to process images without spectral overlap. In order 
to control that the compensation table has been generated flawlessly, it is applied to the single 
staining controls and proper separation of individual channels is verified, as shown in (A). (B) 
Images were randomly selected from single stained populations to verify that, indeed, only the 
expected channel contained fluorescence.




Figure S2. Imaging flow cytometry analysis strategy. In imaging flow cytometry, images are 
taken from cells as they pass by the detector in a flow system. The objective is calibrated such that 
images are taken at the center of the flow. At the magnification used in the experiments reported 
in this manuscript (60X), the lateral resolution corresponds to approximatey 300 nm, whilst the 
depth of focus is 2.5 μm. Therefore, cells that are slightly off the center of the flow may appear 
out of focus. In order to gate the cells that are properly focused, a necessary condition for further 
analysis, the Gradient RMS feature applied to the Brightfield channel was used, as depicted in 
(A). Gradient RMS measures the sharpness quality of images by detecting large changes (average 
gradient of a pixel normalized for variations in intensity levels) of pixel values in the image. (B) 
Examples of events according to their gradient RMS value. Only those events with values higher 
than 60, were further selected for analysis. (C) Since the amount of LCs was low and a minimum 
cell/rate is needed for proper acquisition, samples were spiked with fixed monocyte-derived 
dendritic cells. LCs could be gated by their high Langerin expression. (D) Randomly selected LCs 
showing expression of Langerin and Dectin-1
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Figure S3. Analysis of co-localization by imaging flow cytometry. Bright Detail Similarity R3 
is a feature designed to compare the small bright image detail of two images (pixel by pixel). 
Mathematically, Bright Detail Similarity R3 is defined as the log transformed Pearson’s correlation 
coefficient of the localized bright spots with a radius of 3 pixels or less within the masked area 
in the two input images. In practice, values higher than 3 are hardly ever obtained. To illustrate 
the range of values that can be obtained using this feature and their biological significance, the 
example of dectin-1 and EEA1 co-localization in monocyte-derived dendritic cells is provided. (A) 
Monocyte-derived dendritic cells were incubated with an anti-dectin-1 antibody (AF647-labeled) 
at 4 ºC for 30 min, washed, and chased for 0, 15, and 45 min at 37 ºC. Cells were then washed in 
ice-cold PBS, fixed in 4 % paraformaldehyde, and further stained as described in the Materials 
and Methods section using the anti-EEA antibody (FITC-labeled). Cells were acquired by imaging 
flow cytometry as described in the Materials and Methods section and analyzed for EEA1 and 
dectin-1 co-localization using the feature Bright Detail Similarity R3 applied to the EEA1 and the 
dectin-1 channels. Results clearly indicate a low co-localization at 0 min (approx. 0.5 ± 0.1), which 
increases dramatically after 15 min (approx. 1.2 ± 0.4), to then moderately decrease at time-point 
45 min (approx. 0.8 ± 0.2). Randomly selected images from each of the different time-points 
demonstrate the absence of co-localization at start (with dectin-1 still clearly present at the cell 
membrane, while EEA1 shows its typical intracellular spotted distribution), a dramatic increase 
in fluorescence overlap after 15 min, which decreases at the last time-point. (B) High resolution 
images were selected to depict dectin-1+ endosomes in the merged images (white arrows). The 
number of endosomes is clearly superior at 15 min, correlating with the values obtained using the 
Bright Detail Similarity R3 feature. 3-color co-localization can be interpreted in a similar way and 
is calculated using the Bright Detail Co-localization 3 feature. Its typical values differ dramatically 
from 2-color co-localization and have a much lower range, hardly ever higher than 0.5.




Figure S4. Representative images depicting 3-color co-localization Images were randomly se-
lected from the experiment as described in Figure 5F.
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TLR4 TRIGGERING PROMOTES 
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DC-SIGN is an antigen uptake receptor expressed on dendritic cells (DCs) with 
specificity for glycans present on a broad variety of pathogens and is capable of 
directing its cargo to MHC-I and MHC-II pathways for the induction of CD8+ and 
CD4+ T cell responses, respectively. Therefore, DC-SIGN is a very promising target 
for the delivery of antigen for anti-cancer vaccination. Although the endocytic route 
leading to MHC-II presentation is characterized to a large extent, the mechanisms 
controlling DC-SIGN targeted cross-presentation of exogenous peptides on MHC-I, 
are not completely resolved yet. In this paper, we used imaging flow cytometry and 
antigen specific CD8+ T cells to investigate the intracellular fate of DC-SIGN and its 
cargo in human dendritic cells. Our data demonstrates that immature DCs and Toll-
like receptor (TLR4) stimulated DCs had similar internalization capacity and were 
both able to cross-present antigen targeted via DC-SIGN. Interestingly, simultaneous 
triggering of TLR4 and DC-SIGN in DCs resulted in the translocation of cargo to the 
cytosol, leading to proteasome-dependent processing and increased CD8+ T cell 
activation. Understanding the dynamics of DC-SIGN-mediated uptake and processing 
is essential for the design of optimal DC-SIGN-targeting vaccination strategies aimed 
at enhancing CD8+ T cell responses.
Keywords: Dendritic cells, DC-SIGN, cross-presentation, imaging flow cytometry, 
TLR, MHCI, T cell, proteasome





DCs are antigen-presenting cells (APCs) that reside in all tissues and use germ-line 
encoded receptors to sample the tissue environment for pathogens. Upon pathogen 
recognition, DCs migrate to secondary lymphoid tissues, while they mature and 
process the internalized antigen, to initiate antigen-specific T cells leading to humoral 
and/or cellular immune responses. Amongst the different receptors used by DCs 
to detect pathogens are C-type lectin receptors (CLRs), a large family of receptors 
that recognize carbohydrates in a Ca2+-dependent manner. Whereas some pattern-
recognition receptors, such as TLRs, are specialized in activating intracellular signaling 
cascades to initiate DC maturation, CLRs primarily mediate pathogen endocytosis via 
internalization motifs present in their cytoplasmic domains [1, 2]. This mechanism 
allows the efficient processing of pathogens for loading on MHC class II and I 
molecules and presentation to CD4+ and CD8+ T cells, respectively. These capacities of 
CLRs make them potent targets for vaccine development, especially for the induction 
of cellular responses for cancer treatment. The first studies on the targeting of CLRs 
have been done using DEC205-specific antibodies (Abs). These studies showed that 
targeting antigens to DCs resulted in prolonged and increased T cell responses when 
administered with an adjuvant. Also the amount of antigen needed for the induction 
of this response in vivo was considerately lower than when free antigen was used [3]. 
The CLR DC immunoreceptor (DCIR), containing an immunoreceptor tyrosine-based 
inhibitory motif (ITIM) and present on a variety of blood and skin DC subsets, also 
mediated increased CD8+ T cells responses. This effect was further enhanced by the 
addition of a TLR 7/8 agonist [4]. DC-SIGN is a type II membrane CLR discovered as a 
cell-adhesion receptor that supports primary immune responses [5] and enhances 
HIV infection of CD4+ T cells [6]. DC-SIGN is expressed on monocyte-derived DCs 
(moDCs) in peripheral tissue, CD14+ dermal DCs in the dermal layers of the skin 
[7] and mature DCs in lymphoid tissues, however DC-SIGN expression is lacking on 
follicular DCs and CD1a+ Langerhans cells [8]. The carbohydrate recognition domain of 
DC-SIGN contains a Ca2+-coordination site and has a dual specificity for high-mannose 
and Lewis-type carbohydrate structures (glycans), which gives the receptor the ability 
to recognize a broad variety of ligands [9], both on pathogens and self-glycoproteins 
[10]. Lectin-glycan interactions have classically been considered to be of low affinity 
[11]. As DC-SIGN is present in nano-clusters on the cell surface [12], the concept of 
avidity is of importance in the design of DC-SIGN-targeting compounds for in vivo 
vaccination strategies. We have explored the possibility of using DC-SIGN-targeting 
glycoconjugates for triggering of T cell responses [13-15] and demonstrated that 
SanneDuinkerken-BNW.indd   59 20-11-2020   12:56:04
60
Chapter 3
DC-SIGN not only induces potent CD4+ T cell responses by targeting antigen to the 
endo-lysosomal pathway [16], but also triggers CD8+ T cell responses that can be 
boosted by supplementing a TLR4 stimulus. Unfortunately, the mechanism by which 
the intracellular routing initiated by DC-SIGN results in MHC-I presentation has not 
been fully identified. Understanding this mechanism will help in designing DC-SIGN-
targeting vaccination strategies for the induction of anti-tumor immunity.
DCs are the most potent APC subset capable of priming naïve CD8+ T cells with 
exogenous antigen, for the induction of immunity against antigens derived from 
tumors or pathogens that do not infect DCs [17, 18]. Although processing and 
presentation of endogenous proteins in MHC-II is quite well characterized, the 
mechanisms by which exogenous antigens are processed and loaded in MHC-I for 
presentation to CD8+ T cells (cross-presentation) are not fully understood. Cross-
presentation efficiency and intracellular routing can differ depending on the mode of 
uptake, the antigen and maturation status of the DC [19]. To date two main routes of 
antigen cross-presentation have been described, namely the cytosolic and vacuolar 
pathway. In the vacuolar pathway the exogenous antigens are processed by proteases 
and reloaded on MHC-I molecules without leaving the endosome. Cross-presentation 
via the vacuolar pathway has shown to be independent of TAP and degradation 
by the proteasome. In contrast, in the cytosolic pathway the exogenous acquired 
antigens translocate to the cytosol and are processed by the proteasome, before 
they are loaded on MHC-I molecules. It remains elusive if loading of MHC-I is done 
by the endogenous MHC-I loading mechanism in the ER or by the recruitment of 
these MHC-I peptide loading complexes to phagosomes and endosomes. [18,19].
Here we used imaging flow cytometry to track DC-SIGN and its ligand in DCs and 
their co-localization with the different compartments involved in antigen processing 
and presentation. To further unravel the intracellular fate of the DC-SIGN ligand 
we treated moDCs with different inhibitors of antigen processing. Our results 
demonstrate that DC-SIGN directs its cargo to early endosomal compartments, 
where the receptor-cargo complex partly dissociates. Since maturation status of 
the DCs can influence CD4+ and CD8+ T cell priming by means of co-stimulation 
and cytokine secretion, TLR agonists are often used as adjuvant to induce proper T 
cell responses. However, TLR stimulation can also influence antigen routing within 
the DCs, thereby changing the cross-presentation capacity [32]. We observed that 
the cross-presentation capacity of DC-SIGN greatly depends on concomitant TLR4 




triggering, which induces translocation of the ligand from the endosomes to the 
cytosol, where it can be efficiently routed for loading on MHC-I and subsequent 
CD8+ T cell presentation.
Materials and methods
Chemicals and Abs
The following reagents were used: E. coli lipopolysaccharide (LPS) (Sigma-Aldrich, 
MO), monophosphoryl lipid A (MPLA) from Salmonella enterica (Invivogen), 
Paraformaldehyde (formaldehyde) aqueous solution (Electron Microscopy Sciences), 
Saponin (Sigma Aldrich), BSA (Roche). Abs used include: CD83-PE (Beckman coulter), 
CD80-PE (clone L307.4, BD biosciences), CD86-PE (clone 2331, BD biosciences), EEA1-
FITC (clone 14/EEA1, BD biosciences), HLA-DM-PE (clone MaP.DM1, BD biosciences), 
LAMP-FITC (clone H4A3, BD biosciences), polyclonal rabbit-α-rab 11 (Invitrogen), HLA-
A2-PE (BD, biosciences) CD107a-AF488 (Biolegend), CD107b-AF488 (Biolegend) Pacific 
Orange-labeled goat-α-rabbit IgG (Invitrogen), AF594-labeled goat-α-mouse IgG2a 
(Invitrogen), AF488-labeled goat-α-mouse IgG2b (Invitrogen), biotin-labeled horse-
α-mouse IgG (Vector Labs). CSRD [8], the polyclonal Ab against DC-SIGN, and AZN-D1 
[5], a murine monoclonal IgG1 Ab against the carbohydrate-recognition domain of 
DC-SIGN, were from our own stocks. DC-28 [20], the monoclonal IgG2a Ab against 
the stalk region of DC-SIGN was a kind gift of R. Doms (University of Pennsylvania). 
AZN-D1 was labeled with AF405 (Invitrogen) according to manufacturer’s instructions. 
AZN-D1 coated fluorescent beads were made as previously described [21]. Gp100 
with a C-terminal cysteine was conjugated to AZN-D1 via thiol mediated conjugation 
using the bifunctional linker SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-
1-carboxylate, Thermofisher Scientific, Breda). Briefly, 5 mg AZN-D1 was activated 
with 8 equivalents of SMCC in 50 mM Phosphate buffer pH 8.3 containing 10 mM 
EDTA and 100 mM NaCl. After desalting the activated AZN-D1 over Sephadex-25 
desalting columns (GE Healthcare Life Sciences, Breda), 12 equivalents of gp100 is 
added and vortexed thoroughly. The reaction is incubated for 1 hour at 37ºC. Final 
product is purified over Superdex 75 column (10x300, GE Healthcare Life Sciences, 
Breda).
Cells
Monocytes were obtained from buffy coats of healthy donors, with informed consent 
(Sanquin, Amsterdam, reference: S03.0023-XT). Monocytes were isolated through a 
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sequential Ficoll/Percoll gradient centrifugation (purity, >85%) and cultured in RPMI 
1640 (Invitrogen) supplemented with 10% FCS (BioWhittaker), 1000 U/ml penicillin 
(Lonza), 1 U/ml streptomycin (Lonza), and 2 mM glutamine (Lonza) in the presence 
of IL-4 (262.5 U/ml; Biosource) and GM-CSF (112.5 U/ml; Biosource) for 4-7 days [22]. 
Monocyte-derived DCs (moDCs) differentiation and maturation was monitored by 
FACS analysis (Calibur, Fortessa BD biosciences) of DC-SIGN, CD83, CD80 and CD86. 
Stable CHO/DC-SIGN transfectants [23] were maintained in RPMI 1640 medium 
containing 10% FCS, 1000 U/ml penicillin, 1000 U/ml streptomycin, 2 mM glutamine, 
and 1 mg/ml geneticin (Invitrogen).
Pulse-chase experiments
Approximately 106 DCs were incubated for 20 min in 100 µl of ice-cold culture 
medium. AF405-labeled AZN-D1 10 µg/ml was added and incubated for 30 min on 
ice. Cells were washed once with ice-cold medium and then transferred to 37ºC for 
indicated time points or kept on ice. At indicated time points, cells were washed 
with ice-cold PBS, fixed in ice-cold 4% PFA in PBS for 20 min and then washed two 
times with ice-cold PBS. For intracellular stainings, cells were permeabilized in 0.1% 
saponin in PBS for 30 min at room temperature and then blocked with a solution 
containing 0.1% saponin, 2% BSA and 1% goat serum in PBS. Primary and secondary 
antibody stainings were performed in PBS with 0.1% saponin and 2% BSA at room 
temperature. After staining, cells were kept at 4ºC in PBS supplemented with 0.5% 
BSA and 0.02% NaN3 until analysis.
Antigen presentation to human CD8+ T-cells
Immature moDCs were seeded in 96-well plates (Greiner) at 20x103 cells/well 
and incubated with the different antigens in the presence or absence of the TLR4 
ligand MPLA (10µg/ml). After 3 hours cells were washed 3 times with RPMI and co-
cultured overnight with a gp100280-288 TCR transduced CD8
+ HLA-A2 restricted T cell 
clone [24] (105 cells per well, E:T ratio 1:5). IFNγ in the supernatant was measured 
by sandwich ELISA according to protocol (Biosource). To determine the effect of 
proteasomal and endosomal inhibitors moDCs (30x103 cells/well) were incubated 
with chloroquine (25 μM, Sigma), MG132 (10 μM, Selleck), epoxomicin (0.25 μM, 
Selleck) or cathepsin S inhibitor (5 μM, calbiochem) at 37°C for 30 minutes prior to 
the addition of antigen and the TLR4 ligand LPS (100 ng/ml). After 3h the moDCs were 
washed and co-cultured with a gp100280-288 TCR transduced CD8
+ HLA-A2 restricted 
T cell clone (10x104 cells per well, E:T ratio 3:1) [24]. Degranulation was analyzed by 




flow cytometry, via the membrane staining of CD107a and CD107b, as a measure 
for T cell activation.
CLSM
Stained cells were allowed to adhere to poly-L-lysine-coated glass slides and mounted 
with anti-bleach reagent vinol. Samples were analyzed using a 63×/1.4 HCX PL APO 
CS oil objective on a TCS SP2 AOBS confocal microscope (Leica Microsystems GmbH). 
Images were acquired using LCS 2.61 (Leica Microsystems GmbH) and processed 
using Adobe Photoshop CS4 or ImageJ.
Live cell imaging
CHO/DC-SIGN cells were cultured on gelatin coated glass slides. AZN-D1 coated beads 
were added to the cells and followed for different time points. Cells were analyzed 
by means of a 3I Marianas™ digital imaging microscopy workstation (Zeiss Axiovert 
200M inverted microscope Carl Zeiss), equipped with a nanostepper motor (Z-axis 
increments 10 nm) and a cooled CCD camera (Cooke Sensicam, 1280 × 1024 pixels 
Cooke Co). Visualization was performed with a 40× air lens. The microscope, camera, 
and data viewing process were controlled by SlideBook™ software (version 4.0.8.1 
Intelligent Imaging Innovations).
Imaging flow cytometry
Cells were acquired on the ImageStreamX (Amnis corp.) imaging flow-cytometer. A 
minimum of 15x103 cells was acquired per sample at 40x magnification at a flow rate 
ranging between 50 and 100 cells/s. Analysis was performed using the IDEAS v6.0 
software (Amnis corp.). A compensation table was generated using the compensation 
macro built in the software and applied to the single staining controls. Proper 
compensation was then verified by visualizing samples in bivariate fluorescence 
intensity plots (Figure S1). A template analysis file to gate for single optimally-focused 
cells (Figure S2) and applied to the experimental samples in order to export this 
population to a new compensated image file to allow merging all experimental 
samples within a single file for direct sample analysis. Ag/receptor internalization 
was investigated using a combination of a mask designed to detect the intracellular 
space and the internalization feature (Figure S3).
Co-localization was calculated using the bright detail similarity R3 feature on a whole 
cell mask. Co-localization is calculated as the logarithmic transformation of Pearson’s 
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correlation coefficient of the localized bright spots with a radius of 3 pixels or less 
within the whole cell area in the two input images (bright detail similarity R3). Since 
the bright spots in the two images are either correlated (in the same spatial location) 
or uncorrelated (in different spatial locations), the correlation coefficient varies 
between 0 (uncorrelated) and 1 (perfect correlation). The logarithmic transformation 
of the correlation coefficient allows the use of a wider range for the co-localization 
score. In general, cells with a low degree of co-localization or no co-localization at 
all between two probes show scores below 1.
mRNA isolation, cDNA synthesis, and real-time PCR
After cell lysis, mRNA was isolated by mRNA Capture kit (Roche) and cDNA was 
synthesized with the Reverse Transcription System kit (Promega) following 
manufacturer’s guidelines. cDNA was diluted 1:2 in nuclease-free water and stored at 
-20°C until analysis. Primers specific for human DC-SIGN (5’-aacagctgagaggccttgga-3’, 
5’-gggaccatggccaagaca-3’), and GAPDH [36] were designed with Primer Express 2.0 
(Applied Biosystems) and synthesized at Invitrogen (Invitrogen). Primer specificity 
was computer-tested (BLAST, National Center for Biotechnology Information) and 
confirmed by dissociation curve analysis. Real time PCR reactions were performed 
using the SYBR Green method in an ABI 7900HT sequence detection system (Applied 
Biosystems) as previously described [25].
Statistics
Unless otherwise stated, data are presented as the mean ± standard deviation of 
at least three independent experiments. Statistical analyses were performed using 
the statistical package SPSS. Statistical significance was set at p < 0.05 and it was 
evaluated by the Mann-Whitney U test.
Results
DC-SIGN is exclusively localized at the cell membrane and is quickly 
internalized upon receptor ligation
We first tested the steady state localization of DC-SIGN on moDCs using imaging flow 
cytometry, a technology that allows for the quantification of morphological aspects of 
images acquired from large populations of cells. The localization of DC-SIGN on fixed 
moDCs was assessed via staining with the anti-DC-SIGN polyclonal Ab CSRD [8], which 
does not interfere with the carbohydrate-binding site of DC-SIGN (see Figure 1A). 




Figure 1. DC-SIGN in immature DCs is exclusively expressed on the extracellular membrane and 
quickly internalizes upon triggering. (A) Summary of the anti-DC-SIGN Abss used in the present 
study. (B) Internalization score of resting immature moDCs, after fixation, permeabilization and 
staining with a polyclonal antibody against DC-SIGN (n > 5000). Next to the histogram, three rep-
resentative images are included with their respective internalization score. (C) Still frames of a live 
cell imaging experiment in which DC-SIGN-CHO cells were exposed to AZN-D1-coated fluorescent 
beads. The right-most frame shows the tracking pattern, representative of 8 experiments. (D) 
Time-course of the median internalization score of moDCs triggered with AF405-labeled-AZN-D1 
(n > 5000). (E) Effect of the AF405-labeled-AZN-D1 concentration on the internalization score after 
30 min at 37°C. The dotted line indicates the internalization of the highest antibody concentration 
after 30 min at 4 °C (n > 5000).
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Figure 2. DC-SIGN and its cargo quickly dissociate upon internalization. (A) Time-course of the 
median internalization score of moDCs triggered with AF405-labeled-AZN-D1 and stained intra-
cellular against DC-SIGN (n > 5000). (B) Scatter plot of the internalization scores of both ligand and 
receptor 7.5 min after triggering with AF405-labeled-AZN-D1 (n > 5000). (C) Time-course of the 
median co-localization of AF405-labeled-AZN-D1 and DC-SIGN (n > 5000). (D) Time-course of the 
fluorescence signal intensity of both AF405-labeled-AZN-D1 and DC-SIGN (n > 5000).
An internalization score higher than 0 indicates that the fluorescent signal is mainly 
localized inside the cell, whereas a negative internalization scores reflects exclusive 
membrane localization. When the intracellular and membrane localization are equal, 
the internalization score is set to 0. In the steady state, DC-SIGN in DCs is exclusively 
expressed on the cell membrane (Figure 1.B), since more than 95 % of the moDCs had 
a negative internalization score. We confirmed the exclusive membrane localization 
of DC-SIGN, using the left over cells from the imaging flow cytometry for confocal 
laser-scanning microscopy (CLSM) imaging (Figure S4). To investigate the kinetics of 
internalization, DC-SIGN was stably transfected in CHO cells, exposed to AZN-D1-coated 




fluorescent beads and followed by live cell widefield epifluorescence imaging. AZN-D1 
is a monoclonal Ab against the carbohydrate-binding site of DC-SIGN and is known to 
trigger receptor internalization (see Figure 1A) [16]. The still frames in Figure 1C, show 
how a bead adheres to the surface of the cell within seconds and is quickly internalized, 
approximately two minutes after receptor ligation.
Because the mechanisms of internalization of particulate and soluble antigen may vary, 
we also investigated the internalization of AF405-labeled AZN-D1. First moDCs were 
incubated in the presence of AF405-labeled AZN-D1 for 30 min at 4°C. Then the cells were 
transferred to 37°C for the indicated time points, washed, fixed and analyzed by imaging 
flow cytometry. The maximum level of AZN-D1 internalization was already achieved at 7.5 
min (Figure 1D), indicating that DC-SIGN internalization is a fast process. To investigate 
whether receptor internalization was dependent on the amount of antigen available, we 
repeated the pulse-chase experiment with a titration of AF405-labeled AZN-D1 and then 
fixed, permeabilized and stained the receptor with CSRD [8]. At 1 µg/ml the amount of 
internalized receptor equaled the amount of receptor on the surface (internalization score 
0) and total internalization was achieved using 5 µg/ml of ligand (Figure 1E).
Subsequently, we tracked both ligand and receptor in a time-course pulse-chase 
experiment using the AF405-labeled AZN-D1 Ab to model the ligand and staining 
with CSRD after fixation and permeabilization to track the receptor. Upon DC-SIGN 
triggering, both ligand and receptor were quickly internalized and DC-SIGN did not 
return to the membrane after internalization (Figure 2A). At an early time-point (7.5 
min), the internalization of receptor and ligand almost perfectly correlated, implying 
an interdependence of both processes (Figure 2B). When the co-localization score 
of the ligand and the receptor was assessed, we observed that the co-localization 
score was maximal at baseline (t=0 min) and decreased very quickly once both ligand 
and receptor were internalized (Figure 2C), indicating that ligand and receptor partly 
dissociate. We also assessed the amount of ligand and receptor at the different time 
points during the experiment. The signal for the ligand decayed by almost 80% during 
the experiment (Figure 2D). By blocking vesicular degradation with chloroquine we 
were able to significantly reduce ligand decay after 30 min (Figure S5), indicating 
that the ligand gets (partly) processed in the endosomes.
We stained for the receptor after fixation and permeabilization of the cells, allowing 
us to detect the total amount of intracellular and membrane associated DC-SIGN. 
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We observed a reduction in receptor signal to approximately 50-60 % of the starting 
amount (Figure 2D). The loss of signal indicates that DC-SIGN gets degraded and does 
not recycle to the membrane. This is supported by previous work of Tacken et al. [26] 
showing that in the presence of the protein synthesis inhibitor cycloheximide barely 
any newly synthesized DC-SIGN molecules re-emerged on the cell surface within 3h 
following DC-SIGN mediated internalization. Even when DC-SIGN was targeted for 
a prolonged period of time (up to 2 days), the surface expression of DC-SIGN was 
significantly decreased. Taken into account that the recycling of receptors is a fast 
process that usually takes places within minutes after receptor internalization our 
results suggest that DC-SIGN is slowly degraded and not recycled, while the ligand 
of DC-SIGN quickly gets processed after internalization.
DC-SIGN directs its cargo through early endosomal compartments before 
dissociation
To investigate the fate of both ligand and receptor, we measured the co-localization 
scores of both ligand (AZN-D1) and receptor (CSRD) (see Figure 1A) with Abs 
commonly used to track endocytic compartments. Until approximately 30 min both 
ligand and receptor co-localized evenly with the early endosomal marker EEA1 (both 
scores around 1.05). Hereafter the co-localization for the receptor dramatically 
decreased, whereas co-localization with the ligand slowly decreased, suggesting 
that ligand and receptor partly dissociate in early endosomes (Figure 3A). This is 
further supported by the LAMP1 (lysosomes) co-localization scores, which show that 
the ligand (but not DC-SIGN receptor) reached the lysosomes before 30 min, while 
peaking at around 45 min (Figure 3B).




Figure 3. Intracellular routing of DC-SIGN and its ligand. MoDCs were pulsed with AF405-la-
beled-AZN-D1 for 30 min on ice and transferred to 37°C. Cells were fixed at indicated time point 
and stained with the CSRD Ab to localize DC-SIGN. Time-course of the co-localization scores of 
AF405-labeled-AZN-D1 (mean ± SEM) and CSRD (DC-SIGN) with (A) EEA1, (B) LAMP1, (C) HLA-DM, 
and (D) Rab11 (n > 5000).
In accordance, the MHC-II compartment co-localized with the ligand (at 30 min score 
1.05), but not with the receptor (30-180 min score 0.6, Figure 3C). Interestingly, 
rab11 shows a moderate co-localization with the ligand (30 min score 1.05), but a 
poor co-localization with the receptor (score 0.6), suggesting that routing to this 
compartment is receptor-independent and may follow upon a stay at the early 
endosomes or the lysosomes (Figure 3D). The decay observed for the receptor in 
Figure 2D might be explained by quick lysosomal degradation, but since there is very 
little co-localization of the receptor with the lysosomal marker LAMP1, degradation 
could also already occur in the early endosomes.Our data indicate an internalization 
model in which DC-SIGN mediates the internalization of its antigen ligand, which ends 
up in early endosomes where the receptor-ligand complex dissociates. The released 
cargo continues its way to lysosomes by the maturation of early endosomes, while a 
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fraction of receptor-ligand complexes possibly translocate to the cytosol to initiate 
MHC-I loading.
Simultaneous DC-SIGN and TLR4 triggering affects DC-SIGN internalization
TLR4 triggering is commonly used to address the effects of DC activation and 
maturation, a process that typically occurs upon pathogen recognition and that is 
necessary for proper antigen processing, presentation and CD8+ T cell priming [27]. 
Additionally, DC-SIGN triggering has been described to elicit a signaling cascade 
that modulates the TLR4-induced signaling [28, 29]. We therefore investigated the 
consequences of DC maturation on DC-SIGN internalization. First, we investigated 
the effect of TLR4-mediated moDC activation on DC-SIGN expression levels. LPS 
treatment of moDCs resulted in a dramatic decrease in both DC-SIGN protein (10-
fold) and mRNA (100-fold) after 18h (Figure 4A). The decrease in DC-SIGN expression 
was not accompanied by an internalization of the receptor, as it was still located on 
the cell membrane (Figure 4B), indicating that DC-SIGN was lost by either shedding 
into the supernatant or by incorporation into exosomes, possibilities that have been 
previously described for DC-SIGN [30,31]. Still, simultaneous triggering of DC-SIGN 
and TLR4 (LPS at t=0) or triggering of DC-SIGN on mature moDCs (overnight LPS 
treatment) had no consequences for the overall internalization rate, which proceeded 
as efficiently on mature moDCs as on immature moDCs (Figure 4C).
Nevertheless, the fate of AZN-D1 ligand differed greatly between the simultaneous 
triggering of DC-SIGN and TLR4 (LPS at t=0) and the triggering of DC-SIGN on matured 
moDCs (o/n LPS) (Figure 4D). While ligand degradation was similar in immature 
moDCs and moDCs that received LPS at t=0, triggering of DC-SIGN on mature moDCs 
showed decreased ligand degradation. MoDCs less than 20% AZN-D1 degradation 
occurred in mature moDCs even after an extended incubation time (6h), compared 
to 70-80% ligand degradation in immature moDCs and moDCs receiving LPS at 
t=0 (Figure 4D). This was consistent with a reduced trafficking of AZN-D1 to the 
lysosomes upon overnight (o/n) treatment with LPS (Figure 4E).




Figure 4. TLR4 triggering affects the routing of DC-SIGN and its ligand. (A) Time-course of the 
expression levels of DC-SIGN at both the mRNA and protein level after TLR4 (LPS) stimulation of 
moDCs. (B) Time-course of the internalization score of DC-SIGN after treatment with a TLR4 ligand 
(LPS). (C) Internalization score of AF405-labeled-AZN-D1 after a 60 min incubation at 4 °C or a 15 
min incubation at 37 °C. (D) Time-course of the fluorescence signal intensity of AF405-labeled-
AZN-D1. (E) Co-localization scores (relative to No LPS) of AF405-labeled-AZN-D1 with LAMP1, 60 
min after triggering. Mean ± SEM (n > 5000). *, P < 0.01 compared to No LPS.
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Simultaneous triggering of DC-SIGN and TLR4 affects the cross-presentation 
route in dendritic cells
To evaluate the effect of TLR4 triggering on cross-presentation after DC-SIGN 
targeting we compared the capacity of antigen pulsed immature moDCs and 
TLR4-stimulated moDCs (t=0), to activate CD8+ T cells. We excluded the DCs 
that were incubated o/n with a TLR4 stimulus, because of their greatly reduced 
DC-SIGN receptor surface expression. Therefore, pre-treatment with a TLR4 
stimulus before antigen administration is not a favorable vaccine strategy when 
targeting DC-SIGN. As an antigen we used a gp100 synthetic long peptide (29-mer, 
VTHTYLEPGPVTANRQLYPEWTEAQRLDC) containing both the gp100280-288 CD8
+ and 
gp10045-59 CD4
+ T cell epitope conjugated to the DC-SIGN-targeting monoclonal 
antibody AZN-D1. A 3h antigen pulse was followed by co-culturing of moDCs o/n 
with gp100280-288 specific CD8
+ T cells, after which the released IFNγ was determined 
as a measure for T cell activation (Figure 5A). moDCs that received TLR4 stimulus 
at t=0 outperformed the immature moDCs in their capacity to activate CD8+ T cells. 
Next we determined the specificity of our DC-SIGN targeting Ab by pulsing immature 
DCs for 3h with gp100/AZN-D1 conjugates, gp100/mIgG1 isotype control conjugates, 
functioning as a negative control, the 29-mer gp100 synthetic long peptide (SLP) and 
the 9-mer minimal epitope that can directly bind to MHC-I. After a 3h antigen pulse, 
gp100280-288 specific CD8
+ T cells were added to the moDCs for 45 min and stained for 
degranulation markers (CD107a and CD107b). moDCs pulsed with the gp100/AZN-D1 
were able to activate antigen specific CD8+ T cells as measured by degranulation 
levels. In contrast, the gp100/mIgG1 conjugate induced no CD8+ T cell activation. The 
SLP as a single non-targeted agent induced degranulation of more than 40% of the 
CD8+ T cells, confirming the robustness of this assay (Figure 5B, Figure S6). Therefore, 
the lower response induced by gp100/AZN-D1 is due to the limited amount of SLPs 
that can be conjugated to the antibody, rather than the sensitivity of the experiment.
The enhanced cross-presentation after TLR stimulation has been described to result 
from the induction of a different antigen-processing route [32-36]. To investigate 
if changes in DC-SIGN ligand routing after TLR4 stimulation is responsible for the 
observed increase in cross-presentation, we investigated the antigen-processing 
route by looking at CD8+ T cell activation after DC antigen loading in the presence of 
relevant inhibitors. For this experiment we incubated immature and LPS-stimulated 
moDCs with chloroquine for blocking of endosomal acidification, Cathepsin S 
inhibitors to block endosomal antigen-processing or MG132 and epoxomicin to inhibit 




proteasomal degradation of antigens. Treatment with the inhibitors mentioned above 
showed only minor differences in viability (Figure S7). Interestingly, the routing of 
antigen in immature and LPS-treated moDCs differed substantially (Figure 5C-D). 
While the activation of CD8+ T cells by immature moDCs was not affected by the 
proteasome inhibitors MG132 and epoxomicin, LPS stimulated moDCs showed 
decreased CD8+ T cell activation in the presence of these inhibitors.
Figure 5. TLR4 triggering facilitates antigen translocation to the cytosol. (A) Immature moDCs 
and moDCs that received a TLR4 stimulus at t=0 (MPLA), were pulsed with gp100/AZN-D1 for 3h 
and subsequently co-cultured o/n with gp100280-288 CD8
+ T cells. IFN γ production was analyzed by 
ELISA as a measure for T cell activation. (B) Immature moDCs were incubated with 0.1% DMSO 
(vehicle), gp100/AZN-D1 (10 µg/ml), gp100 synthetic long peptide (SLP) (10 µM) and the gp100280-
288 9-mer minimal epitope (1 µg/ml) for 3h. Thereafter, moDCs were co-cultured with gp100280-288 
CD8+ T for 45 min and CD107a/b expression on the cell surface was analyzed as a measure for 
CD8+ T cell activation. Groups are significantly different compared to none, vehicle and isotype. 
(C) Immature moDCs and moDCs that received a TLR4 stimulus (LPS) at t=0 (D) were incubated 
30 min prior and during the 3h antigen (gp100/AZN-D1) pulse with 0.1% DMSO (vehicle), chloro-
quine (25 µM), MG132 (10 µM), Epoxomicin (0.25 µM) and Cathepsin S inhibitor (5 µM). Groups 
are significantly different compared to AZN-D1. Data represented in mean ± SD, one-way ANOVA 
was performed , experiments are representative of a N=2 for graph A and B and a N=3 for graph 
C and D (* = P < 0.05, ** = P< 0.01, *** = P< 0.001).
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Also inhibition of the protease Cathepsin S reduced cross-presentation by LPS 
stimulated moDCs, while it did not affect cross-presentation DC-SIGN targeted 
antigens in immature moDCs. This indicates that DC-SIGN-mediated uptake and 
proteolysis of antigen in the endosomes/lysosomes of immature moDCs is not 
dependent on the protease Cathepsin S. In contrast, chloroquine, a drug that inhibits 
acidification of endosomes, significantly reduced CD8+ T activation by both immature 
and LPS stimulated moDCs. When we checked for HLA-A2 molecules on the cell 
surface after the inhibitor treatment we observed a decrease of HLA-A2 expression 
on chloroquine treated moDCs, while the other inhibitors did not affect HLA-A2 
expression (Figure S9). However, the external loading of membrane expressed MHC-I 
molecules with the 9-mer minimal epitope in the presence of inhibitors did not result 
in a decrease in CD8+ T cell activation (Figure S8). Therefore it is difficult to say if the 
observed decrease in CD8+ T cell activation after chloroquine treatment is related 
to the lower expression of HLA-A2.
Surprisingly, we did not observe any enhanced cross-presentation of TLR4-stimulated 
moDCs within the time frame of the degranulation assay (Figure S10), which could 
possibly be explained by the short time window of antigen processing after the 
pulse. These results were further validated by measuring IFN-ɣ secretion after an o/n 
culture with the gp100 specific CD8+ T cells (Figure S11), confirming the enhanced 
CD8+ T cell activation by combining DC-SIGN targeting with a TLR4 stimulus. We 
observed a smaller inhibitory effect of the Cathepsin S inhibitor on CD8+ T cell 
activation. This can be explained by the different time points and assays used to 
analyze the amount of CD8+ T cell activation. The secretion of IFN- ɣ was measured 
in the supernatant after a co-culture of 16h. While the percentage of degranulation 
was analyzed after a 45 min co-culture. In both experiments the cells were treated 
with the inhibitors during the 3h antigen pulse. Thereafter cells were washed and 
co-cultured with the CD8+ T cells. All the inhibitors are reversible, therefore the 
effect can decrease overtime explaining the difference in inhibitory capacity of the 
Cathepsin S inhibitor (Figure S11).
Together our results indicate that the combination of DC-SIGN targeting and TLR4 
triggering leads to the escape of antigen to the cytosol, where it is further processed 
via the proteasome for cross-presentation.





In this study, we investigated the intracellular routing of the CLR DC-SIGN and its 
involvement in loading antigens on MHC-I through cross-presentation. While DC-
SIGN targeting of antigen leads to cross-presentation by both immature and TLR4-
stimulated DCs, we found a major contribution for TLR4 signaling, instigating an 
alternative intracellular cross-presentation route via the cytosol, which resulted in 
an increased capacity of moDCs to activate CD8+ T cells.
Targeting DC-SIGN with antigen conjugated Abs, glycan conjugated antigens or HIV 
virus, a natural ligand of DC-SIGN , results in efficient MHC-II and MHC-I loading 
and CD4+ T cell and CD8+ T cell activation, respectively [15,16,37,38, 39]. This makes 
DC-SIGN an attractive candidate for vaccine targeting strategies. Since vaccination 
strategies also rely on adjuvants inducing DC maturation, such as TLR agonists, 
understanding the intracellular fate of DC-SIGN and its ligand in both immature and 
TLR stimulated DCs is vital for vaccine development.
Previous studies have shown that pathogens and AZN-D1, both binding to the 
carbohydrate recognition domain (CRD), are taken up in a clathrin-dependent manner 
[40,41], while DC-SIGN targeting via the neck region results in clathrin-independent 
internalization [42]. Our data demonstrates that upon targeting the CRD with AZN-
D1, DC-SIGN on immature moDCs is internalized within minutes and directed to early 
endosomes. At this stage, parts of the DC-SIGN-ligand complexes begin to dissociate 
and proceed to late endosomes and lysosomes. Co-localization of the DC-SIGN ligand 
with the receptor was decreased after 15-30 min, which was followed in parallel 
with an increase of the antigen in the lysosomes. This indicates that once DC-SIGN 
ligands are dissociated from the receptor in the early endosomes they are at least 
partly routed to maturing endosomes. Interestingly, the dissociation between the 
ligand and receptor occurs at the maturing endosomes, indicating that ligand and 
receptor follow different intracellular routes. Although DC-SIGN does not return 
to the membrane, we were not able to clarify its intracellular fate upon release 
from its ligand. Nevertheless, the clear fluorescence signal decay and previous 
work showing that prolonged DC-SIGN targeting with AZN-D1 significantly reduced 
the surface expression for up to 48h [26] suggests that DC-SIGN is targeted for 
destruction. Since we observed that DC-SIGN poorly co-localizes with the lysosomes, 
we hypothesize that it is degraded by a different mechanism, which has not yet 
been identified. Endocytosis via DC-SIGN is regulated by a dileucine (LL) motif in the 
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cytoplasmic tail of the receptor [16,43] which might function as potential targets for 
ubiquitination. Different modes of ubiquitination exist that regulate amongst other 
protein degradation [44]. Polyubiquination of the C-type lectin Mannose receptor 
(MR) facilitates antigen translocation from the endosomes to the cytosol [45], 
indicating that this process of receptor ubiquitination is a recognized mechanism, 
whereby C-type lectin receptors redirect their cargo to the cytosol. Possibly DC-SIGN 
also uses this mode of action.
Our data shows an important role for the timing of the maturation stimulus when 
targeting antigens via DC-SIGN for cross-presentation to CD8+ T cells. Triggering 
of TLR4 has been described to lead to an enhanced cross-presentation of soluble 
antigen until 16h after stimulation, while fully matured DCs (LPS for >24 h) showed 
a decreased ability to cross-present antigen [32,33]. Apparently, 16h or 24h of LPS 
stimulation can make a major difference for the ability of DCs to efficiently cross-
present antigen. In our experimental setup, moDCs were stimulated with LPS o/n 
(16h) and therefore should still be in the enhanced cross-presentation phase. In 
fact, we saw decreased shuttling of the ligand to LAMP1 positive compartments in 
line with the findings of Alloatti et al., who showed a decreased phago-lysosomal 
fusion after TLR triggering, resulting in a prolonged retention of the ligand in early 
endosomes, thereby supporting cross-presentation [33]. While LPS did not affect the 
uptake capacity of the DC-SIGN receptor, its expression was dramatically decreased 
on both mRNA and protein level, which would result in an overall decrease in antigen 
uptake. Based on these data, administration of the adjuvant before providing the 
antigen via DC-SIGN targeting would not be a favorable vaccination strategy. Multiple 
studies have described that the enhanced efficiency of cross-presentation after 
TLR triggering is due to a change in antigen routing and processing, like enhanced 
translocation to the cytosol and increased activity of the proteasome [33-36]. To 
investigate if a different route of antigen processing was responsible for the increase 
in cross-presentation, we blocked different molecules known to be important for 
MHC-I and MHC-II presentation in immature DCs and DCs that received a TLR4 
stimulus at t=0. We observed a striking difference in antigen routing as early as 3h 
after antigen pulse. Both the immature and TLR4-stimulated moDCs were sensitive to 
chloroquine, a drug that inhibits endosomal acidification. Unexpectedly, chloroquine 
had a reducing effect on MHC-I expression, making it difficult to conclude if the 
observed effect on CD8+ T cell activation is due to the inhibition of cross-presentation 
or to the reduced expression of MHC-I on the cell surface. moDCs that received 




a TLR4 trigger at t=0 showed a significant dependence on proteasome activity, a 
mechanism not observed in immature DCs. Thus, our results suggest that following 
TLR4 triggering antigens translocate from the endosome to the cytosol, thereby 
entering the cytosolic pathway of cross-presentation. This route of MHC-I loading 
also has been described for natural DC-SIGN ligands (HIV-1 virions) [37]. It has been 
described that TLR triggering can result in antigen translocation from endosomes 
to the cytosol. Dingjan et al. showed that upon LPS triggering the NOX2 complex in 
phagosomes produces reactive oxygen species (ROS) resulting in lipid peroxidation, 
thereby inducing membrane damage and the release of antigen from these ‘leaky’ 
endosomes [34]. This was a rather quick process, already observed 30 min after LPS 
stimulation. Also a role for sec61 in the endosomal escape after TLR triggering has 
been reported [35]. Our results stress the importance of appropriately timing the 
maturation stimulus when targeting antigens to DC-SIGN, as not only the antigen 
enters a more efficient route of cross-presentation, also the fate of the DC-SIGN 
receptor is dependent on maturation status of the DC.
The recycling endosome is characterized, amongst others, by Rab11, which allows 
direct recycling to the plasma membrane but also to the secretory pathway through 
the trans-Golgi network [46]. Our data shows that co-localization of the DC-SIGN 
ligand with Rab11 follows the same pattern as HLA-DM, a molecule associated with 
the MHC-II loading compartment. Since we cannot observe the return of DC-SIGN 
ligands to the plasma membrane and the MHC-II compartment originates from the 
trans-Golgi network, it is likely that Rab11 facilitates a connection between early 
endosomes and the MHC-II loading compartment without further contribution of 
lysosomal degradation.
The regulation of the internalization and intracellular routing of DC-SIGN on DCs 
is an important aspect for the rational design of antibody and glycan-based DC-
SIGN-targeting vaccines [47]. Based on this study, the use of DC-SIGN ligands in 
combination with TLR4 ligands would serve as excellent antigen targeting platforms 
to enhance the antigen cross-presentation in DC-based anti-tumor vaccination 
strategies.
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Figure S1. (left page) MoDCs were fixed and measured by imaging flow cytometry. Once the com-
pensation table was calculated for each of the staining sets, it wasapplied to the single staining 
samples that were acquired using the same settings as experimental samples. Proper compensa-
tion was then verified by visualizing samples in bivariate fluorescence intensity plots. Represen-
tative images are displayed underneath the corresponding dotplots.
Figure S2. (A) After the application of the compensation table, cells were plotted in an area vs 
aspect ratio intensity bivariate scatter plot. Several populations could be identified. Population 1 
was characterized by small area and high aspect ratio intensity. Images from the population 1 gate 
clearly show the events correspond to beads. Population 2 had an average area of approximately 
100 square pixels and high aspect ratio intensity. Images from the population 2 gate show that 
these cells are small single cells with a large nucleus, suggesting these cells could be lymphocytes, 
a common contamination in Percoll-isolated monocyte-derived cell cultures. Population 3 had an 
area between 150 and 300 square pixels and an aspect ratio intensity higher than 0.6. These cells, 
the biggest population, represent dendritic cells in single cell suspension. The remaining popula-
tions (4 and 5) had a larger area and/or low aspect ratio intensity, suggestive of cell doublets and 
aggregates, as demonstrated in the corresponding imagery. (S2B) Gradient RMS on the brightfield 
channel 1 shows that the majority of the cells had a sharp contrast. Images have been selected 
with gradient RMS values across the whole range of gradient RMS values of the population. The 
threshold can then be manually set up in approximately 60.
SanneDuinkerken-BNW.indd   83 20-11-2020   12:56:07
84
Chapter 3
Figure S3. (A) First, a morphology mask is applied to the brightfield channel (channel 1). This mask 
takes the whole perimeter of the cell. Then, 5 pixels are eroded from this mask until the membrane 
of the cell is left out of the mask. The resulting mask is applied to the channel containing the probe 
of interest and a ratio of the intensity inside the mask relative to the total intensity of the cell is 
calculated. (B) moDCs exposed to AZN-D1 for 30 min at 4 ºC show a membrane-bound pattern 
of staining, with a median internalization score of -0.985. When these cells are incubated at 37 
ºC for 2 h, the probe is internalized and the internalization score increases to 1.002. A selection 
of cells with internalization scores ranging from -1 to 1 are depicted as a merge of the brightfield 
(1) and the AZN-D1 (7) channels.




Figure S4. Cells used for Figure 1A were analyzed by CLSM. Sagital, longitudinal and transversal 
two-dimensional sections of a three-dimensional reconstruction are shown. Representative of 
10 cells.
Figure S5. Immature moDCs were pre-treated with chloroquine (50-25 µM) for 30 min at 37˚ 
and pulsed with AF-488-labeled-AZN-D1 (10 µg/ml) for 30 min at 4˚C. Next they were washed 
and transferred to 37˚C for 30 min followed by fixation. Degradation of the ligand was analyzed 
by flow cytometry, N=3. Data is represented in mean ± SD, a two-way ANOVA was performed.
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Figure S6. Representative flow cytometry dot plots of CD8+ T cell degranulation.
Figure S7. Immature and LPS stimulated (t=0) moDCs were treated with the inhibitors: chloro-
quine (25 µM), MG132 (10 µM), epoxomicin (0.25 µM), Cathepsin S inhibitor (5 µM) and 0.1% 
DMSO (vehicle) for 4h and thereafter stained with a viability dye and analyzed by flow cytometry. 
Representative of a N=2.




Figure S8. Immature and LPS stimulated (t=0) moDCs were treated with the inhibitors: chloroquine 
(25 µM), MG132 (10 µM), epoxomicin (0.25 µM), Cathepsin S inhibitor (5 µM) and 0.1% DMSO 
(vehicle) 30 min prior and during the 3h antigen pulse with the 9-mer minimal epitope of gp100 
peptide. Followed by a co-culture with gp100280-288 CD8
+ T cells for 45 min. The degranulation 
markers CD107a/b were stained as a measure of CD8+ T cell activation, N=3.
Figure S9. Immature and LPS stimulated (t=0) moDCs were incubated with chloroquine (25 µM), 
MG132 (10 µM), Epoxomicin (0.25 µM), Cathepsin S inhibitor (5 µM) and 0.1 % DMSO (vehicle) 
for 3h at 37˚C. Thereafter, cells were stained with a α-HLA-A2 Ab and the surface expression of 
HLA-A2 after inhibitor treatment was analyzed by flow cytometry. Representative of a N=2.
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Figure S10. Vehicle control of immature and LPS stimulated (t=0) moDCs. Representative of a N=3. 
(S11) Immature and LPS stimulated (t=0 ) moDCs were incubated 30 min prior and during the 3h 
antigen (gp100/AZN-D1) pulse with chloroquine (25 µM), MG132 (10 µM), Epoxomicin (0.25 µM), 
Cathepsin S inhibitor (5 µM) and 0.1% DMSO (vehicle). Thereafter, moDCs were co-cultured with 
gp100280-288 CD8
+ T cells o/n, IFN γ production was analyzed by ELISA as a measure for T cell activa-
tion. Statistical analysis was performed by executing a one-way ANOVA. Groups are significantly 
different compared to AZN-D1.
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The human skin is an attractive anti-tumor vaccination site due to the vast network 
of dendritic cell (DC) subsets that carry antigens to the draining lymph nodes and 
stimulate tumor specific CD4+ and CD8+ T cells in. Specific vaccine delivery to 
skin DC can be accomplished by targeting glycan coated antigens to C-type lectin 
receptors (CLRs) such as DC-SIGN expressed by human dermal DCs and Langerin 
expressed by Langerhans cells (LCs), which facilitate endocytosis and processing 
for antigen presentation and T cell activation. Although there are multiple human 
skin DC subsets, targeting individual DC subsets and receptors has been a focus in 
the past. However, the simultaneous targeting of multiple human skin DC subsets 
that mobilize the majority of the skin antigen presenting cells (APC) is preferred to 
accomplish more robust and efficient T cell stimulation. Dual CLR targeting using a 
single tumor vaccine has been difficult, as we previously showed Langerin to favor 
binding and uptake of monovalent glyco-peptides whereas DC-SIGN favors binding 
of larger multivalent glyco-particles such as glyco-liposomes.
Methods We used branched polyamidoamine (PAMAM) dendrimers as scaffold for 
melanoma specific gp100 synthetic long peptides and the common DC-SIGN and 
Langerin ligand Lewis Y (LeY), to create multivalent glyco-dendrimers with varying 
molecular weights for investigating dual DC-SIGN and Langerin targeting. Using 
DC-SIGN+ monocyte derived DC (moDC) and Langerin+ primary LC we investigated 
glyco-dendrimer CLR targeting properties and subsequent gp100 specific CD8+ T 
cell activation in vitro. In situ targeting ability to human dermal DC and LC through 
intradermal injection in a human skin explant model was elucidated.
Results Dual DC-SIGN and Langerin binding was achieved using glyco-dendrimers 
of approximately 100kD, thereby fulfilling our criteria to simultaneously target LCs 
and CD1a+ and CD14+ dermal DC in situ. Both DC-SIGN and Langerin targeting by 
glyco-dendrimers resulted in enhanced internalization and gp100 specific CD8+ T 
cell activation.
Conclusion We designed the first glyco-vaccine with dual CLR targeting properties, 
thereby reaching multiple human skin DC subsets in situ for improved anti-tumor 
CD8+ T cell responses.
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Introduction
Dendritic cells (DC) have a unique capacity to endocytose antigens and to activate 
naïve antigen-specific T-cells in the lymph nodes and thus are considered as the 
initiators of adaptive immune responses [1, 2]. Hence, DCs are widely explored 
for targeted anti-tumor immunotherapies. Efficient tumor elimination can be 
accomplished by the simultaneous induction of tumor specific CD4+ and CD8+ T 
cells [3]. CD4+ T cells are activated via recognition of exogenous derived antigen 
loaded in major histocompatibility complex (MHC) class II, whereas CD8+ T cells via 
endogenous derived antigen loaded in MHC class I. For tumor cell killing anti-tumor 
immune responses rely on the induction of cytotoxic CD8+ T cells for which DCs need 
to shuttle endocytosed particles into the cross-presentation pathway to load tumor-
derived epitopes into MHC class I [4]. Various DC subsets have been described to 
have cross-presenting capacity in vivo, and are attractive targets to generate robust 
anti-tumor T cell immunity [4].
An important requirement for intracellular trafficking of antigens is the recognition 
of antigen by uptake receptors such as pathogen recognition receptors (PRR). A 
well-known group of PRRs is the C-type lectin receptor (CLR) family. CLRs have been 
extensively studied for their specific expression on DC subsets, their specificity of 
ligands, often carbohydrates, and their intracellular routing of antigen for loading on 
MHC class I and II for presentation to T cells [5]. It is for this reason that CLRs have 
been used for vaccine delivery of (nano)particles to specific DC subsets using either 
antibody targeting or natural glycan ligands [5]. Multiple CLRs showed potential in 
DC-targeted strategies inducing DC cross-presentation, e.g. DEC205, CLEC9A, the 
mannose receptor (MR) and dendritic cell-specific ICAM-grabbing non-integrin (DC-
SIGN) [6-8]. However, these receptors are often used to target a single DC subset, 
whereas targeting multiple subsets simultaneously may induce superior immune 
responses [9, 10].
In vivo vaccines are often applied in the human skin, since there is a high abundance 
of DCs and intradermal injections have shown to be dose-sparing compared to 
intramuscular delivery [11-13]. Multiple DC subsets reside in the skin with LCs 
populating the epidermis and CD1a+, CD14+ and CD141+ DCs the dermis. CD1a+ dermal 
DC are inducers of cellular T cell responses, CD14+ dermal DC are better equipped to 
activate humoral responses and the CD141+ dermal DC subset is considered the most 
potent cross-presenting DC subset [14]. As such, targeting multiple skin DC subsets 
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simultaneously might elicit broader immune responses compared to single subset 
targeting. Though, it is becoming clear that the function of the different DC subsets 
can change depending on the vaccine format and mode of delivery [15]. Especially 
specific CLR targeting can alter intracellular trafficking thereby influencing choice 
of CLR and DC subset targeting.
Although all subsets express multiple and partly overlapping CLRs, Langerin and DC-
SIGN are two well-defined CLRs expressed by LCs and dermal DCs, respectively. Their 
glycan binding profile is partly overlapping as both recognize the Lewis type antigens, 
though DC-SIGN binds Lewis (Le) A,B , Y and X, whereas Langerin only recognizes LeB 
and LeY. Interestingly, both receptors show high affinity for LeY, making this glycan an 
interesting candidate for dual CLR targeting [16]. Furthermore, both receptors have 
been shown to efficiently deliver their cargo into the cross-presentation pathway, 
especially when combined with toll-like receptor (TLR) triggering [17, 18]. TLRs are 
PRRs expressed by DCs that induce DC-mediated T cell activation via DC maturation 
and modulation of intracellular antigen trafficking in DCs [19]. Combined triggering 
of TLR4 with DC-SIGN targeting resulted in cargo translocation to the cytosol, thus 
releasing it for proteasomal degradation and subsequent MHC I loading [17]. For LCs 
combined targeting of Langerin and TLR3 using poly I:C enhanced cross-presentation 
and subsequent CD8+ T cell activation [18]. Both DC-SIGN and Langerin are excellent 
targets for in vivo intradermal anti-tumor vaccination strategies.
The design of an off-the-shelve vaccine targeting multiple CLRs and skin DC subsets 
is difficult to accomplish via antibody targeting, however natural glycan ligands might 
be an option especially those that are shared by Langerin and DC-SIGN and display 
high affinity binding such as LeY [18, 19]. Vaccine particle formulation can influence 
processing by DCs and subsequent adaptive immune responses [20-22]. Spatial 
orientation of compounds and number of receptor ligands can change CLR binding 
and handling due to changes in avidity [23]. Langerin and DC-SIGN appear to require 
different formulations to meet the needed combination of affinity and avidity for 
ligand endocytosis and cross-presentation. Indeed, our previous work demonstrated 
that relatively small sized glyco-peptides are targeted to Langerin (~3.5kD), whereas 
DC-SIGN preferentially binds large size glyco-particles (200nm) [16]. This illustrates 
that a single glycan LeY structure may be used for Langerin targeting, whereas DC-
SIGN may require multivalent presentation of LeY, such as glyco-liposomes (200nm) 
to accomplish receptor mediated uptake, and the induction of cross-presentation 
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[19]. This different requirement to establish receptor-mediated uptake may be linked 
to functional differences of LCs and DCs to mediate viral and bacterial responses, 
respectively [24, 25]. Moreover these DC subsets express a differential repertoire of 
TLR receptors to trigger maturation, such as viral TLR3 (Poly I:C) on LC and bacterial 
TLR4 (LPS) on dDC [26].
To meet the criteria for dual DC-SIGN and Langerin targeting, we explored different 
glyco-vaccine formulations which have the proper avidity for both receptors. To 
this end, we synthesized two multivalent LeY vaccines incorporating the CD4 and 
CD8 melanoma-specific gp100 antigen using two generations of well-defined, 
commercially available PAMAM dendrimer scaffolds which consist of branched 
subunits of amide and amine functionality [27]. By creating glyco-dendrimers 
with either 4 or 32 functional groups containing the gp100 synthetic long peptide 
and LeY we elucidated dual targeting capacity and subsequent induction of cross-
presentation. We describe generation 3 (G3) glyco-dendrimers simultaneously 
targeting DC-SIGN and Langerin, thereby enhancing gp100 specific CD8+ T cell 
activation when combined with a TLR stimulus. Furthermore, G3 glyco-dendrimers 
target both LCs and CD1a+ and CD14+ dDCs by which we have created the first glyco-
vaccine targeting multiple human skin DC in situ for induction of anti-tumor immune 
responses.
Results
Multivalent Generation 3.0 glyco-dendrimers efficiently target both DC-SIGN 
and Langerin
To design a glyco-vaccine that simultaneously targets DC-SIGN and Langerin, we 
generated two multivalent glyco-dendrimers differing in molecular weight, diameter 
and valency using the generation 0 (G0) or generation 3 (G3) PAMAM dendrimers, 
that have either 4 (G0) or 32 (G3) functional groups. As antigen, we included a 
synthetic long peptide of the melanoma epitope gp100 containing both HLA-DR4 CD4 
and HLA-A02 CD8 restricted epitopes [17]. Coupling of the gp100 peptide to the G0 
or G3 dendrimers (Figure S1A) resulted in antigen specific multivalent dendrimers 
of 16.4kD (G0) (Figure S1B) and approximately 52nm (G3) (Figure S1C). Dendrimers 
were further modified with AF488 for tracking purposes and the targeting glycan 
LeY [16], thereby creating multivalent fluorescent glyco-dendrimers (schematic 
representation Figure S1A). Fluorescent labeling was done such that coupling 
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ensured equal fluorescence and epitope content of total molecules between non-
glycosylated and glyco-dendrimers (schematic representation Figure 1A). Using DC-
SIGN- and Langerin-Fc we confirmed recognition of both G0 and G3 glyco-dendrimers 
by the carbohydrate recognition domain (CRD) of both receptors, whereas the non-
glycosylated dendrimers were not recognized by either soluble receptor in an ELISA 
detection system (Figure 1B). Further, calcium-dependent binding of the dendrimers 
to DC-SIGN- and Langerin-Fc was confirmed using the calcium chelator EGTA. To 
verify whether the membrane organization of DC-SIGN and Langerin, that cluster 
in tetra- and trimers in the membrane respectively, may influence the binding and 
internalization of the different glyco-dendrimers, we made use of an OUW cell-line 
transduced with DC-SIGN or Langerin. After one hour pulse the smaller G0 glyco-
dendrimers did not bind DC-SIGN-expressing OUW cells, but did bind to Langerin-
expressing OUW cells (Figure 1C, left panel). This is in keeping with our previous 
findings that in contrast to DC-SIGN, Langerin has a preference for binding smaller 
molecules [16]. Interestingly, the G3 glyco-dendrimers could efficiently target both 
DC-SIGN and Langerin after one hour incubation (Figure 1C, middle panel). Glyco-
liposomes served as a positive control for DC-SIGN and, as expected, they solely 
bound DC-SIGN and not Langerin as previously shown (Figure 1C, right panel). 
Using blocking antibodies specific for either DC-SIGN or Langerin, we could confirm 
specific binding of G3 glyco-dendrimers to both receptors (Figure 1D). We therefore 
concluded that G3 glyco-dendrimers have all the requirements to serve as skin multi-
DC subset targeting glyco-vaccine via its binding to both Langerin and DC-SIGN.
Enhanced uptake of glyco-dendrimers by moDC and primary LC mediated via 
DC-SIGN and Langerin
To determine whether the uptake of G3 glyco-dendrimers by moDCs and primary LCs 
is also mediated by Langerin and DC-SIGN, we compared uptake of glyco-dendrimers 
to that of non-glycosylated dendrimers. Glyco-dendrimers are efficiently taken up 
by moDCs as compared to non-glycosylated dendrimers within 3 hours at 37 oC, and 
a targeting effect is already evident at low concentrations (Figure 2A). To elucidate 
whether glyco-dendrimers show increased binding and uptake over time compared 
to non-glycosylated dendrimers at constant exposure, we pre-incubated moDC at 
4oC with the respective dendrimers to ensure receptor binding, followed by direct 
incubation up to one hour at 37oC. We observed a clear increase of AF488 signal from 
glyco-dendrimers over-time as compared to non-glycosylated dendrimers, indicating 
that glyco-dendrimers are rapidly bound and internalized by moDC (Figure 2B).
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Figure 1. Generation 3.0 (G3) glyco-dendrimers efficiently target both DC-SIGN and Langerin. 
DC-SIGN and Langerin targeting was evaluated for different glyco-particles using CLR-Fc or a 
cell line transduced with DC-SIGN or Langerin A Schematic representation of (glyco)-dendrimer 
synthesis. B Binding of G0 (upper panels) or G3 (lower panels) (glyco)-dendrimers to human 
DC-SIGN-Fc (left panel) or Langerin-Fc (right panel) in the presence or absence of calcium de-
pletion (EGTA) as measured by binding ELISA. C Binding to membrane DC-SIGN and Langerin of 
different (glyco)-particles within 1 hour at 37 degrees; G0 (grey) or G3 (pink) (glyco)-dendrimers 
and (glyco)-liposomes (blue). D DC-SIGN and Langerin specific binding by G3 glyco-dendrimers 
was evaluated using specific blocking antibodies for DC-SIGN and Langerin, or matched isotype 
control, prior to incubation. Data are representative of at least two independent experiments 
measured in triplicate ±SD (Statistical analysis: B two-way ANOVA Sidak’s post hoc, C-D two-way 
ANOVA Tukey’s post-hoc)
Imaging microscopy confirmed internalization of the glyco-dendrimers by moDC 
following 3 hours incubation at 37 oC (Figure 2C). Involvement of DC-SIGN in enhanced 
uptake by moDC was elucidated using an anti-DC-SIGN antibody known to bind the 
CRD and induce internalization of DC-SIGN.
Prior to incubation with dendrimers, moDC were incubated with anti-DC-SIGN at 
37oC to ensure receptor occupation and partial internalization. Since DC-SIGN is a 
non-recycling receptor, internalized DC-SIGN will no longer be available for ligand 
binding. Interestingly, targeting of glyco-dendrimers to DC-SIGN appeared to be very 
efficient since pre-incubation with anti-DC-SIGN for 30 minutes did not affect binding 
and uptake, which for glyco-liposomes was sufficient (Figure S2A).
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To demonstrate DC-SIGN-mediated internalization of glyco-dendrimers, moDC had 
to be pre-incubated for at least 3 hours using the blocking antibody (Figure 2D). 
Remarkably, a clear blocking effect of glyco-dendrimer uptake was seen when moDC 
were pre-incubated with increasing concentrations of the high affinity ligand of 
DC-SIGN, mannan, confirming that DC-SIGN is indeed responsible for the enhanced 
binding and uptake of glyco-dendrimers by moDC (Figure 2E).
To elucidate whether our compound also targeted Langerin on primary LCs, we used 
LCs obtained by two day emigration from epidermal sheets. Langerin expression 
is lower in emigrated LC compared to steady-state LC, nevertheless, expression 
levels were sufficient to elucidate Langerin targeting (Figure S2B). To track G3 glyco-
dendrimer binding and uptake over time, primary LC were pre-incubated at 4oC for 
45 minutes, followed by incubation at 37oC for multiple time-points. Similar as for 
moDC, we found increased signal for glyco-dendrimers compared to non-glycosylated 
dendrimers already at 15 minutes, indicating rapid binding and uptake by primary LCs 
as confirmed by imaging microscopy (Figure 2F,H). For primary LCs, pre-incubation 
with an anti-Langerin blocking antibody resulted in an almost complete abrogation 
of enhanced glyco-dendrimer uptake (Figure 2G), confirming the targeting ability of 
G3 glyco-dendrimers to Langerin.
Enhanced uptake of glyco-dendrimers by DC-SIGN+ and Langerin+ human skin 
DCs in situ
Since we confirmed Langerin and DC-SIGN mediated targeting and uptake specificity 
by G3 glyco-dendrimers, we set out to explore whether this specificity remained 
when injected in human skin that harbors all the different human skin DC subsets 
expressing DC-SIGN or Langerin. We used a human skin explant model [28] to inject 
the G3 (glyco)-dendrimers and verify targeting to human skin DCs expressing DC-SIGN 
or Langerin. This model represents a steady-state environment with the physiological 
localization, phenotype and ratio of the different human skin DC subsets. As such, 
it supplies the best possible representation of the human skin to study specific DC 
targeting by the glyco-vaccine upon intradermal delivery. Following injection, cells 
were allowed to emigrate for two days and analyzed by FACS. Skin APC subsets 
were defined based on HLA-DR and subset-specific markers CD1a, CD14, CD141 and 
EpCAM (Figure 3A) using manual gating and unsupervised clustering to confirm 
number of subsets. DC-SIGN and Langerin expression was evaluated after two day 
skin DC emigration for all subsets. In concordance with literature we found Langerin 
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on LCs and DC-SIGN expressed by CD14+ dDC and to a very small extent by CD1a+ 
dDC (Figure 3B). As expected, CD14+ dDC
Figure 2. Enhanced glyco-dendrimer binding and uptake by moDC via DC-SIGN and primary LC 
via Langerin Binding and uptake of G3 (glyco)-dendrimers was evaluated for DC-SIGN+ moDC 
and Langerin+ primary LCs. A Dose-response following a 3 hour pulse, wash and 45 minutes 
chase of moDC with G3 (glyco)-dendrimers in the presence (dotted line) or absence (solid line) of 
TLR4 stimulus MPLA. Representative of n=3 measured in triplicate ±SD B Binding and uptake of 
(glyco)-dendrimers over-time by moDC following a 45 minutes pulse (no wash) at 4oC. n=2, ±SD C 
Imaging microscopy of moDC following 3 hour incubation at 37 oC with glyco-dendrimers (green). 
Membrane was stained using anti-CD1a (red) and nucleus using DAPI (white) D-E Involvement of 
DC-SIGN in binding and uptake of G3 (glyco)- dendrimers was evaluated using a 3 hour pre-in-
cubation with anti-DC-SIGN (C) or 30 minutes pre-incubation with the natural ligand mannan (D) 
followed by 1 hour incubation with (glyco)-dendrimers. (C) n=4, each symbol represents a donor 
(D) representative of n=2 measured in triplicate ±SD F Binding and uptake of (glyco)-dendrimers 
over-time by primary LC following a 45 minutes pulse (no wash) on 4oC. Representative of n=2 
measured in triplicate G Langerin involvement in binding and uptake of (glyco)-dendrimers by 
primary LCs was evaluated using 30 minutes pre-incubation an anti-Langerin blocking antibody 
followed by 1 hour co-incubation with (glyco)-dendrimers. Representative of n=3 measured in 
triplicate ±SD H Imaging microscopy of primary LC following 3 hours incubation at 37 oC with 
glyco-dendrimers (green). Membrane was stained using anti-CD1a (red) (Statistical analysis: A,E 
two-way ANOVA Sidak’s post hoc; B,D,F two-way ANOVA Tukey’s post hoc; C one-way ANOVA 
Dunnett’s post hoc)
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Figure 3. Glyco-dendrimers target multiple skin DC subsets for enhanced uptake A Gating 
strategy of human skin DC subsets following injection and two day emigration B DC-SIGN and 
Langerin surface expression on two day emigrated skin DC subsets C-D Binding and uptake of 
(glyco)-dendrimers by human skin DC subsets following in situ injection. n=3 plus representative 
histograms. Each dot represents a donor. (Statistical analysis: two-way ANOVA Dunnett’s post hoc)
and LC showed higher uptake of G3 glyco-dendrimers compared to the non-
glycosylated dendrimers. Interestingly, we found CD1a+ dDC to also efficiently take 
up the glyco-dendrimers (Figure 3C-D) despite their low expression levels of DC-SIGN 
(Figure 3B), suggesting G3 glyco-dendrimers can already efficiently target DC-SIGN 
at lower expression levels. For the Langerin- and DC-SIGN- CD141+ dDCs we did not 
find any enhanced uptake of the glyco-dendrimers (Figure 3C-D). Altogether, these 
data show the ability of G3 glyco-dendrimers to efficiently target multiple skin DC 
subsets in situ.
G3 glyco-dendrimers enhance cross-presentation for tumor specific CD8+ T cell 
activation
To ensure proper delivery for CD4+ and CD8+ T cell activation, we used gp100 specific 
T cell clones recognizing either the CD4 or CD8 minimal epitope. First, we verified 
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activation of CD4+ T cells following overnight co-culture with moDC. We found gp100 
specific CD4+ T cell activation as measured by IFNγ secretion, which increased upon 
glyco-dendrimer pulse both in the absence and presence of TLR4 stimulation (MPLA) 
(Figure S3). To verify whether targeting and enhanced uptake of the G3 glyco-
dendrimers to both DC-SIGN and Langerin results in enhanced CD8+ T cell activation, 
we first verified cross-presentation via DC-SIGN using a DC-SIGN expressing OUW 
cell line and DC-SIGN+ moDC. Briefly, APCs exposed to (glyco)-dendrimers were co-
cultured with a gp100 specific T cell clone recognizing the gp100 HLA-A2 minimal 
epitope and degranulation or IFNγ secretion were subsequently measured (Figure 
4A). We observed that the G3 glyco-dendrimers induced CD8+ T cell activation by 
DC-SIGN+ OUW cells as measured by increased IFNγ secretion, without addition of 
a TLR stimulus (Figure 4B, upper panel). For moDC we have previously shown that 
TLR4 signaling alters routing for DC-SIGN targeted vaccines inducing enhanced CD8+ 
T cell activation compared to untargeted vaccines [17]. To elucidate the influence 
of TLR4 signaling on cross-presentation of the glyco-dendrimers compared to 
non-glycosylated dendrimers, we pulsed moDC in the presence or absence of the 
TLR4 stimulus MPLA followed by a direct short co-culture to avoid influence of 
MPLA induced moDC maturation. MoDC show enhanced degranulation of gp100 
specific CD8+ T cells already after a short co-culture following combined triggering 
of TLR4 (MPLA) with G3 glyco-dendrimer targeting compared to non-glycosylated 
dendrimers (Figure 4C). In concordance, overnight co-culture of gp100 T cells with 
glyco-dendrimer pulsed moDC in the presence of MPLA enhanced IFNγ production 
compared to non-glycosylated dendrimers, but also overall IFNγ production (Figure 
4D). This indicates DC-SIGN expressed by moDC efficiently routes antigens into the 
cross-presentation pathway only under the influence of TLR4 signaling, underlining 
the need for the presence of a potent adjuvant in the vaccine formulation.
Next, we verified whether the enhanced G3 glyco-dendrimer targeting to Langerin 
also resulted in antigen cross-presentation and enhanced CD8+ T cell activation. LC 
derived from MUTZ cells induced increased IFNγ production by gp100 specific CD8+ T 
cells when pulsed with glyco-dendrimers compared to non-glycosylated dendrimers 
(Figure 4D). As primary LCs are the in vivo target, we isolated primary LCs from 
human epidermal sheets to elucidate cross-presentation of G3 glyco-dendrimers in 
combination with the TLR3 stimulus Poly I:C, known to enhance primary LC induced 
CD8+ T cell activation [18]. There was increased IFNγ production by gp100 specific 
CD8+ T cells following o/n culture with G3 glyco-dendrimer-pulsed primary LCs 
compared to primary LCs pulsed with non-glycosylated dendrimers (Figure 4E). 
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This indicates Langerin targeting by G3 glyco-dendrimers on primary LCs routes 
antigens into the cross-presentation pathway for enhanced CD8+ T cell activation. 
Overall, these data show that the enhanced binding and uptake of G3 glyco-
dendrimers by DC via DC-SIGN or Langerin, combined with a TLR stimulus, induces 
an increase in degranulation and IFNγ production by gp100 specific CD8+ T cells.
Discussion
Here, we successfully designed a gp100 melanoma-specific vaccine that targets 
multiple skin DC subsets through its dual specificity for DC-SIGN and Langerin 
receptors. We show that the molecular architecture of the vaccine is essential in 
enabling efficient dual targeting, as conditions for targeting need to be met for two 
different receptors. Generation 3.0 glyco-dendrimers have the ability to target both 
DC-SIGN and Langerin through binding the LeY glycan, thereby reaching LC, CD1a+ and
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Figure 4. Enhanced cross-presentation of glyco-dendrimers by moDC and primary LC A APC 
were pulsed with the (glyco)-dendrimers for 3 hours or 30 minutes, washed and co-cultured with 
a gp100 specific T cell clone for either 45minutes or o/n. CD8+ T cell activation was measured by 
FACS using CD107a/b staining for degranulation or by ELISA for IFNγ secretion in the supernatant 
B IFNγ production of gp100 specific T cells after o/n culture with pulsed OUW cells transduced 
with DC-SIGN (upper panel) or non-transduced (lower panel). Representative of n=2±SD measured 
in triplicate C Degranulation of gp100 specific T cells following 45min culture with 3 hour pulsed 
moDC in the absence (left) or presence (right) of the TLR4 stimulus MPLA. n=3-5, each symbol 
represents a donor. Representative dot plots for MPLA 1µM D IFNγ production by gp100 specific 
T cells following o/n culture with 30 minutes pulsed moDC in the absence or presence of the TLR4 
stimulus MPLA. n=5, each symbol represents a donor. E-F IFNγ production by gp100 specific T 
cells following o/n co-culture with 3 hour pulsed (E) MUTZ-LC or (F) primary LC in the presence 
of TLR3 stimulus Poly I:C. Representative of n=2±SD measured in triplicate. (Statistical analysis: 
C,D two-way ANOVA Sidak’s post hoc, D,E one-way ANOVA Tukey’s post hoc)
CD14+ dDC within the human skin in situ. Combination of glyco-dendrimer targeting 
to DC-SIGN and Langerin with a TLR stimulus resulted in cross-presentation and 
enhanced gp100 specific CD8+ T cell activation, illustrating their great potential for 
intradermal anti-tumor vaccination strategies and shedding additional light on the 
requirements for glyco-vaccine formulation.
Although DC-SIGN and Langerin have overlapping glycan binding specificity, their 
internalization and intracellular processing differs greatly. Despite their difference 
in intracellular compartmentalization, different studies showed that both receptors 
process antigen intracellularly for cross-presentation. However, our earlier work 
showed induction of cross-presentation by Langerin via small glyco-peptides, 
whereas by DC-SIGN via large glyco-liposomes [16]. Interestingly, often viruses and 
bacteria use DC-SIGN to either escape the immune system or alter T helper cell 
responses via intracellular signaling cascades [29]. In contrast, Langerin-mediated 
uptake of viruses such as HIV and fungi mediates clearance [30], which might be due 
to the specific formation of Birbeck Granules upon Langerin-mediated internalization. 
Birbeck Granules are subdomains of the endosomal recycling compartment [31] that 
regulate antigen degradation differently from other endocytic compartments. [32, 
33]. These discrepancies might explain why until now no glyco-vaccine has been 
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developed with the capacity to target both receptors simultaneously whilst inducing 
cross-presentation.
Interestingly, DC-SIGN can also be efficiently targeted for in vivo cross-presentation 
via LeX coupled glyco-dendrimers with increasing multivalency, a technique not 
yet explored for Langerin targeting [34]. In this study, we used PAMAM dendrimer 
scaffolds to create two formulations of melanoma-specific glyco-dendrimers that 
differed in molecular weight to investigate targeting properties to both DC-SIGN and 
Langerin. The smallest G0 glyco-dendrimers with four functional groups only showed 
targeting ability towards Langerin and not DC-SIGN, whereas higher multivalency G3 
glyco-dendrimers harboring 32 functional groups showed binding to both receptors 
on the cellular membrane. Targeting with G3 glyco-dendrimers resulted in enhanced 
binding and uptake for both moDC and primary LC over time. Interestingly, low 
generation PAMAM dendrimers have high flexibility [27, 35] and efficient binding 
to Langerin and DC-SIGN may require membrane movement of the CLRs explaining 
enhanced binding at 37oC.
Membrane organization of DC-SIGN can affect glycan-coated ligand binding, as 
shown for synthetic hyperbranched polymers containing mannose, but also viral 
entry [36, 37]. Interestingly, our results show that the same targeting moiety on 
different formulations of cargo can alter targeting properties to a single receptor. 
Using previously described glyco-liposomes known to target DC-SIGN [16] we found 
efficient blocking when moDC were simultaneously incubated with the common 
blocking antibody AZN-D1. Strikingly, for G3 glyco-dendrimers the strong binding 
to moDC showed partial DC-SIGN blocking with the AZN-D1 antibody, whereas 
pre-incubation with the high affinity natural binding ligand mannan [38] efficiently 
blocked the binding and uptake of glyco-dendrimers by DC-SIGN+ moDC, indicating 
high binding efficiency of G3 glyco-dendrimers to DC-SIGN. Although mannan can 
also bind to other receptors such as the mannose receptor (MR), our glycan of choice 
(LeY) is high affinity for DC-SIGN and thus binding to other receptors on DC is unlikely. 
[39]
Glyco-dendrimer targeting to primary LC was considerably lower compared to moDC, 
possibly due to lower expression levels of Langerin. MoDC have high expression of 
DC-SIGN, whereas primary LCs, migrated from the epidermis for two days, show 
decreased Langerin expression levels (Figure S2B). The phagocytic capacity of the 
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different cell types can also be important for in situ targeting, since DC-SIGNhigh CD14+ 
dDC showed greater glyco-dendrimer uptake compared to DC-SIGNlow CD1a+ dDC and 
epidermal LCs. CD14+ dDC are considered to have a monocytic lineage background 
[40] and hence may have higher phagocytic capacity compared to other skin DCs, 
as represented by moDC.
Anti-tumor vaccination strategies aim to induce cross-presentation for the priming 
of tumor-specific CD8+ T cells and effective tumor cell killing. In murine models, 
XCR1+ DCs, present in lymph nodes and peripheral tissues, have been postulated as 
potent target candidates for induction of cytotoxic T cell responses [41] and anti-
tumor immune responses [42]. The dermis of human skin contains CD141+ cross-
presenting DCs, which are considered to be the homologue of murine CD103+XCR1+ 
dermal DCs [43]. Nonetheless, we did not observe in situ targeting towards CD141+ 
dDCs by the G3 glyco-dendrimers, consistent with their lack of DC-SIGN or Langerin 
expression. Although this skin DC subset is considered a potent target candidate for 
induction of cytotoxic anti-tumor immune responses [44], it represents a minority of 
the total dermal DC pool. In contrast, we show efficient G3 glyco-dendrimer targeting 
towards LCs and the larger pool of CD1a+ and CD14+ dDCs. Targeting of LCs and CD14+ 
dDCs via Langerin and DC-SIGN, respectively, can induce cross-presentation when 
different glyco-vaccines are used [8, 18, 28]. Here we show that G3 glyco-dendrimers 
are cross-presented via both DC-SIGN and Langerin when combined with a TLR 
stimulus, thereby enhancing gp100 specific CD8+ T cell activation. Combining CLR 
targeting with TLR stimuli can induce cross-talk and alter the intracellular fate of CLR 
bound cargo. We previously showed that simultaneous TLR4 and DC-SIGN triggering 
translocated DC-SIGN cargo into the cross-presentation pathway, most likely via 
endosomal escape and proteasomal degradation [17]. Also combined activation of 
Langerin and TLR3 enhanced CD8+ T cell activation [18], but a direct link between 
Langerin and TLR3 signaling for cross-presentation has not yet been demonstrated.
Combination of glycan CLR targeting and TLR stimulation is gaining interest in 
the vaccination field as it can elicit superior humoral and cellular immunity when 
incorporated within a single vaccine particle [45, 46]. Our dual CLR targeting G3 
glyco-dendrimers have the potential for adjuvant coupling, which is an interesting 
feature for future research into glyco-adjuvant vaccines for intradermal anti-tumor 
vaccination strategies. Furthermore, recent advances in anti-tumor immunotherapies 
show the importance of neo-antigens and CD4+ T cell help for induction of long 
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lasting anti-tumor CD8+ T cell immunity [47, 48]. The high branched multivalent 
G3 glyco-dendrimers allow inclusion of multiple TAA, such as neo-antigens and 
combined CD4 and CD8 restricted epitopes, thereby generating a highly diverse 
vaccine platform. Here we already combined the melanoma specific gp100 HLA-DR4 
and HLA-A2 restricted epitopes for activation of both CD4+ and CD8+ gp100 specific 
T cells (Figure S3 and figure 4).
Evaluating the therapeutic efficacy and immune responses induced upon multiple DC 
subset targeting of our newly designed glyco-vaccine would be of great importance. 
However, since we specifically designed a glyco-vaccine for dual targeting of DC-
SIGN and Langerin on human skin DC, a murine model with comparable expression 
by similar DC subsets is imperative. Although the murine CD209a/SIGNR5, or mDC-
SIGN, displays some similarities to the human counterpart [49] the glycan binding 
profile has not been studied. As such, a humanized DC-SIGN murine model would 
be needed to evaluate in vivo efficacy of our glyco-vaccine specifically designed to 
target human DC-SIGN. While a humanized DC-SIGN murine model is available, it 
harbors DC-SIGN expression under the CD11c promotor thereby containing multiple 
hDC-SIGN+ DC subsets [50]. Unfortunately, this renders the model unsuitable for the 
glyco-vaccine of this study since human skin has restricted DC-SIGN expression to 
CD14+ and CD1a+ dermal DCs (Figure 3B).
In summary, we designed an intradermal glyco-vaccine simultaneously targeting 
multiple human skin DC subsets in situ. Simultaneous targeting was accomplished by 
the use of G3 glyco-dendrimers targeting both DC-SIGN and Langerin, which enhanced 
activation of gp100 specific CD8+ T cells in combination with TLR stimulation. These 
promising results pave the way for future studies investigating the in vivo behavior 
of G3 glyco-dendrimers following intradermal vaccination and induction of systemic 
anti-tumor immune responses via dual DC-SIGN and Langerin targeting.
Material and methods
Cells
OUW, OUW-DC-SIGN and OUW-Langerin B cell lines were cultured in RPMI (Invitrogen, 
USA) supplemented with 10% FCS (Lonza), 50U/ml penicillin, 50ug/ml streptomycin, 
2mM glutamine (all BioWhittaker, USA) (complete RMPI).
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Monocytes were isolated from buffy coats (Sanquin, The Netherlands) using serial 
Ficoll/Percoll gradient centrifugation and cultured in complete RPMI. For human 
moDC differentiation and DC-SIGN expression, rhGM-CSF plus rhIL-4 (500U/ml; 
Biosource, Belgium) were added for 4-6 days.
Primary LCs were isolated from human skin explants (Bergman Clinics, Bilthoven, 
The Netherlands) obtained within 24 hours following abdominal resection of 
healthy donors with informed consent. Part of the epidermal and dermal sheet 
(5-mm thickness) were removed using a dermatome blade (Zimmer, Germany), 
rinsed with PBS plus gentamycin (10µg/ml; Lonza) and incubated in serum free 
IMDM supplemented with 50U/ml penicillin, 50ug/ml streptomycin, 2mM glutamine, 
gentamycin and dispase II (1mg/ml, Roche Diagnostics) for 2 hours at 37oC. The 
epidermal sheet was separated from the dermis using tweezers, followed by two 
day culture in IMDM supplemented with 10% FCS, penicillin, streptomycin, glutamin, 
gentamycin (complete IMDM skin medium) and rhGM-CSF (500U/ml) for LC migration 
at 37oC. LCs were harvested and purified using a Ficoll gradient (>85%). For purity 
evaluation LCs were incubated with anti-human antibodies against HLA-DR (clone 
G46-6, BD Biosciences), CD1a (clone HI149, BD Biosciences) and Langerin (clone 
10E2, Biolegend).
MUTZ-LC were kindly provided by Prof. dr. S. Gibbs and cultured as previously 
described [51]. Cells were used when >70% were CD1a and Langerin positive.
The retroviral TCRαβ transduced T cell clone specific for the gp100280-288 HLA-A2 
minimal epitope (YLEPGPVTA) [52] and HLA-DRB1*0401-restricted T cell line Bridge 
gp:44 B8 [53] were cultured in IMDM medium (Invitrogen), supplemented with Yssel’s 
medium (20 μg/ml human transferrin (Boehringer), 5 μg/ml insulin (Sigma-Aldrich), 
2 μg/ml linoleic acid (Calbiochem), 2 μg/ml palmitic acid (Calbiochem), 0.25% BSA 
(Sigma-Aldrich), and 1.8 μg/ml 20-amino ethanol (Sigma-Aldrich)), 1% human serum 
(Sigma-Aldrich) and penicillin, streptomycin, glutamin. Cells were expanded for 10-12 
days in the presence of IL-2 (100IU/ml; Peprotech) and PHA-L (2µg/ml; Sigma) prior 
to storage in liquid nitrogen. For co-cultures T cells were either used at day 12 in 
expansion or thawed and rested for at least 6 hours before co-culture.
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FACS staining, measurement and analysis
A pre-mix of surface marker antibodies diluted in PBS plus 0,5% BSA (0,5% PBA; 
Roche) was prepared prior to incubation for 30 minutes on ice. Unbound antibodies 
were washed away with PBS, followed by fixation using 4% paraformaldehyde (PFA; 
Electron Microscopy Science) for 20 minutes on ice. Next, cells were washed two 
times with PBS and resuspended in 0,5% PBA for measurement using the FACS 
Fortessa-X20 (BD). Analysis was performed with FlowJo 10 software (Tree Star, 
Ashland, OR, USA).
Peptide synthesis
Thz-VTHTYLEPGPVTANRQLYPEWTEAQRLD-(Abu)3-C peptide was synthesized at the 
GlycO2pep unit at our lab by microwave assisted solid phase peptide synthesis using 
Fmoc chemistry on a peptide synthesizer (Liberty blue peptide synthesizer, CEM). 
The peptide was deprotected with 92.5% TFA, 2.5% MilliQ, 2.5% TIS and 2,5% EDT 
cleavage solution. After collection, the peptide was lyophilized and purified on a 
preparative Ultimate 3000 HPLC system (Thermo Fisher) over a Vydac 218MS1022 
C18 25x250mm column (Grace Vydac). Mass and purity were confirmed by UHPLC-
MS on a Ultimate 3000 UHPLC system (Thermo Fisher) hyphenated with a LCQ-Deca 
XP Iontrap ESI mass spectrometer (Thermo Finnigan) using a RSLC 120 C18 Acclaim 
2.2um particle 2.1 x 250 mm column and ionizing the sample in positive mode.
Glyco-dendrimer synthesis
G0/G3-Gp100-AF488-Lewis Y constructs were synthesized via thiol-ene mediated 
reactions. In short, PAMAM generation 0 or 3 dendrimer (Sigma) were functionalized 
with maleimide or LC-SMCC bifunctional crosslinker (ThermoFisher), respectively. 
After purification, the dendrimer was loaded with GP100 long synthetic peptide Thz-
VTHTYLEPGPVTANRQLYPEWTEAQRLD-(Abu)3-C through its C- terminal cysteine. After 
removing the excess peptide, labelling and glycation was achieved by unmasking the 
N-terminal thioproline (Thz; Novabiochem) and reacting it with AF488 (Invitrogen) 
/Lewis Y (Elicityl) pentasaccharide maleimide. G0 dendrimer MW was determined 
using mass spectrometry. Particle size of G3-PAMAM-GP100, dissolved in MilliQ at 
0.1 mg/ml and 0.05 mg/ml, was determent using a dynamic and static light scattering 
measurement (Malvern Zetasizer Nano S, Breda, Netherlands). The average of 3 
measures was used to calculate the particle size. These measurements indicate that 
the average particle size of our peptidic dendrimer is 52.03 nm.
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Binding ELISA DC-SIGN-Fc and Langerin-Fc
DC-SIGN-Fc and Langerin-Fc were obtained as previously described [54]. Dendrimers 
with and without LeY conjugation were coated on NUNC maxisorb plates (Roskilde) 
o/n at 4oC. Following removal of free dendrimers with TSM for DC-SIFN-Fc or HBSS 
(Invitrogen) for Langerin-Fc wash, wells were blocked using 1% BSA (Fraction V, 
Fatty acid free, PAA laboratories) in TSM or HBSS. Next, dendrimers were incubated 
with 2µg/ml DC-SIGN-Fc or Langerin-Fc diluted in TSM or HBSS plus 0,5% BSA, 
respectively, for 2 hours at RT. After 3 washes, binding was detected using a HRP-
labeled F(ab’)2 goat anti-human IgG specific antibody. HRP binding was visualized 
using 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (Sigma Aldrich) followed by 
measurement at 450nm.
Binding and uptake assays
Triplicates of 5x104 cells were plated in a 96-U bottom plate (Greiner) and incubated 
with AF488 conjugated (glyco)-dendrimers or vehicle control (max. 0,2% DMSO) 
diluted in serum free IMDM for LCs and complete RPMI for moDCs. When indicated 
cells were pre-incubated for 1 hour at 4oC, followed by incubation at 37oC for 
indicated time-points. Next, cells were stained with a fixable viability dye eFluor780 
(FVD; eBioscience), anti-human HLA-DR BV510, CD1a APC (clone HI149; BD) (moDC) 
and EpCAM BV421 (clone EBA-1; Biolegend) (LCs). Binding and uptake was analyzed 
using FACS.
For antibody blocking assays cells were pre-incubated with 20µg/ml mouse-anti-
human IgG1 Langerin (10E2) or DC-SIGN (AZN-D1) for 30 minutes at 37oC, followed 
by addition of (glyco)-dendrimers for 1 hour at 37oC with blocking antibodies at a 
final concentration of 10µg/ml. For 3 hour pre-incubation cells were incubated with 
a 10x serial dilution starting at 10µg/ml AZN-D1, washed and cultured for 1 hour 
with (glyco)-dendrimers at 37oC. Liposomes with LeY were taken along as positive 
control for AZN-D1 blocking assays. For DC-SIGN block using mannan moDC were 
pre-incubated for 30 minutes with a 10x serial dilution starting at 100µg/ml, followed 
by co-incubation with 0,01µM (glyco)-dendrimers.
Imaging microscopy
MoDC or primary LC were pulsed for 3 hours with glyco-dendrimers at 37 oC, as 
described above. Cells were transferred to ice and stained with anti-human CD1a-
biotin (clone HI149; Biolegend) for 30 minutes, washed and subsequently stained 
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using streptavidin-AF555 (Invitrogen) for 30 minutes on ice. Next, cells were washed 
in ice cold PBS and fixed with 4% PFA for 20 minutes on ice prior to nuclei stain using 
DAPI for 10 minutes at RT. Cells were mounted on slides using MoWIOL. Z-stack 
images were taken with the Leica DM6000 at 63x magnification and images were 
analyzed using Imaris Software.
Antigen presentation assay
APC were seeded in 96-wells plates at a concentration of 2x105/ml and pulsed with 
(glyco)-dendrimers or DMSO vehicle control in complete medium for 3 hours at 37oC. 
MoDC were pulsed in presence or absence of 10µg/ml MPLA (Invivogen) and primary 
LCs of 20µg/ml Poly I:C (Invivogen). Pulsed APC were washed and co-cultured with 
the gp100280-288 specific T cell clone. For T cell degranulation, moDC were washed 
two times at 900rpm to remove free products and co-cultured with gp100 T cells in 
a 3:1 effector to target ratio for 45 minutes at 37oC. To measure degranulation cells 
were stained with a FVD, anti-human CD8 BV421 (clone RPA-T8, BD), CD107a (clone 
H4A3, Biolegend) and CD107b Fitc (clone H4B4, Biolegend).
For IFNγ production by T cells, moDC were pulsed for 30 minutes and LC for 3 
hours at 37oC and co-cultured in a 1:5 effector to target ratio for 16-21hours. IFNγ 
production was measured in supernatant using human cytokine ELISA (IFNγ Ready-
Set-Go kit, eBioscience) according to manufacturer’s protocol. Incubation with a 
short peptide containing the HLA-A2 minimal epitope was used to set maximum 
activation levels per experiment.
In situ human skin DC targeting
Human skin explants (obtained as described above) were prepared by cleaning with 
PBS supplemented with gentamycin. Products were diluted in serum free IMDM prior 
to injection. Insulin needles were used to inject 20µl/biopsy i.d. at 66pmol/ml so a 
small blister appeared. A punch biopsy (8mm; Microtec) surrounding the blister was 
taken and 8 biopsies per condition were cultured with the epidermis facing upwards 
in a 48-wells-plate with 1ml IMDM complete skin medium for 48hours. Biopsies were 
discarded and crawl-out cells harvested and pooled per condition prior to FACS 
staining. To distinguish the different emigrated skin DC subsets cells were stained 
using the following anti-human antibodies: HLA-DR BV510, CD1a APC, CD14 AF700 
(clone M5E2, Sony), CD141 BV711 (clone 1A4, Biolegend), EpCAM BV421 and FVD. 
For DC-SIGN and Langerin expression levels extra biopsies were taken and emigrated 
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DCs stained with above cocktail plus anti-DC-SIGN AF488 (AZN-D1; own production) 
and anti-Langerin PE (10E2; Biolegend).
Statistical analysis
Statistical analysis were performed using Graphpad Prism version 7.02 software (San 
Diego, CA). Statistical significance was determined using one- or two-way ANOVA 
followed by Tukey’s, Sidak’s or Dunnett’s post hoc analysis as indicated per graph 
in figure legends. Data are represented as mean ±SD or symbol per donor. ns = not 
significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Abbreviations
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Supplementary material and methods
MPBH functionalization of Lewis Y pentasaccharide - The bifunctional cross-
linker (4-Nmaleimidophenyl) butyric acid hydrazide (MPBH) was covalently linked 
to the reducing end of the Lewis Y pentasaccharide via reductive amination. Briefly 
1 equivalent of Lewis Y pentasaccharide (50 mg, 0.06 mmoles ) was dissolved in 
1 ml 20% acetic acid in DMSO containing 2.7 equivalents of MPBH (50 mg, 0.16 
mmoles). 5.4 Equivalents of 2-Methylpyridine borane complex (34 mg, 0.32 mmoles) 
was added as reductant and the mixture was incubated at 650C for 2 hours. After 2 
hours 3 ml DCM is added and vortexed thoroughly. 10 ml Diethyl ether is added to 
precipitate further the MPBH activated Lewis Y pentasaccharide. After pelleting by 
centrifugation and pellet was washed 2 times more with diethyl ether. The activated 
glycan was dissolved in 0.1% TFA-MilliQ, lyophilized and subsequently purified on a 
preparative Ultimate 3000 HPLC system (Thermo Fisher) over a Vydac 218MS1022 
C18 25x250mm column (Grace Vydac). Mass and purity were confirmed by UHPLC-
MS on a Ultimate 3000 UHPLC system (Thermo Fisher) hyphenated with a LCQ-Deca 
XP Iontrap ESI mass spectrometer (Thermo Finnigan) using a RSLC 120 C18 Acclaim 
2.2um particle 2.1 x 250 mm column and ionizing the sample in positive mode.
G0-PAMAM-Maleimide synthesis -To a solution of ethylenediamine core PAMAM 
Generation 0.0 dendrimer (15.4 mg, 29.81 µmoles) in 1 ml anhydrous DMSO was added 
to 5 equivalents of (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) (50 
mg, 149.05 µmoles). After thoroughly vortexing 15 uL of 2,4,6-Trimethylpyridine was 
added in 5 aliquots of 3 µL over 30 minutes. The reaction mixture was placed on a shaker 
for 1 hour at room temperature. Subsequently the reaction mixture was transferred 
into a 50 ml falcon tube and 20 ml DCM was added. After vortexing thoroughly 25 ml 
Diethyl ether mixture was added to precipitate maleimide functionalized dendrimer. G0-
PAMAM-maleimide was pelleted by centrifugation and washed 3 times with diethyl ether. 
Final product was dissolved and purified on a preparative Ultimate 3000 HPLC system 
(Thermo Fisher) over a Vydac 218MS1022 C18 25x250mm column (Grace Vydac). Mass 
and purity were confirmed by UHPLC-MS on a Ultimate 3000 UHPLC system (Thermo 
Fisher) hyphenated with a LCQ-Deca XP Iontrap ESI mass spectrometer (Thermo Finnigan) 
using a RSLC 120 C18 Acclaim 2.2um 2.1 x 250 mm column. Mass spectrometer analysis 
was measured in positive mode.
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G3-PAMAM-LC-SMCC synthesis - To a solution of ethylenediamine core PAMAM 
Generation 3.0 dendrimer (16.08 mg, 2.33 µmoles) in 1 ml anhydrous DMSO was 
added to 48 equivalents of (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxy-(6-amidocaproate)) (50 mg, 149.05 µmoles). After thoroughly vortexing 15 
uL of 2,4,6-Trimethylpyridine was added in 5 aliquots of 3 µL over 30 minutes. 100 µL 
of 3% TFA in MilliQ was added to the reaction mixture and product was purified on 
a preparative Ultimate 3000 HPLC system (Thermo Fisher) over a Vydac 218MS1022 
C18 25x250mm column (Grace Vydac). Fractions containing the product were pooled 
and lyophilized.
G0/G3-gp100-Thz synthesis - To a solution of G0-PAMAM-maleimide (3.7 mg, 2.66 
µmoles) or G3-PAMAM-maleimide (5.8 mg, 0.331 µmoles) in 1 ml anhydrous DMSO 
either 5 (G0) or 40 (G3) equivalents of Thz-VTHTYLEPGPVTANRQLYPEWTEAQRLD-
(Abu)3-C peptide (50 mg, 13.24 µmoles) were added in a 15 ml falcon tube. After 
thoroughly vortexing 15 uL of 2,4,6-Trimethylpyridine was added in 5 aliquots of 
3 µL over 30 minutes. The reaction mixture was placed on a shaker for 3 hours at 
room temperature in the dark. 100 µL of 3% TFA in MilliQ was added to the reaction 
mixture and product was purified on a preparative Ultimate 3000 HPLC system 
(Thermo Fisher) over a Vydac 218MS1022 C18 25x250mm column (Grace Vydac). 
G0-gp100-ThZ mass and purity were confirmed by UHPLC-MS on a Ultimate 3000 
UHPLC system (Thermo Fisher) hyphenated with a LCQ-Deca XP Iontrap ESI mass 
spectrometer (Thermo Finnigan) using a RSLC 120 C18 Acclaim 2.2um 2.1 x 250 mm 
column. Mass spectrometer analysis was measured in positive mode. G3-gp100-Thz 
fractions containing the product were pooled and lyophilized.
G0/G3-gp100-SH - For unmasking the N-terminal thioproline lyophilized peptidic 
dendrimer was dissolved in 1 ml Thz-deprotection solution (NaAc buffer pH 4.5, 
6M Gu.HCl, 0.1M Methoxylamine) and incubated at room temperature for 4 hours 
while shaking. The unmasked peptidic dendrimer G0-or G3-GP100-SH was purified 
over C18 500 mg SPE according to manufacturer’s protocol. Deprotected peptidic 
dendrimer was brought to dryness by lyophilisation.
G0/G3-Gp100-AF488/LewY construct - The G0- and G3-Gp100-SH were 
functionalized with either 1 (G0) or 3 (G3) equivalents of AF488-maleimide in 1 ml 
DMSO containing 100 mM 2,4,6-Trimethylpyridine. After 10 minutes, either 4 (G0) or 
42 (G3) equivalents of Lewis Y-MPBH were added to half of the mix and the reaction 
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was prolonged for 2 hours at room temperature on a shaker. 3 ml of DCM was added 
and after vortexing thoroughly 10 ml Diethyl ether was added to precipitate the 
labelled and glycated peptidic dendrimer. Construct was pelleted by centrifugation 
and washed 2 times with diethyl ether. Pellet was dissolved in MilliQ and brought 
to dryness by lyophilisation. Lyophilized construct was dissolved in 2 ml MilliQ-0.1% 
TFA and washed 6 times over 10 kD centrifugal filter to remove all excess labels and 
glycans. Retentate was collected and brought to dryness by lyophilisation.
Figure S1. (Glyco)-dendrimer synthesis and characterization A Schematic representation of 
(glyco)-dendrimer synthesis. B Mass spectrometry profile of G0-gp100-dendrimers depicting 
their molecular weight (MW) without (upper panel) and with AF488 (lower panel). C Size de-
termination of G3-gp100-dendrimers using a dynamic and static light scattering measurement. 
Average particle size was determined based on volume (upper panel) and intensity (lower panel).
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Anti-tumor glyco-dendrimers targeting Langerin and DC-SIGN
Figure S2. A Binding and uptake of (glyco)-dendrimers (left panel) or (glyco)-liposomes (right 
panel) by moDC following pre-incubation with an anti-DC-SIGN blocking antibody or matched 
isotype control. B Langerin expression by LC isolated from human epidermal sheets using disso-
ciation (steady-state) or two day emigration.
Figure S3. Enhanced activation of gp100 specific CD4+ T cells by glyco-dendrimer pulsed moDC 
MoDC were pulsed with (glyco)-dendrimers for 30 minutes followed by an o/n co-culture with 
gp100 specific CD4+ T cells. T cell activation was evaluated by IFNγ ELISA. n=4, each symbol rep-
resents a donor. (Statistical analysis: two-way ANOVA Tukey’s post hoc)
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The activation of adaptive immunity through vaccination can occur either prophylactic 
or therapeutically. The use of therapeutic anti-cancer vaccination strategies aiming 
to instruct DC in vivo are emerging, as it brings advantages compared to ex vivo 
DC instruction. Prophylactic vaccines against viruses such as the flu benefit from 
intradermal injection compared to the current standard of intramuscular delivery. 
This can be attributed to the presence of a vast network of dendritic cells (DC) 
within the skin. As such, developing intradermal anti-cancer vaccination strategies to 
specifically activate skin DC holds promise to enhance anti-tumor immune responses. 
Though, vaccines which only harbor tumor specific peptides have low immunogenicity 
and need addition of adjuvants for DC maturation to trigger T cell mediated cancer 
immunity. DC express a variety of pattern recognition receptors (PRR) that react to 
pathogen associated molecular patterns (PAMP) to induce DC maturation. The use of 
synthetic PRR agonists have paved the way for making vaccines more immunogenic. 
Within the PRR family are toll-like receptors (TLR) and NOD-like receptors (NLR), 
which synergize for induction of DC maturation and subsequent T cell responses. 
The effect of NLR stimulation on human skin DC phenotype and function following 
intradermal vaccine delivery has not yet been investigated. Using a PAMAM-
dendrimer core we developed a multivalent tumor antigen-adjuvant complex (MAAC) 
harboring a NOD2 agonist. Here we tested the effects of MAAC on human skin micro-
milieu, DC maturation, and its antigen processing and presentation upon intradermal 
vaccination. Intradermal injection of the NOD2 agonist conjugated MAAC, resulted 
in enhanced pro-inflammatory cytokine secretion within the skin micro-milieu and 
CD8+ T cell activation by human skin DC. This was enhanced in combination with 
the TLR4 stimulus MPLA. Overall, this newly developed tumor specific MAAC shows 
potential as vaccine adjuvant that warrants further investigation of NOD2 stimulation 
to induce anti-tumor immunity through intradermal vaccination.
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Introduction
Dendritic cells (DC) are imperative for the working mechanism of vaccination, as they 
initiate adaptive immune responses by instruction of T cells. This instruction induces 
both effector T cell responses and, importantly, immunological memory. Initially 
developed for infectious diseases, now vaccination strategies are also being explored 
for anti-tumor immunotherapy [1]. Anti-tumor vaccines aim to induce cytotoxic T 
lymphocytes (CTL) due to their killing capacity and recognition of MHC I bound 
antigens expressed by all tumor cells. To this end, peptides holding tumor specific 
antigen sequences are used to give the vaccine its tumor specificity.
Intradermal vaccination shows promise due to the presence of a vast DC network 
and the relative easy accessibility of the skin [2]. However, skin DC have an immature 
phenotype and will induce immune tolerance, rather than inflammation, when only 
antigenic peptides are administered [1]. Hence, vaccines need adjuvants combined 
with the antigenic peptides to induce DC maturation and robust anti-tumor immune 
responses.
DC express pattern recognition receptors (PRRs), including C-type lectin receptors 
(CLRs), Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) and NOD-like receptors 
(NLRs), which are the innate immune sensors for invading pathogens. Triggering 
of PRR on DC with pathogen associated molecular patterns (PAMP) induces 
DC maturation for co-stimulatory, survival and skewing signals to T cells [3]. 
Consequently, PRR properties are explored for the use in vaccination strategies to 
induce proper adaptive immunity. Synthetic antigenic peptides are combined with 
mainly TLR agonists to induce DC maturation and increase vaccine immunogenicity 
[4]. Different TLR agonists have been explored for intradermal vaccination strategies, 
such as agonists for TLR3 (poly I:C) [5], TLR4 (LPS, MPLA) [6] and TLR7/8 (R848, 
imiquimod, Aldara) [7], showing diverse responsiveness by the different skin DC 
subsets. Simultaneous triggering of different classes of PRR can result in synergy, 
such as described for TLR and NOD in DC derived from monocytes and in in vivo 
settings using mouse models [8-10]. Interestingly, NOD2 stimulation is implicated 
with positive effects in anti-cancer immunotherapy [11], also following intradermal 
administration in the skin [12]. Though, the combination of antigen and a NOD2 agonist 
for intradermal anti-tumor vaccination has yet to be elucidated in human skin.
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The peptidoglycan (PGN) minimal bioactive motif muramyl dipeptide (MDP) is a 
NOD2 specific agonist [13], which has potent adjuvant activity for vaccination. MDP 
can be added within its soluble form in in vitro culture systems to investigate its 
effect on DC activation. However, in vivo it is easily cleared from the system and in 
tissues it may activate (immune) cells other than DC. Many different variations of the 
MDP derivatives have been developed to overcome these issues [11]. Interestingly, 
studies show that conjugation of MDP-like molecules within antigenic constructs can 
enhance vaccine efficacy [14]. As the skin is rich in many immune cell types, such as 
mast cells, T cells and APC, and strongly irrigated, the use of an antigenic construct 
with conjugated MDP is an attractive option to investigate skin DC specific uptake 
and activation.
In this study, we developed a tumor specific, multivalent antigen-adjuvant construct 
(MAAC) harboring a NOD2 agonist. We show conjugation of a synthetic MDP variant 
remained functional for induction of DC cytokine secretion, in combination with TLR4 
stimulation. Furthermore, there is induction of pro-inflammatory cytokine secretion 
within the skin micro-milieu upon in situ vaccination. Upon ex vivo DC stimulation 
with the MAAC and a TLR agonist, we show enhanced tumor specific CD8+ T cell 
activation. Overall, our MAAC with NOD2 agonist can be used to further investigate 
induction of anti-tumor immunity upon intradermal vaccination.
Results and discussion
Conjugation of synthetic MDP to the tumor specific antigenic construct retains 
DC stimulating properties
To synthesize a tumor specific, antigenic construct containing a NOD2 agonist, we 
used the generation 0 PAMAM-dendrimer core (G0-PAMAM). First, we synthesized 
a tumor specific multivalent antigenic dendrimer (MAD), with reactive N-terminal 
sites for NOD2 agonist conjugation. A synthetic long peptide (SLP) containing a CD4 
and CD8 specific epitope of the gp100 melanoma model peptide was synthesized 
and conjugated through the C-terminal end to the G0-PAMAM. Since the commonly 
used NOD2 agonist muramyl-di-peptide (MDP) cannot be conjugated to the MAD, 
we used the synthetic variant muramyl tripeptide (M-triLYS), shown to have similar 
activating properties [10, 15]. M-TriLYs was conjugated at the N-terminal end of 
the gp100 specific MAD, to create a multivalent antigen-adjuvant complex (MAAC) 
(schematic representation Figure 1A).
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The conformation of MDP-like molecules which are covalently linked to antigenic 
constructs can influence their functionality [14]. To test whether the NOD2 MAAC 
retained NOD2 stimulation for DC activation, monocytes were cultured for 5 days 
with GM-CSF and IL4 for moDC differentiation. MoDC were subsequently stimulated 
for 3 hours with the MAD, MAD plus soluble MDP or the MAAC, washed and cultured 
overnight. Soluble MDP was added in an equal concentration as conjugated within the 
MAAC. Activation was measured by the release of cytokines within the supernatant. 
As expected, addition of MAD alone did not induce moDC activation (Figure 1B, 
grey bars).
Figure 1. Antigenic dendrimer scaffold harboring a synthetic NOD2 agonist activates moDC (A) 
schematic representation of antigen and synthetic MDP coupling to a generation 0.0 dendrimer 
scaffold. (B) Cytokine secretion by moDC pulsed with MAD, MAAC and MAD plus soluble MDP 
(12,5µg/ml) in the presence of MPLA for 3 hours, followed by o/n culture (n=2±SD) (C) Dose 
dependent cytokine secretion by moDC following 3 hour pulse with dendrimers and o/n culture. 
(IL1β repr of n=2, IL10/23 n=2±SD). (D) gp100 specific CD8+ T cell activation, as measured by IFNy 
production of T cells co-cultured overnight with moDC pulsed with antigenic-dendrimers for 3 
hours in the absence or presence of MPLA (n=3, each dot represents a donor).
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It has been previously shown that moDC need the subsequent activation of TLRs to 
perceive NOD2 signaling [8], because TLR signaling induces release of NOD2 ligands 
from and NOD2 recruitment to the endosome [16]. We incubated moDC with the 
MAD and MAAC in the presence of the TLR4 agonist monophosphoryl lipid A (MPLA). 
We observed secretion of IL1β, IL6 and IL10 following addition of soluble MDP in 
combination with the TLR4 stimulus MPLA (Figure 1B striped bars), showing the 
need of dual PRR stimulation. Cytokine secretion by moDC was maintained with 
conjugation of the synthetic variant to the MAAC, with a slight decrease in IL10 
secretion (Figure 1B closed bars). This indicates that NOD2 stimulation can be 
induced by addition of synthetic MDP (M-TriLYS) to the MAD.
Next, we elucidated the dose-response curve for cytokine secretion by moDC 
stimulated with the MAAC, in the presence of a constant concentration MPLA. MDP 
is known to activate the inflammasome through NOD2 stimulation [17]. Therefore, we 
measured secretion of the inflammasome induced cytokines IL1β and IL23, and the 
anti-inflammatory cytokine IL10. As expected, no cytokine secretion was observed 
following MAD and MAAC stimulation in the absence of MPLA (Figure 1C solid line). 
In contrast, both IL1β and IL23 secretion increased with increasing concentrations of 
the MAAC in the presence of MPLA (Figure 1C dotted line). Interestingly, we observed 
a decrease in IL10 production with increasing concentration of the MAAC and, hence, 
increasing concentration of the synthetic MDP. Other studies show the production of 
IL10 upon simultaneous TLR4 and NOD2 triggering. Though, here the concentration 
of both MDP and LPS remains equal, or, only a varying concentration of LPS is used. 
This indicates that the IL10 production is mainly driven by the TLR triggers and 
not NOD2 [8]. The negative effect of increasing concentrations of MDP for NOD2 
stimulation on IL10 production as seen here, has not been described elsewhere. 
These data show the simultaneous stimulation of TLR4 and NOD2 has a delicate 
balance for the induction of pro-inflammatory versus anti-inflammatory responses.
Simultaneous stimulation of NOD2 and TLR was shown to affect DC antigen handling 
and presentation [18-20]. Thus, we verified antigen cross-presentation capacity of 
moDC upon endocytosis of the MAD and MAAC. To this end, moDC followed a 3 
hour pulse with the respective antigenic dendrimers and were subsequently co-
cultured overnight with a gp100 specific T cell clone recognizing the HLA-A2 minimal 
epitope build within the MAD (Figure 1A). We observed a significant increase in 
gp100 specific CD8+ T cell activation when moDC were pulsed with the MAAC, that 
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included the synthetic NOD2, compared to the MAD (Figure 1D). When moDC were 
pulsed simultaneously with MAD or MAAC and MPLA this further enhanced CD8+ 
T cell activation (Figure 1D). These data show that synthetic MDP can be used for 
conjugation to MAD for DC stimulation and antigen handling to induce antigen 
specific CD8+ T cell responses. This allows us to further elucidate the effect of human 
skin DC NOD2 stimulation following intradermal vaccination using the MAAC.
MAAC enhance pro-inflammatory cytokine secretion within skin micro-milieu
To evaluate the effect of in situ MAAC injection on the human skin micro-milieu, 
we made use of a human skin explant model [7]. The human skin explant model 
represents the steady-state situation of skin resident (immune) cells to investigate 
the effect of our vaccine following intradermal injection. The model can either be 
used for in situ vaccine injection (Figure 2A), or by specifically isolating the DC for 
ex vivo antigen loading (Figure 3A). First, we evaluated whether human skin DC 
endocytose the MAD following in situ intradermal injection. To this end, AF488 was 
conjugated to the N-terminal end of the MAD instead of synthetic MDP, according to 
a similar synthesis scheme as presented in Figure 1A [21]. Dendrimers were injected 
below the epidermis until a small blister appeared. Next, biopsies were directly taken 
and cultured for 2 days to allow skin DC emigration. DC were harvested and uptake 
per subset was analyzed using flow cytometry by staining of the cell surface markers 
CD1a, CD14, CD141 (dermal DC) and EpCAM (LC), as previously described [21] (Figure 
2A). We observed uptake of the MAD-AF488 by all human skin DC subsets (Figure 
2B), but not by HLA-DR negative non-APC (data not shown).
To analyze the effect of NOD2 stimulation following intradermal injection, we 
measured cytokine secretion within biopsy cultured supernatants. Since we observed 
the need for concomitant TLR stimulation in moDC (Figure 1), we co-injected MAD 
and MAAC with MPLA for TLR4 stimulation. We found increased secretion of IL1β, 
IL6 and IL8 in the presence of MPLA and the MAAC (Figure 2C). There was a minimal 
increase in IL10 production (Figure 2C), which might reflect the decrease in IL10 
production with higher concentration MAAC and thus synthetic MDP, as seen in 
figure 1C.
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Figure 2. MDP-dendrimers enhance pro-inflammatory cytokine secretion within the skin mi-
cro-milieu (A) Schematic representation of dendrimer injection in a human skin explant model 
followed by 2 day culture of skin biopsies for skin DC emigration and supernatant conditioning. 
(B) Uptake of antigenic dendrimers with AF488 by human skin DC subsets as measured by FACS. 
(C) Cytokine secretion in full skin biopsy conditioned medium following injection of antigenic 
MAD or MAAC (33µM) in the absence or presence of MPLA (10µg/ml). n=3±SD, each symbol 
represents a donor
Cytokines were measured within full skin biopsy conditioned medium and, thus, we 
cannot discriminate whether human skin DC were responding to the MDP-dendrimer 
or via other skin resident cell types such as keratinocytes through immune cell cross-
talk [22]. Keratinocytes also express NLRs and can potentially respond to NOD2 
agonists [23]. However, the synthetic MDP is covalently linked to the MAD and we 
did not observe any uptake of MAD by non-APCs, which makes it is unlikely that 
keratinocytes will directly respond via NOD2 stimulation. Overall, these data indicate 
that the skin micro-milieu may be altered through the appearance of influx of innate 
immune cells such as neutrophils (IL8) upon NOD2 stimulation [24].
Human skin DC process MAAC for antigen retrieval and subsequent CD8+ T cell 
activation
To elucidate antigen presentation by human skin DC following MAD uptake, epidermal 
and dermal sheets from skin explants were cultured for 48 hours to allow dermal 
DC and LC emigration (Figure 3A). In moDC we observed the additive effect of 
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concomitant TLR4 stimulation with MAAC pulse, for cytokine secretion and CD8+ T 
cell activation (Figure 1B-D). However, TLR expression differs between dermal DC 
and LC, causing the need for differential TLR stimulation. LC express viral sensing 
TLR, such as TLR3, whereas dermal DC express both viral and bacterial sensors such 
as TLR4 [25]. As such, we used the TLR3 stimulus Poly I:C for LC activation and MPLA 
for dermal DC stimulation through TLR4 activation.
Emigrated skin DC were harvested and equal amount of LC and dermal DC were 
pulsed with the dendrimers ex vivo for 3 hours in the presence of Poly I:C (LC) or 
MPLA (dermal DC). Next, DC were washed prior to overnight co-culture with the 
gp100 specific T cell clone (Figure 3A). Interestingly, when testing two donors, we 
observed for dermal DC that one donor clearly responded to NOD2 stimulation 
leading to increased cross-presentation, whereas LC showed enhanced antigen 
presentation by both the MAD and MAAC (Figure 3). It appears that the increased 
CD8+ T cell activation was dependent on the simultaneous NOD2-TLR4 triggering.
Figure 3. Gp100 specific CD8+ T cell activation by human skin DC following MAAC pulse (A) 
Human skin was shaved and epidermal and dermal sheet separated for 2 day culture and LC and 
dermal DC emigration. Emigrated human skin DC were harvested and pulsed for 3 hours with 
(gp100) MAD or MAAC in the absence or presence of a TLR stimulus prior to o/n co-culture with 
a gp100 specific T cell clone. (B) CD8+ T cell activation by dermal DC (left) pulsed in the presence 
or absence of MPLA and LC (right) pulsed in the presence of Poly I:CPoly I:C. CD8+ T cell activation 
was measured using IFNγ cytokine ELISA. (n=2, each symbol represents a donor)
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The simultaneous NOD2-TLR3 stimulation induced MAAC cross-presentation by LC 
for one of the two donors (Figure 3, round symbol). Thus, further investigation is 
necessary to pin point what dictates donor dependent enhancement of antigen 
processing for CD8+ T cell activation upon MAAC endocytosis and NOD2 stimulation. 
NOD2 comes in a variety of polymorphisms differing between individuals which may 
explain the variety in antigen processing following stimulation [26]. Furthermore, 
there is a delicate balance between the human skin microbiome and resident immune 
cells [27]. Changes in this symbiotic relationship may influence APC responses to PRR 
stimuli, such as NOD2, thereby inducing differential antigen processing upon NOD2 
stimulation between human donors.
NOD2 MAAC for future intradermal vaccination strategies
In light of our findings with moDC and partly human skin DC (Figures 1D and 3B), 
it would be interesting to further investigate the effect of simultaneous TLR and 
NOD2 stimulation on the processing of antigens for MHC I loading by human skin 
DC. NOD2 stimulation by MDP is implicated with enhanced DC autophagy for MHC 
II peptide loading and subsequent CD4+ T cell activation [18, 28]. In this study we 
did not investigate the induction of gp100 specific CD4+ T cell activation, however 
HLA-DR gp100 epitopes are included in the MAD and MAAC, indicating that this can 
be studied in future experiments.
Our designed MAAC harboring synthetic MDP can serve as tool for these type of 
studies. However, the SLP sequence can influence solubility and subsequent MAD 
synthesis and processing by DC. We found that substitution of the gp100 SLP with a 
CD8+/HLA-A2 human CMV pp65 specific epitope hindered solubility. The hydrophobic 
nature of the CD8+ specific epitope resulted in aggregation of the peptide (Figure 
S1A). Surprisingly, this aggravated when the SLP was conjugated to the G0 PAMAM-
dendrimer core to synthesize the MAD (Figure S1A), although these are described 
to enhance solubility [29].
The advantage of using synthetic peptide vaccines is the possibility to chemically 
alter solubility. With our melanoma gp100 specific peptide we increased solubility by 
incorporating a CD4+ T cell specific sequence, which has a more hydrophilic nature. 
Another approach is the addition of hydrophilic amino acids such as lysine (K). To this 
end, we elongated our CMVpp65 SLP with either a “CEEK-KEEK” sequence instead 
of the natural flanking amino acids, or added a lysine-tale (5K). Although the CEEK-
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KEEK addition indeed ensured proper dissolving of the CMVpp65 SLP (Figure S1B), 
the SLP was no longer efficiently processed by DC for CD8+ T cell activation (Figure 
S1C square). In contrast, the 5K tale showed clear solution of the CMVpp65 SLP 
(Figure S1B) and processing by DC for CD8+ T cell activation (Figure S1C triangle). 
Interestingly, the 5K-tale CMVpp65 SLP showed higher CD8+ T cell activation by DC 
compared to the initial CMVpp65 SLP at lower concentration (Figure S1C).
An important aspect of DC induced immune responses is their migration to the 
draining lymph nodes for (naïve) T cell activation. Whether stimulation of NOD2 
also induces enhanced DC migration has not been investigated. Though, it would be 
very interesting to evaluate the effect of simultaneous TLR and NOD2 stimulation on 
human skin DC migration. It has been described that DC CCR7 expression can increase 
upon TLR4 and NOD2 stimulation, however, this does not directly denote migration 
capacity [30]. Similarly, the spontaneous emigration of human skin DC from biopsies 
does not reflect lymph node homing properties. We developed an ex vivo human skin 
DC migration assay, where biopsy emigrated DC are loaded in a transwell system with 
the lymph node homing chemokine CCL21 (Figure S2A). Migration of the different 
human skin DC subsets can be evaluated using FACS by staining the different DC 
subsets as described in figure 2A. We tested the possibility to pre-inject human skin 
DC stimuli in situ prior to ex vivo migration using the previously described human skin 
DC stimuli GM-CSF and IL4 (GM/4). We found CD1a+ dermal DC and LC to have high 
migrational capacity towards CCL21 (Figure S2B). Interestingly, also approximately 
20% of the CD14+ dermal DC subsets showed chemokine induced migration, which 
was further enhanced upon GM/4 stimulation (Figure S2B). It would be interesting 
to investigate migrational capacity of the different human skin DC subsets following 
intradermal delivery of the NOD2 MAAC, using this assay.
Overall, this study shows the MAAC harboring both antigen and a NOD2 agonist 
can be used to elucidate the effect of NOD2 stimulation via intradermal delivered 
vaccines.
Material and methods
Multivalent antigenic dendrimer and antigen-agonist complex synthesis
Multivalent antigenic dendrimers were synthesized as previously described [21]. 
In short, the gp100 SLP (Thz-VTHTYLEPGPVTANRQLYPEWTEAQRLD-(Abu)3-C) 
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and CMVpp65 SLP (Thz-ILARNLVPMVATVQGQN / ILARNLVPMVATVQGQNKKKKK 
/ CEEKNLVPMVATCKEEK -(Abu)3-C) were synthesized using microwave assisted 
solid phase peptide synthesis at our GlycO2pep unit. To multimerize the SLP, a 
maleimide functionalized generation 0 PAMAM-dendrimer core was used. The 
SLP was conjugated through its C-terminal cysteine and added in 5 equivalents 
per dendrimer-core followed by removal of excess peptide, thereby synthesizing 
multivalent antigenic dendrimers (MAD). Next, the N-terminal thioproline (Thz) was 
unmasked and reacted with 4 equivalents maleimide-AF488 (Invitrogen) or M-TriLYS 
(Sigma) to synthesize MAD-AF488 or the multivalent antigen-agonist complex (MAAC) 
(Figure.1A), respectively.
Monocyte derived DC culture and stimulation
Monocytes isolated from buffycoats (Sanquin) using sequential Ficoll/Percoll gradient 
centrifugation, were cultured for 4-6 days in complete RPMI (10% FCS, pen/step/glut) 
containing rhIL4 and rhGM-CSF (500U/ml; Biosource) to generate moDC as previously 
described [31]. For moDC stimulation 5x104cells/well were stimulated overnight with 
a serial dilution of either MAD or MAAC in the absence or presence of MPLA (10µg/
ml). Soluble MDP (Sigma) was added in an equal concentration (12,5µg/ml) as present 
with addition of the MAAC. Supernatants were harvested and secretion of IL1β, 
IL6, IL10 and IL23 was measured using sandwich ELISA according to manufacturer’s 
protocol (Bioscource).
Human skin explant model
Human skin explants (Bergman Clinics, Bilthoven, The Netherlands) were obtained within 
24 hours following abdominal resection of healthy donors with informed consent.
In situ – Human skin explants were prepared by cleaning with PBS supplemented with 
gentamycin. Products were diluted in serum free IMDM prior to injection. Insulin 
needles were used to inject 20µl/biopsy i.d. at 66pmol/ml so a small blister appeared. 
A punch biopsy (8mm; Microtec) surrounding the blister was taken and 8 biopsies 
per condition were cultured with the epidermis facing upwards in a 48-wells-plate 
with 1ml IMDM complete skin medium (10% FCS, penicillin, streptomycin, glutamin, 
gentamycin) for 48hours. Biopsies were discarded and emigrated cells harvested and 
pooled per condition prior to FACS staining. To distinguish the different emigrated 
skin DC subsets cells were stained using the following anti-human antibodies: 
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HLA-DR BV510, CD1a APC, CD14 AF700 (clone M5E2, Sony), CD141 BV711 (clone 
1A4, Biolegend), EpCAM BV421 and FVD.
Ex vivo – For ex vivo assays, primary LC and dermal DC were isolated by partially 
removing the epidermal and dermal sheet (5-mm thickness) using a dermatome 
blade (Zimmer, Germany). The skin sheet was rinsed with PBS plus gentamycin 
(10µg/ml; Lonza) and incubated in serum free IMDM supplemented with 50U/ml 
penicillin, 50ug/ml streptomycin, 2mM glutamine, gentamycin and dispase II (1mg/
ml, Roche Diagnostics) for 2 hours at 37oC. The epidermal sheet was separated from 
the dermis using tweezers, followed by two day culture in complete IMDM skin 
medium supplemented with rhGM-CSF (500U/ml) for LC and dermal DC emigration at 
37oC. Skin sheets were discarded and LC and dermal DC were harvested and purified 
using a Ficoll gradient (>85%). For purity evaluation cells were incubated with anti-
human antibodies against HLA-DR (clone G46-6, BD Biosciences), CD1a (clone HI149, 
BD Biosciences), CD14 (clone M5E2, Sony) and Langerin (clone 10E2, Biolegend).
Antigen presentation assay
For antigen presentation assays 5x103 APC were pulsed for 3 hours, washed and 
co-cultured with a gp100 specific T cell clone recognizing the HLA-A2 minimal 
epitope (YLEPGPVTA) [32] in a 1:5 T:E ratio. T cell activation was measured using 
IFNγ (Invivogen) sandwich EILSA according to manufacturer’s protocol.
Human skin DC migration assay
Human skin DC were harvested following two day culture from biopsies as described 
above. Harvested DC from 8 biopsies were pooled and loaded on the top well of 
an 8µm pore transwell system (Corning, Sigma) with the chemokine CCL21 (250ng/
ml) in the lower well. DC were incubated for 4 hours at 37˚C to allow chemokine 
induced migration to the lower well. To evaluate human skin DC subset specific 
migration cells from both top and lower well were harvested and stained for 
HLA-DR, CD1a, CD14, CD141 and EpCAM, followed by acquisition for 1 minute 
per sample using FACS. Migrated cells were calculated as percentage of total 
cell number (top + lower well) loaded on top: % migrated = #DC lower well x 100 
        total # DC
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Cell staining and FACS measurement
Cells were incubated with membrane markers diluted in 0,5% BSA in PBS (PBA) for 30 
minutes on ice, washed and fixated in 4% paraformaldehyde (PFA;..) for 20 minutes 
on ice. Next, cells were stained with a fixable viability dye (FVD; Invitrogen) for 5 
minutes on RT, washed and resuspended in 0,5% PBA. Cells were measured using 
the FACS Fortessa X-20 and analyzed with FLowJo10 software.
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Supplementary data
Figure S1. SLP sequence for MAD can influence solubility and processing (A) Aggregation of 
CMVpp65 SLP when dissolved in PBS. (B) Solubility of CMVpp65 SLP with chemically altered flank-
ing amino acids. (C) Processing and presentation to CD8+ T cells of three differential flanking 
sequences in the CMVpp65 SLP by moDC.
Figure S2. Human skin DC migration assay (A) schematic representation of the transwell mi-
gration assay using primary human skin DC emigrated out of human skin explants. (B) Migration 
towards CCL21 of the different human skin DC subsets as percentage of total cells loaded in 
topwell. Skin was injected prior to emigration with medium or GM-CSF and IL4 (GM/4). n=5 each 
dot represents a donor
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Human skin is a prime vaccination site containing multiple antigen presenting cells 
(APC), including Langerhans cells (LC) and dendritic cells (DC). APC deliver antigens 
to lymph nodes for induction of adaptive immunity through stimulating antigen 
specific T- and B-cells. Since intradermal (ID) injections require specific training, 
easy applicable delivery systems like laser microporation are emerging. In mice, 
combination of laser treatment and allergen injection showed enhanced T-cell 
responses and skewing of B-cell responses without adjuvants. However, it remains to 
be elucidated whether laser microporation can alter human skin DC phenotype and 
function without adjuvants. In an ex-vivo human skin explant model, we compared 
ID injection and laser microporation as anti-tumor vaccination strategy. A melanoma 
specific synthetic long peptide and multivalent dendrimer with gp100 antigen were 
used as vaccine formulation to measure APC phenotype, emigration and ability 
to stimulate gp100 specific CD8+ T-cells. We show that skin APC phenotype and 
emigration capacity was similar after laser microporation and ID injection. However, 
laser microporation reduced vaccine uptake by APC, resulting in decreased induction 
of gp100 specific CD8+ T-cell activation. To conclude, in our human skin model ID 
injection remains the most potent strategy to deliver antigens to skin APC for T-cell 
induction.
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INTRODUCTION
The human skin is a potent vaccination site as it contains numerous antigen 
presenting cells (APC), including epidermal Langerhans cells (LC), dermal dendritic 
cells (dDC) and monocyte derived macrophages (moMØ)1. APCs in the dermis can be 
subdivided into three distinct subsets: CD1a+ dDC, CD141+ dDC, CD14+ moMØ and a 
small population of Langerin+ dDC1,2. APC constantly scan their environment to detect 
changes in homeostasis, and are equipped with a plethora of pattern recognition 
receptors (PRR), such as toll-like receptors (TLR) that detect invading pathogens3. 
To help DC internalize antigenic content, DC express uptake receptors like C-type 
lectin receptors (CLR) that further process endocytosed pathogens into antigenic 
fragments to present on major histocompatibility complex (MHC) molecules. DC 
carry MHC presented antigenic peptides to draining lymph nodes for instruction of 
T-cell mediated adaptive immune responses4. LC and CD1a+ dDC are natural inducers 
of cytotoxic CD8+ T-cell responses, whereas the skin resident CD14+ moMØ can do 
so following specific CLR targeting and uptake5. CD141+ dDC can rapidly migrate to 
the skin draining lymphnodes and represent 20-40% of the DCs in the lymphnode 
1,2. Furthermore, CD141+ dDC can skew the CD4+ T cell response to a th1 phenotype. 
Overall, the different skin APCs are excellent targets for vaccination strategies that 
can induce CD8+ T-cell responses required in the context of pathogens or tumors.
Compared to standard vaccine administration routes, skin immunization is more 
potent and dose-sparing6. Though, as intradermal (ID) injections require specific 
training and handling, most vaccination strategies still use subcutaneous or 
intramuscular vaccine delivery. In recent years new administration techniques have 
paved the way for easier and even pain free ID vaccination7. One of these techniques 
uses fractional laser ablation at a wavelength of water absorption to create clean 
micropores without thermally damaged ridges8. Depending on the settings, 
micropores can either disrupt the stratum corneum, reach into the epidermis or 
deeper into the dermis9. Multiple studies showed vaccine deposition within the skin 
already at minor disruption of the epidermis, thereby likely making vaccine particles 
available for endocytosis by skin APC9.
An important aspect for induction of adaptive immunity by DC, is the activation of 
PRRs which induces DC maturation and is often accomplished by adjuvant inclusion 
into the vaccine. Mature APC present antigens in MHC molecules, express co-
stimulatory markers and secrete cytokines for proper T-cell activation in the lymph 
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nodes10,11. The human skin is a plastic environment also containing non-immune cells 
such as keratinocytes and fibroblasts which can alter the environment by secretion 
of inflammatory cytokines12 and thereby activate skin resident APCs. Furthermore, 
dermal vasculature allows for influx of innate cells such as monocytes. Interestingly, 
recent murine studies showed immunomodulation upon non-destructive laser 
treatment in combination with ID vaccine injection. This included enhanced vaccine 
uptake, DC motility and increased CD4+ T-cell numbers and antigen specific antibody 
titers13. Since this technique still requires ID injection, other studies investigated 
the potency of destructive lasers creating micropores for vaccine delivery and 
enhancement of immune responses. Although laser microporation efficiently delivers 
vaccine particles into the dermis14, it was not directly compared to ID injection. 
Furthermore, the type of antigen appears to determine Th1 or Th2 skewing of 
immune responses and addition of adjuvant did not further enhance antibody titers 
compared to single laser treatment15. Thus, implying that laser microporation can 
be used for ID vaccine delivery and triggering of immune responses without a need 
for adjuvants.
Since both vaccination against pathogens and cancer require the induction of 
antibody responses and effective CD8+ T-cell responses, laser microporation may also 
be beneficial for anti-tumor vaccination strategies. A direct comparison between ID 
injection and laser microporation with tumor specific antigenic compounds needs to 
be tested in a human skin setting. In this study, we used a human skin explant model 
to investigate laser induced effects on human skin APC subsets. Using the P.L.E.A.S.E. 
laser device we compared epicutaneous laser microporation to ID injection of two 
tumor specific antigenic vehicles without adjuvant. Since tumor specific epitopes 
can be included in different types of vaccines, thereby favoring APC endocytosis16, 
we tested a linear synthetic long peptide (SLP) of the melanoma antigen gp100 and 
a larger multivalent dendrimer comprising multiple gp100-SLP bound to a scaffold. 
Both laser microporation and ID injection resulted in equal numbers human skin 
APC subset emigration with identical phenotype. Although laser microporation 
supplied both vaccine compounds to all human skin APC subsets, a lower amount 
accumulated compared to ID injection, that resulted in decreased gp100 specific 
CD8+ T-cell activation. Overall, our data shows that tumor specific compounds reach 
human skin APC more efficient through ID injection, resulting in efficient tumor 
specific CD8+ T-cell stimulation.
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RESULTS
ID injection and laser microporation induce equal skin APC emigration
The skin consists of the epidermis covered by the stratum corneum (SC) and the 
dermis which are connected by a basal membrane containing tight-junctions that 
provide a barrier function17. To ensure proper vaccine delivery to APCs in the skin, 
both the SC and basal membrane need to be crossed. Laser microporation creates 
micropores in the skin with different depths depending on the laser settings. We 
verified that in a human skin explant model, laser ablation with 23.7J/cm2, four pulses 
and a depth of approximately 95µm as indicated by the P.L.E.A.S.E laser (Figure S1a) 
was sufficient to penetrate through the epidermis and basal membrane, while leaving 
the dermis intact to allow vaccine delivery to LC, dDC and moMØ. Therefore, these 
settings were used for vaccine delivery in comparison to ID injection in a human 
skin explant model.
First, we evaluated whether laser microporation can enhance skin APC emigration 
compared to ID injection by analyzing subset ratio and absolute number of skin 
resident APC emigrated out of cultured skin biopsies (schematic representation 
Figure 1a). Using specific markers, MHC II+ (HLA-DR) human skin APC subsets were 
separated into the different epidermal and dermal subsets based on their marker 
expression (Figure S1b), as previously described18. No differences were observed in 
skin APC subset emigration after two days of biopsy culture when skin was either 
untreated, ID injected or treated with laser microporation (Figure 1b,c). This indicates 
that laser microporation potentiates all human skin APC subsets to emigrate from 
the human skin equally well as ID injection.
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Figure 1. Equal human skin APC emigration following ID injection or laser microporation (A) 
Human skin explants were untreated or treated with ID injection using insulin needles or laser 
microporation using the P.L.E.A.S.E. Professional laser device. Biopsies were cultured for two days 
followed by evaluation of emigrated skin APC subset ratio (B) and absolute number for ID injection 
or laser poration. (C) n=6±SEM each dot represents a donor (Statistical analysis: Student’s t-test 
showed no significant differences).
ID injection outperforms laser microporation for vaccine delivery to human 
skin APC
An important DC feature is their endocytic capacity for antigen or vaccine particle 
processing and subsequent presentation to T-cells in the lymph nodes. Antigen 
endocytosis by skin APC can be influenced by particle size and, as such, we used two 
sizes of synthetic vaccines to verify uptake by the different skin APC subsets following 
ID injection or laser microporation. A single SLP containing the melanoma specific 
gp100-epitope for presentation in MHC I, was either injected as linear peptide (~3kD) 
or coupled to a dendrimer with four functional groups to create a larger multivalent 
peptide structure (~20kD).
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Figure 2. Superior vaccine uptake by skin APC following ID injection (A) Human skin explants 
were used to evaluate in situ uptake of SLP or dendrimers by the different skin APC subsets follow-
ing ID injection or laser microporation. (B,C) HA-signal of gp100-peptides compared to medium 
ID injection with the secondary antibody against the HA-tag (none) and (D,E) AF488 signal of 
multivalent gp100-dendrimers taken up by the different human skin APC subsets compared to 
medium ID injection (none). n=3 with representative histograms, each dot represents a donor. 
Symbols represent different treatments.
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To evaluate uptake, the SLP amino acid sequence was elongated with an HA-tag 
and an AF488 was coupled to the dendrimer extremities (schematic representation 
Figure 2a). Using an insulin needle SLP or dendrimers were ID injected creating a 
small blister just under the epidermis of approximately 0.8cm2. For delivery following 
laser microporation the SLP or dendrimers were topically applied on an area of 
1cm2. To avoid evaporation of the vaccine dissolvent, micropores were covered 
with Tegaderm followed by gentle massage of the applied vaccine area (schematic 
representation Figure 2a). Biopsies were cultured for two days to allow skin APC 
emigration. Following ID injection we could find HA-signal with FACS analysis in all 
APC subsets after two day emigration from skin biopsies (Figure 2b,c). Strikingly, 
application following laser microporation decreased uptake by all skin DC, moMØ 
and LC for both gp100-SLP (Figure 2b,c) and gp100-dendrimers (Figure 2d,e). No 
uptake for both gp100-SLP and gp100-dendrimers was found in the HLA-DR negative 
population (Figure S2a). These data indicate that despite similar amount of vaccine 
molecule application, ID injection may facilitate better vaccine uptake by skin APC 
compared to topical application following laser microporation.
Similar skin APC phenotype and skin micro-milieu following ID injection and 
laser microporation
Although skin APC subset emigration was similar following ID injection and laser 
microporation (Figure 1b,c) without an adjuvant, we wanted to verify if lowered 
antigen uptake by APC following laser microporation was due to phenotypical 
changes. Therefore, we analyzed co-stimulatory marker surface expression by the 
different skin APC subsets after two-day emigration. Overall, CD14+ moMØ showed 
lower expression levels of CD40, CD80, CD83 and CD86 compared to the other APC 
subsets, as previously described19. However, no differences in co-stimulatory marker 
expression after emigration were observed within the APC subsets between ID 
injection and laser microporation (Figure 3). Also, no differences were observed for 
CD83 and CD86 within the APC subsets between untreated and ID injected skin (Figure 
S2b) Human skin APC mature upon emigration20, so two days of emigration from the 
biopsy might overrule any initial differences in co-stimulatory marker expression 
induced upon laser treatment. Hence, we also elucidated cytokine secretion within 
the whole skin micro-milieu upon ID injection and laser microporation. During skin 
culture, biopsy conditioned supernatant was evaluated for presence of IL-1β, IL-6, 
IL-10, IL-12p70 and TNF-α at multiple time-points. Measurable levels of IL-6, IL-8 and 
IL-10 were detected after 6, 24 and 48 hour migration, whereas IL-1β, IL-12p70 and 
TNF-α were not detected. Figure 4 shows a significant decreased secretion of IL-6 and 
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a trend for IL-8 after 48 hours when human skin was treated with laser microporation 
compared to ID injection (Figure 4). Overall, these data show that laser microporation 
does not induce phenotypical changes in APC marker expression and slightly alters 
cytokine micro milieu compared to ID injection in the absence of an adjuvant.
Figure 3. Similar co-stimulatory marker expression by skin APC subsets following ID injection 
and laser microporation Human skin explants were either ID injected with culture medium or laser 
micro-porated followed by two-day biopsy culture. Emigrated skin APC subsets were analyzed for 
expression of maturation markers CD40, CD80, CD83 and CD86 using FACS analysis. n=6±SEM, 
each dot represents a donor. Representative histograms of one donor.
Figure 4. Skin micromilieu cytokine profile slightly changes upon laser microporation Human 
skin explants were either ID injected with culture medium or laser micro-porated followed by two-
day biopsy culture. Next, biopsy cultured supernatant was harvested and analyzed for secretion 
of cytokines after 6, 24 and 48 hours. Time course samples of 6h, 24h and 48h for 3 donors, 48h 
samples alone for 2 (IL-6) or 3 (IL-10 and IL-8) donors and each dot represents a donor.
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Higher CD8+ T-cell activation by skin APC following ID vaccine injection 
compared to laser microporation
Anti-tumor vaccination strategies rely on the induction of tumor specific CD8+ T-cells 
which requires APC to shuttle tumor antigens into the cross-presentation pathway for 
MHC I loading21. Therefore, cross-presentation of peptides and dendrimers by human 
skin APC was assessed following the different administration routes. We applied the 
gp100-SLP or the gp100-dendrimer as tumor vaccine to the human skin through 
injection or upon laser microporation. After two-day skin APC emigration, total skin 
APC were harvested and co-cultured with a gp100 specific T-cell clone recognizing 
the cross-presented vaccine gp100 minimal epitope in MHC I, and evaluated gp100 
specific CD8+ T-cell activation by IFNγ secretion. Clearly, ID injected vaccines that 
targeted APC showed an increase in gp100 specific CD8+ T-cell activation for both the 
gp100-peptide and gp100-dendrimer vaccine (Figure 5a,b open bars). Surprisingly, 
but in line with the decreased uptake by skin APC following laser microporation 
(Figure 2), we observed that similar content of vaccine antigen delivered through 
laser microporation led to lower gp100 specific CD8+ T-cell activation compared to 
ID injection (Figure 5a,b closed bars).
To verify whether direct changes within the skin biopsy alter the capacity of skin APC 
to activate CD8+ T-cells, we first treated the skin with laser microporation followed by 
injection of the gp100-SLP vaccine in the skin. The capacity of the skin emigrated APC to 
activate CD8+ T-cells was restored as when the vaccine was only ID injected in the skin 
(Figure 5c). This indicates that a decreased uptake of the vaccine by human skin APC 
following laser microporation results in reduced gp100 specific CD8+ T-cell activation.
Figure 5. Higher gp100 specific CD8+ T-cell activation following ID vaccine injection Melanoma 
specific gp100-peptides (a) or gp100-dendrimers (b) compared to a medium control (none) were 
either ID injected, applied topically following laser microporation or ID injected following laser 
microporation (c). After two-day biopsy culture emigrated APC were harvested and co-cultured 
with a gp100 specific T-cell clone. T-cell activation was measured by IFNγ secretion in the superna-
tant. (a) n=5, (b) n=4, each dot represents a donor. (c) representative of n=2 measured in triplicate.
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DISCUSSION
In this study we compared the use of ID anti-tumor vaccine delivery to human skin 
APC via injection or laser microporation without adjuvant. Laser microporation 
creating micropores with a depth just through the epidermis did not compromise 
human skin APC emigration or phenotype. However, tumor-specific vaccine particles 
were more efficiently delivered to the different human skin APC subsets upon ID 
injection compared to application following laser microporation. This resulted in 
higher tumor specific CD8+ T-cell activation following ID injection. Overall, our data 
show that in the ex-vivo human skin model, ID delivery of unmodified tumor-specific 
particles reaches human skin APC subsets best through ID injection.
For anti-tumor immune responses, the induction of cytotoxic CD8+ T-cells for tumor 
cell killing is important22. To achieve this, APC must shuttle exogenous derived 
tumor specific antigens into the cross-presentation pathway for loading on MHC 
I21. Cross-presentation by APC is influenced by mode of antigen uptake, but also 
signaling events occurring during antigen uptake. For example, concomitant TLR4 
signaling enhances cross-presentation by retention of antigens in the endosomes 
through delay of endo-lysosmal fusion for antigen destruction23. As such, vaccines are 
often administered in the presence of TLR activating adjuvants to induce productive 
anti-tumor immune responses. However, laser microporation might induce so 
called adjuvanting effects e.g. by enhancing APC motility and antigen uptake. Our 
vaccination setting using unmodified peptidic compounds without adjuvant, did not 
benefit from laser microporation compared to ID injection. Leading to diminished 
activation of the CD8+ gp100 T cell clone, which appeared to be due to failure of 
particle uptake by the different APC subsets, although this might be underestimated 
due to processing of the SLP or dendrimer by the APC in the two-day culture and 
thereby removing the HA-tag or fluorescent label. Furthermore, there is a difference 
in diffusion of the products over time after laser treatment as shown by HX Nguyen 
et al 24 where the diffusion in vertical direction is highest in the first four hours and 
the horizontal diffusion in the skin after laser treatment is strongest after 8 hours. 
This will also impact uptake of the products by APCs over time.
The characteristics of vaccine compounds appear to dictate vaccine distribution and 
uptake by APC14. Interestingly, an important characteristic that can be altered to 
increase vaccine particle uptake is the size of the antigenic component25, however, 
even with the multivalent dendrimers we did not see a favorable contribution of laser 
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microporation to uptake by skin resident APC. This is in line with previous studies 
where the molecular weight of particles did not influence vaccine distribution in the 
skin following laser microporation14.
Alternatively, the ability to specifically target vaccine formulations to APC via CLRs, 
such as DC-SIGN and the mannose receptor, which recognize specific carbohydrate 
structures, is an option26. Targeting vaccines can be created by coupling of 
carbohydrates to antigen specific vaccine particles. Using the grass pollen Phl p 5 
protein functionalized with the mannose receptor binding carbohydrate mannan, 
Machado et al showed efficient targeting of skin APC18. Interestingly, this study 
showed synergy between targeting ability of the vaccine and laser microporation, 
where laser microporation enhanced uptake of the targeting particles in human 
skin APC compared to ID injection. In contrast, our study uses unmodified SLP 
and dendrimers without specific targeting characteristics that might be necessary 
for enhanced antigen delivery to human skin APC in combination with laser 
microporation.
In a murine study by Terhorst et al, XCR1 targeting anti-tumor vaccibodies were 
combined with (epi) cutaneous laser microporation and showed enhanced anti-tumor 
immune responses and both therapeutic and prophylactic efficacy27. Interestingly, 
here laser microporation induced immunomodulatory responses, thereby bypassing 
the need for adjuvant application. In our study we did not observe enhanced 
APC maturation as measured by co-stimulatory marker expression upon laser 
microporation. Though, co-stimulatory marker expression is often induced upon 
TLR activation. The immunomodulation of laser microporation does not appear to 
rely on signaling through TLR, but rather be an effect of signaling cascades initiated 
through local cell death and immune cell influx27. Unfortunately, we cannot study 
effects of laser microporation in the context of immune cell influx in the human skin 
explant model. Though, local cell death of KC is most likely induced which may alter 
local cytokine levels in the skin thereby affecting local (immune) cells and immune 
cell influx28. Interestingly, we observed a minor decrease in secretion of IL-6, IL-8 and 
IL-10 within the skin biopsy micro-milieu compared to ID injection. This hints to a 
micro-milieu with less attraction of e.g. neutrophils (IL-8). Importantly, this secretion 
of cytokines were measured within the total skin biopsy, whereas conflicting data is 
published when looking at the cytokine secretion profile of T-cells harvested from 
the spleen8,29. Where Weiss et al showed that deeper microporation into the dermis 
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of mice increases Th1/2/17 cytokine secretion profiles by splenic T-cells8, Chen et 
al observed an overall decrease in cytokine responses29. Overall, it appears either 
immune cell influx induced upon laser microporation, or, skin layer dependent cell 
death is important for immunomodulatory effects of laser microporation.
Besides ablative fractional lasers (AFL), as used in this study, also non-ablative 
fractional lasers (NAFL) have been developed for the disruption of skin tissue without 
the formation of micropores. Combination of NAFL prior to ID injection enhanced 
uptake of unmodified vaccine through enhanced APC motility13. This resulted in 
both increased antigen uptake and migration toward the lymphatic system within 
the skin. Therefore, NAFL might be a better approach for intradermal vaccinations 
using unmodified antigenic compounds as used in our study, since we did not observe 
enhanced uptake following AFL treatment. Overall, our study demonstrates that 
using the human skin explant model ID injection results in better antigen uptake by 
skin APC compared to laser microporation reflecting a superior tumor specific CD8+ 
T-cell activation.
MATERIAL AND METHODS
Human skin explant culture and DC isolation
Human skin explants were obtained within 24 hours after abdominal resection 
surgery (Bergman Clinics, Hilversum, The Netherlands) from healthy donors following 
informed consent as approved by the VUmc Medical Ethical Committee and research 
was performed according to the local guidelines and regulations of the Amsterdam 
UMC location VUmc. Obtained skin was rinsed with PBS substituted with 10µg/ml 
Gentamycin (Lonza) and subsequently ID injected using an insulin needle or porated 
using the P.L.E.A.S.E. Professional laser device (Pantec Biosolutions) with the following 
settings: fluency of 23.7 or 35,6 J/cm2, 4 pulses/pore, repetition rate 200Hz, pulse 
duration 75µs and 10% pore density. Per condition 8-12 biopsies were taken using 
8mm biopsy-punches (Microtek, Zutphen, Netherlands) and cultured for 48 hours in 1 
ml IMDM supplemented with 10% FCS, 10ug/ml gentamycin, penicillin/streptomycin 
(Lonza), and L-glutamin (Lonza) at 37˚C and 5% CO2. Conditioned supernatant was 
collected at 6, 24 and 48 hours during culture for cytokine measurements. Following 
culture, skin biopsies were discarded and emigrated cells were harvested and pooled 
per condition for further analysis.
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Human skin section staining
For pore depth evaluation following laser microporation, skin biopsies were dried 
shortly on a tissue followed by emersion in TissueTek (Sakura Finetek, USA) and 
immediate freezing under liquid nitrogen. Skin biopsies were cut in 7mm sections 
(CryoStar NX70, ThermoFisher scientific), placed on 1% gelatin (Merck, Darmstadt, 
Germany) coated slides, dried and stored at -80⁰C. Prior to staining, sections were 
dried o/n at RT. Standard Haematoxylin Eosin (H&E) staining was performed and 
microscopic pictures were captured using the Leica DM6000 (Leica microsystems).
Phenotypical analysis LC dDC and moMØ
Emigrated cells were washed in PBS with 1% BSA and 0.02% NaN3 and incubated for 
30 minutes on 4˚C with subset markers HLA-DR BV510 (clone G46-6, BD biosciences), 
CD1a APC (clone HI149, BD), CD14 AF700 (clone M5E2, Antibody Chain), CD141 BV711 
(clone 1A4, BD), EpCAM BV421(clone 9C4, Antibody Chain) and maturation markers 
CD86 FITC (clone BU63, ImmunoTools), CD80 FITC (clone 2D10, Biolegend), CD40 
PE-Cy7 (clone 5C3, Biolegend), CD83 PE-Cy7 (clone HB15e, BD) and Fixable Viability 
Dye eFluor780 (eBioscience). Cells were measured by flow cytometry (Fortessa X-20, 
Beckton Dickinson, San Jose, CA, USA) and analyzed with FlowJo (V10, Tree Star, 
Ashland, OR, USA).
Cytokine secretion skin biopsies
Cytokine secretion was measured using sandwich ELISA according to manufacturer’s 
protocol with specific cytokine antibody pairs for IL-1b, IL-6, IL-8 (BioSource), IL-10, 
IL-12p70 and TNF-a (eBioscience).
Peptide and dendrimer synthesis
In short, the gp100-SLP containing the CD8+ T-cell epitope (bold) and HA-tag 
(underlined) (Thz-VTHTYLEPGPVTANRQLYPEWTEAQRLDYPYDVPDYA-C) was 
synthesized by microwave assisted solid phase peptide synthesis using Fmoc 
chemistry on the Liberty blue peptide synthesizer (CEM).
A generation 0.0 PAMAM dendrimer core was functionalized with maleimide followed 
by coupling at the C-terminal end of the gp100-SLP containing a specific linker (Thz-
VTHTYLEPGPVTANRQLYPEWTEAQRLD-(Abu)3-C). Next, AF488-maleimide was added 
at the unmasked N-terminal (Thz) end for tracking. Mass and purity of all steps were 
confirmed by UHPLC-MS (Ultimate 3000 UHPLC, Thermo Fisher) hyphenated with a 
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LCQ-Deca XP Iontrap ESI mass spectrometer (Thermo Finnigan) using a RSLC 120 C18 
Acclaim 2.2um 2.1 x 250 mm column. Mass spectrometer analysis was measured in 
positive mode (Figure S3).
Human skin APC in-situ vaccine uptake
HA-tagged peptides or AF488-labeled dendrimers were diluted in serum-free 
IMDM and 20µl was ID injected or 10µl (2x concentration) was applied topically 
on 10mm2 following laser microporation and gently massaged (10seconds). Laser 
microporated areas were covered with Tegaderm film (Newpharma, Luik, Belgium) to 
avoid evaporation. Ten 8mm punch-biopsies were taken per condition and cultured 
as described above. For peptide uptake, APCs were fixed and permeabilized using a 
Cytofix/Cytoperm kit (BD) according to manufacturer’s instructions and stained with 
an anti-HA-AF488 (clone 6E2; Cell Signaling) antibody for 30minutes at 4⁰C. Cells 
were stained for subset markers and analyzed by flow cytometry as described above.
Human skin APC antigen presentation
For antigen presentation a specific T-cell clone recognizing the gp100 HLA-A2 
minimal epitope was produced and cultured as previously described30. HLA-A2+ skin 
was used for vaccine injection or application after laser microporation and 8 biopsies 
were taken and cultured as described above. Harvested cells were co-cultured in a 
96-well round bottom plate with the T-cells in a 1:5 ratio (triplicate). After 24 hours 
supernatants were harvested and T-cell activation measured using an IFNγ Ready-
Set-Go kit (eBioscience) according to manufacturer’s protocol.
Statistical analysis
GraphPad Prism (V7.02) was used for statistical analysis. Student’s T-test was used 
to compare percentage or number of cells. For group comparison two-way ANOVA 
followed by Tukey multiple comparison test were used with paired analyses for 
multiple donors. P-values <0.05 were considered to be significant.
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Supplementary data
Figure S1. (A) H&E staining of laser microporated human skin using 4 pulses and 23,7J/cm2 (top) 
or 35,6J/cm2 (bottom). (B) Gating strategy of human skin DC subsets following two day emigration 
using FACS.
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Figure S2. (A) Uptake of the SLP with HA-tag (left) and dendrimer-AF488 (right) by HLA-DR- cells 
following ID injection and laser poration. (B) CD83 and CD86 relative to FMO in the different skin 
DC subsets upon no treatment or medium injection.
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Figure S3. Purity and mass analysis of peptide and dendrimer synthesis as measured by UHPLC-MS 
and mass spectrometer systems. (A) SLP (B) functionalized G0-PAMAM-dendrimer (C) SLP conju-
gation to G0-PAMAM-dendrimer (D) Unmasking of G0-PAMAM-gp100 dendrimer (E) Conjugation 
of AF488 to antigenic dendrimer.
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Anti-tumor immonutherapy: exploring the human skin (DC) 
potential
Immunotherapy to treat cancer has gained much interest over the past two decades 
and strategies are rapidly developing. Approaches explored include antibody therapy 
(tumor-targeted, targeting TNF-R family members or immune checkpoint blockade 
[1]) cell-based therapy using innate immune cells (NK cells [2], neutrophils [3]), 
adoptive T cell transfer [4] and DC vaccines, or immune modulatory therapies (e.g. 
oncolytic viruses, TLR-L), or combinations of the above. Unfortunately, a treatment 
modality effective for a majority of patients has not yet been defined. This can have 
many reasons but is certainly attributed to the complex nature of cancer which 
comes in many types, residing in different tissues and varying in aggressiveness, 
immune suppression and mutational load.
It is becoming clear that anti-tumor immunotherapy benefits from the induction of 
tumor specific T cells resulting in systemic and long-lasting immunity against existing 
tumors, but also providing protection against the development of new tumors [5]. 
Anti-cancer immunotherapy largely relies on the induction of CD8+ cytotoxic T cells 
which have tumor killing capacity. DC play an important role in the priming and 
activation of these T cells. Recent insights show that CD8+ T cell priming by DC 
occurs in a two-step process. Both migratory DC and LN resident DC, which have 
encountered CD4+ helper T cells, successively present antigen to CD8+ T cells thereby 
enhancing the quality of the CD8+ T cell response [6, 7]. The pivotal role of DC in 
T cell activation has led to the development of DC based vaccination strategies 
for anti-tumor therapy. Initial efforts, and tested in clinical trials, included the ex 
vivo loading and activation of patient derived DC followed by injection into the 
patient. However, the fact that this type of vaccination is individualized, makes it 
ambitious due to time-management, costs and logistic issues [8]. Consequently, in 
vivo vaccination strategies are being developed to instruct DC using a single off-
the-shelf vaccine applicable for a large patient cohort [8]. The use of DC specific 
receptors, and especially CLR, for targeting purposes and facilitating antigen cross-
presentation in MHC I is a promising strategy to enhance anti-tumor immunity [9-
11]. There are multiple DC subsets residing in different tissues with varying receptor 
expression and function [12]. Consequently, there is a major ongoing research effort 
to discover the optimal DC-receptor targeting combination in order to induce potent 
anti-tumor immunity.




In this PhD thesis we explored the potential of the human skin, as prime site for 
vaccination, and its richness in DC subsets for the development of an in vivo anti-
tumor vaccination strategy, specifically targeting multiple human skin DC subsets. 
We used a human skin explant model to evaluate the targeting capacity in situ and 
subsequent CD8+ T cell activation. Multiple parameters may dictate whether our 
designed vaccine will show effectiveness in vivo, such as human skin DC migration, 
lymphatic drainage and local immune cell influx upon vaccination.
Human skin DC targeting for the induction of anti-tumor immunity. 
Targeting anti-tumor vaccines to intradermal DC for anti-cancer immunity has shown 
its potential in both murine models and human skin explants [13, 14]. In chapter 4, 5 
and 6 of this thesis we used the human skin explant model to evaluate the local effect 
of our vaccines. First, we evaluated the targeting efficiency of our glycan-modified 
tumor specific (glyco-dendrimer) vaccine to multiple human skin DC subsets. We 
did this via dual Langerin and DC-SIGN targeting of which the intracellular routing 
for cross-presentation was investigated in chapter 2 and 3, respectively. Second, 
we elucidated the immune responses induced by our NOD2 multivalent tumor 
antigen-adjuvant complex (MAAC) through human skin DC activation and cross-
presentation. Lastly, the feasibility of applying the vaccines with either injection or 
laser microporation for DC antigen uptake and presentation was evaluated.
The human skin explant model encompasses the various human skin DC subsets 
present in their natural 3D environment and physical state. As such, it can address 
targeting efficiencies and internalization by DC for processing and presentation to 
T cells. However, within human skin explants it remains challenging to elucidate 
the combination of local effects at the injection site with systemic effects inducing 
immunity. In chapter 4 the hypothesis is tested that targeting to multiple DC subsets 
simultaneously may enhance vaccine efficiency. Although we could evaluate the 
targeting capacity of our glyco-dendrimers to the multiple skin DC subsets, the 
question remains whether this will indeed enhance anti-tumor immunity in vivo.
The intrinsic capacity to activate and modulate adaptive immunity is described to 
differ between the human skin DC subsets. Where LC and CD1a+ dermal DC are 
considered to initiate cellular responses, CD14+ dermal DC appear to induce humoral 
responses by TFH differentiation [15, 16]. One can argue that stimulating different 
DC subsets simultaneously can hence induce broad and possibly complementary 
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adaptive immune responses. By addition of targeting moieties, such as glycans, 
uptake and antigen processing by DC can be enhanced, as we show in chapter 4. 
Additionally, in this thesis we focus on augmenting cross-presentation by specific CLR 
targeting, particularly Langerin (chapter 2) and DC-SIGN (chapter 3), regardless of 
the intrinsic capacity of the different human skin DC. The discussion remains which 
human skin DC subset would be the prime target for cross-presentation of tumor 
antigens, and thus the activator of anti-tumor CD8+ T cell responses. In literature 
the CD141+ dermal DC (or cDC1) often wins this battle owing to its inherent capacity 
for cross-presentation and high MHC I expression [17, 18]. We observed uptake of 
our (glyco)-dendrimers by LC and both CD1a+ and CD14+ dermal DC, yet hardly by 
the CD141+ dermal DCs (chapter 4). As such it is questionable whether these so-
called prime cross-presenters will take part in the induction of adaptive immunity 
upon intradermal vaccination with our glyco-dendrimers. Furthermore, with the right 
targeting strategy many different DC subsets can cross-present exogenous derived 
antigens for CD8+ T cell activation [11]. Indeed, both the lower (CD1a+ dermal DC) 
and high (CD14+ dermal DC) DC-SIGN expression levels of dermal DC can be used to 
efficiently target glycan-modified vaccines to these DC (chapter 4) for induction of 
cross-presentation, as previously described [14, 19]. Furthermore, while DC have 
always been considered the prime cross-presenting APC, a recent study showed that 
both monocyte derived DC (moDC) and macrophages (moMac) have cross-presenting 
ability [20]. However, the discrepancy lay in the activation of effector CD8+ T cells 
which was accomplished by moDC, but not moMac.
In this thesis we used the human skin explant model in combination with melanoma 
specific T cell clones. These clones do not require co-stimulation for activation and 
are a great tool to evaluate loading and presentation of the vaccine antigens in MHC 
class I. However, this also means it does not resemble naïve T cell priming in the 
lymph nodes (LN), though previous studies show the priming capacity of human skin 
DC [21-23]. An interesting development is the recognition that not only CD8+ T cell 
priming for effector CTL induction is important for anti-tumor immunity. Also (re)
activation of CD8+ tissue resident memory T (TRM) cells impacts the efficacy of cancer 
immunotherapy, as they induce superior immunity compared to effector cells [24] 
and potentially induce long-term protection against tumor recurrence as described 
for melanoma [25]. In melanoma it was shown that upon intradermal vaccination 
using a DEC205 targeting strategy, tumor antigen-specific TRM accumulated in the 
skin and suppressed tumor growth in vivo in mice [26]. Interestingly, CD14+ dermal 




DC have been reported to play a role in the maintenance/activation of skin-resident 
TRM. It would be interesting in future studies to evaluate the specific induction of 
various CD8+ T cell subsets and differentiation states, including effector and memory 
cells, upon intradermal vaccination with our multivalent (glyco)-vaccines.
Lymphatic drainage of vaccins, implications for DC targeting
Naïve T cell activation requires antigens to arrive at the draining LN, or tumor-
adjacent tertiary lymphoid structures, for presentation by DC. This can occur via 
two routes; namely via migratory DC which present processed antigen in MHC 
or transfer the antigen to LN resident DC, or by drainage of the vaccine antigens 
via the lymphatics and subsequent uptake and presentation by LN (resident) DC. 
For intradermal vaccination, targeting of numerous DC populations at their site of 
residence is important [7, 27]. However, lymph drainage of the vaccine itself may 
result in uptake by DC present in skin-draining LN. These include LN DCs which stem 
from blood precursors, but also DCs that have migrated from the skin via the afferent 
lymph vessels [12, 28]. This might enhance vaccine efficacy as LN resident DCs are 
capable of antigen cross-presentation upon activation and can induce strong CD8+ 
T cell responses [29]. Importantly, vaccine delivery-systems can promote antigen 
transport to lymphoid organs e.g. through size requirements. Particles of (up to) 200 
nanometer sizing are preferentially trafficked into the lymphatic vessels [30]. Our 
tumor specific glyco-dendrimers described in chapter 4 have a size of approximately 
50nm and thus comply with the LN trafficking size requirement. As such, the glyco-
dendrimers might reach the LN by drainage via the lymphatics. Interestingly, in steady 
state DC-SIGN+ (dermal) DCs are present in the paracortex of the LN, the site where 
DCs and T cells interact [28, 31]. Also Langerin+ LCs can be found in the skin draining 
LN [12]. Currently it is not known whether our glycan-modified DC targeting cancer 
vaccine will drain to the LN and subsequently instruct LN resident DC that express 
Langerin or DC-SIGN besides the skin DC. It would be interesting to elucidate whether 
vaccine trafficking to LN occurs and, if so, what the impact on vaccine efficacy could 
be.
Studying human skin DC migration
Intradermal vaccination strategies are designed with the rationale that DCs will take 
up antigens in the skin, followed by migration and presentation in the LN to T cells. 
However, not all skin resident DC subsets are equally well equipped to migrate from 
the skin to the draining LN to activate naive CD4+ and CD8+ T cells. In CCR7 deficient 
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mice no skin DCs were present in the skin draining LN during inflammation, which 
highlights the importance for DCs to express CCR7 for LN trafficking [32]. Indeed, 
upon inflammation mature LCs and CD1a+ dermal DCs are able to migrate from the 
dermis to the LNs through CCR7 expression [33, 34]. Furthermore, these subsets 
have also been found in sentinel LN of melanoma patients [28], resembling steady 
state human skin DC migration. Interestingly, although expression of CCR7 on CD14+ 
dermal DC is controversial, it has been observed that CD14+ dermal DCs can emigrate 
spontaneously from the skin. The past years the CD14+ dermal DC ontogeny has been 
re-evaluated. It is postulated that the CD14+ dermal DC subset closely resembles 
monocyte derived macrophages [35], though they are not to be confused with the 
CD14+ resident macrophages of human skin. The CD14+ resident macrophages are 
sporadically replenished, whereas the CD14+ dermal DC is a transient population 
more rapidly replenished through monocyte influx [35]. Furthermore, the CD14+ 
dermal DC emigrate from the human skin biopsies during culture, while CD14+ 
macrophages remain situated in the skin. When imaging of steady state human skin, 
CD14+ dermal DC were not observed within the skin lymph vessels [35]. So far, the 
localization of CD14+ dermal DCs is unclear as they may lose their CD14 expression 
during migration, which makes it difficult to trace this subset [36].
The human skin explant model lacks dynamics such as that of chemokine induced DC 
migration, since all the different human skin DC subsets migrate out of skin biopsies 
spontaneously. As such, this does not denote chemokine induced migration upon 
vaccine challenge. To elucidate which human skin DC subset can migrate to LN in 
response to the chemokines CCL19 and CCL21, we developed an ex vivo human skin 
DC migration assay using a transwell system (chapter 5). The LN homing receptor 
CCR7 is described to be restricted to CD1a+ dermal DC and epidermal LC, though, 
also shows variable expression by CD14+ dermal DC [37]. Interestingly, approximately 
20% of the CD14+ dermal DC also showed migration towards CCL21 within 4 hours 
(chapter 5), which concurs with the variable expression of CCR7 [37]. Notably, CD14+ 
dermal DC migration could be increased to ~45% when the activation stimuli GM-CSF/
IL4 were injected prior to DC emigration from biopsies (chapter 5). The combination 
of GM-CSF and IL-4 injection in the skin was previously shown to prevent switching of 
CCR7+ DC to a non-migratory macrophage-like phenotype [38]. The use of GM-CSF/
IL4 as adjuvant for intradermal vaccines targeting skin DC might be a viable option 
to enhance (CD14+) dermal DC migration to draining LN.




The functional implications of the CD14+ dermal DC migration capacity towards 
draining LN for induction of tumor specific immune responses remains elusive. It is 
clear they are capable of cross-presentation and subsequent activation of effector 
CD8+ T cells, especially upon DC-SIGN mediated antigen uptake [14]. Interestingly, 
in breast cancer patients skin-emigrated CD14+ dermal DC were increased, though, 
induced a Treg phenotype rather than priming of effector T cells under the influence 
of IL10 [39]. However, these emigrated CD14+ dermal DC displayed a more immature 
phenotype while the mature CD1a+ dermal DC subset did induce efficient priming of 
effector T cells. The addition of adjuvants such as Aldara might overcome this issue 
by induction of skin DC maturation [40]. Though, no study has elucidated whether 
there might be a difference in the migrating versus non-migrating CD14+ dermal 
DC, for example in relation to induction of effector or memory T cell responses. 
In chapter 4 we show that the CD14+ dermal DC subset can be efficiently targeted 
for antigen uptake via DC-SIGN, together with CD1a+ dermal DC. The next step 
would be to investigate whether both dermal DC subsets can migrate to draining 
lymph nodes, or, whether they have different immunological outcomes in regard to 
effector or memory T cell activation. Importantly, CD14+ dermal DC can be rapidly 
replenished via monocyte influx thereby resembling CD14+, DC-SIGN+, monocyte 
derived DC (moDC) [37]. These DC-SIGN+ moDC are important inducers of anti-
tumor immune responses especially after challenge of antigen in combination with 
specific adjuvants, such as AddaVax, that rapidly induces local influx of monocytes 
and neutrophils, with moDC accumulating at 12 hours after injection. Addavax 
enhanced antigen specific CD4+ and CD8+ T cells while targeting moDC with DC-SIGN 
additionally boosted antigen specific antibody responses [41, 42]. Overall, future 
studies should investigate the contribution of the different resident skin DC subsets, 
and possibly moDC, in induction and maintenance of anti-tumor immune responses 
upon intradermal vaccination using our multivalent glyco-dendrimers.
Intradermal vaccination and influx of innate immune cells
Central to the efficacy of clinically approved adjuvants are DC [43]. With the design 
of in vivo intradermal vaccination strategies the main focus lies on the effect of the 
vaccine formulation on skin DC, since these are the cells able to initiate adaptive anti-
tumor immune responses. However, with intradermal injections the vaccine comes 
into contact with more than just DC since the tissue also comprises supportive cell 
types, such as stromal cell types like keratinocytes, melanocytes and fibroblasts, 
which are considered to play an important role in immune responses [44]. The 
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vaccine is also able to accumulate various immune cells that are recruited from the 
blood to the dermis upon inflammatory signals provided by the vaccine (Figure 1).
Many vaccine adjuvants have shown to depend on local activation and recruitment 
of neutrophils or monocytes that may differentiate into DC [45]. Fibroblasts can 
play an important role in the induction of an innate immune cell influx, since they 
can respond to TLR agonists by cytokine secretion e.g. IL-6 and IL-8 [46] (Figure 1). 
Intradermal vaccination with influenza virus using micro-needle patches can increase 
multiple inflammatory cytokines in the skin, such as IL-1β, macrophage inflammatory 
protein 1 and 2 (MIP-1/2), TNF-α and monocyte chemoattractant protein 1 (MCP-
1), thereby attracting monocytes and neutrophils [47]. Furthermore, adjuvants that 
stimulate DC maturation, such as the TLR4-agonist monophosphoryl lipid A (MPLA) 
and the TLR7/8 agonist imidazoquinoline (Resiquimod, R848) can recruit macrophages 
and affect the relative percentages of macrophages and inflammatory monocytes in 
the human skin, respectively [48]. Squalene-based adjuvants MF59 or AddaVax (oil-
in-water nano-emulsion formulations), which is regularly used in seasonal influenza 
vaccines [49], are described to induce monocyte recruitment via the CCR2/CCL2-
axis in mice [50]. Influx of monocytes upon intradermal vaccination may result in 
transport of the vaccine by monocytes or monocyte-derived DC. Indeed, addition 
of small amounts MF59 could increase the migration capacity of intramuscularly 
differentiated monocyte-derived DCs in mice [51]. In fact, MF59 may have similar 
effects in the murine skin, recruiting monocyte-derived DC expressing the mouse 
orthologue of DC-SIGN [42]. These monocyte-derived DC can take up antigen and 
are capable of inducing T cell activation in the draining LN [52], thereby influencing 
immunological outcome following intradermal vaccination. With our NOD2-MAAC 
vaccine described in chapter 5 we found increased levels of IL6 and IL8, indicating 
that this vaccine might also induce innate immune cell influx. Furthermore, the 
absence of innate immune cell influx within our human model skin explant might 
explain why in chapter 6 we did not find the benefits of laser microporation for 
intradermal vaccine delivery, as described in other studies using mouse models [53, 
54]. Influx of innate immune cells such as neutrophils and monocytes may alter the 
skin micro-milieu and uptake of the vaccine.




Figure 1 Influx of innate immune cells in the skin after vaccination. Upon vaccination inflammatory 
cytokine (IL-1b, MIP1/2, TNF-a and MCP-1) levels are increased to which monocytes, neutrophils 
and macrophages are attracted. Since fibroblasts express TLRs they might react to TLR ligands 
(blue) after which fibroblast can change the local environment of the skin thereby inducing innate 
immune cell influx. After injection of a MPLA-containing vaccine (red) neutrophils and monocytes/
macrophages are recruited from the blood to the skin.
Modelling skin immune complexity to predict vaccine efficacy
At this time, the full complexity of how local vaccine injection can drive systemic 
responses can only be modeled in live organisms such as mice. However, they show 
many differences with humans [55] and there is an urgent need for humanized 
models [56]. These can be mouse models that include microbial composition [57], 
expression of human receptors (for example DC-SIGN [58]), humanized immune cell 
compositions [59, 60] and the inclusion of both sexes [61].
The potential of multivalent glycan-modified anti-tumor vaccines was shown in a 
mouse model with human DC-SIGN expression [STT Schetters et al Biomaterials, 
submitted]. Here vaccination with OTI-OTII specific antigen matrices (AMAX) induced 
tumor specific T cell activation. Though the restricted DC-SIGN expression in humans 
calls for the use of artificial, humanized models to test our glyco-dendrimer vaccine 
in vivo. Although a mouse model with human DC-SIGN (hSIGN) under the control of 
the CD11c promotor has been generated [62], this does not reflect the DC restricted 
DC-SIGN expression as observed in humans. Currently, a new mouse model is being 
developed which controls DC-SIGN expression under its own promotor region, 
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thereby mimicking DC-SIGN expression in man. This model would be useful for the 
in vivo testing of our glycan-modified vaccine of chapter 4, simultaneously targeting 
multiple human skin DC subsets through DC-SIGN and Langerin.
Meanwhile, there are new developments which might make the use of mouse models 
redundant in the future. One such an approach is the use of skin-on-chip technology 
[63], which aims to mimic the physiology of the human skin. This model consists of 
three layers, including epidermis, dermis and fat tissue, in which the dermis and 
fat tissue are linked to a systemic circulation system via micro-capillaries [12]. The 
present skin-on-chip models contain epidermal LC [64], however the incorporation 
of dermal DC has yet to be resolved and, therefore, these skin-on-chip systems are 
not yet suitable to study the effect of intradermal vaccination. However, induced 
pluripotent stem cells could be integrated in the skin-on-chip model to induce the 
presence of immune cells [12]. These induced pluripotent stem cells can differentiate 
into B cells, NK cells and T cells [65, 66]. Combined with a micro-capillary system 
for influx of innate immune cells this could be a promising strategy in the future to 
optimize the skin-on-chip model. Moreover, with advanced microfluidics connecting 
different tissue compartments like bone marrow, lymph node and tumor, one could 
envision studying combined local and systemic effects of vaccination like immune cell 
recruitment, T cell priming, trafficking and anti-tumor effector T cell efficacy. Thus, 
future directions should be aiming to develop these complete ex vivo human-on-
a-chip immune networks that allow us to study the dynamics of (adjuvant-induced) 
anti-tumor immunity of DC targeted vaccines.
Targeted intradermal anti-tumor vaccines: one size fits all?
Besides the model systems which are important for the research encompassing 
targeted intradermal anti-tumor vaccination strategies, also the type of tumor 
to fight may determine vaccine efficacy. In this thesis we focused on designing 
anti-melanoma vaccines, using melanoma specific antigens (gp100) to synthesize 
our glycan-modified vaccines. Future research should focus on how we can use 
intradermal glycan-modified vaccines for other solid tumors and what other factors 
are of importance. One of these factors is the choice of antigen, since they may in 
large part determine immunogenicity [67]. Tumors which are virally induced [68] 
or have a high mutational load (such as melanoma or lung cancer [69]), can be 
targeted using highly immunogenic viral antigens or neoantigens, respectively. For 
the design of the glyco-modified vaccines which we generated, this should be easy 




to implement, as they are built with synthetic long peptides. Synthesis of the right 
peptidic sequences, based on individual patient tumor sequences, together with 
MHC binding prediction programs, may be easily accomplished and the synthesized 
peptides could subsequently be coupled to the dendrimer core, in effect leading to 
personalized vaccines.
Viral antigens for solid tumor eradication: glioblastoma and 
human CMV
Viral infections can induce cancer formation, e.g. HPV infection and cervical cancer 
[70], which can be used to vaccinate prior to cancer development. On the other hand, 
viruses may also contribute to cancer progression. Although here a prophylactic 
vaccine will not work, it can open the door to develop therapeutic vaccines with 
higher immunogenicity due to the presence of viral, non-self antigens. Especially in 
cancers which have a low mutational load, such as glioblastoma multiforme (GBM) 
[69], and hence, hardly express immunogenic neoantigens, targeting the viral 
antigens might be the solution for effective anti-cancer vaccination.
GBM is the most aggressive brain tumor and median survival time with current 
therapies is only 14.6 months. Although multiple immunotherapeutic strategies 
are being explored, efficacy remains poor. Neuro-oncologists are increasingly 
interested in the presence and involvement of human cytomegalovirus (HCMV) in 
the pathogenesis of GBM and its potential use for targeted therapy. GBM comprises 
80% of malignant brain tumors in adults and, owing to the highly infiltrative nature 
of GBM, surgical resection is unable to remove the entire tumor, therefore current 
standard-of-care treatment also includes chemoradiation. Unfortunately, GBM 
stem-like cells (SLC) are resistant to chemoradiation and often patients experience 
recurrence [71]. It is increasingly clear that new therapies are warranted and 
immunotherapeutic strategies are widely explored. Unfortunately, ongoing 
immunotherapeutic strategies based on vaccination against tumor antigens such as 
rindopepimut, a peptide-based vaccine targeting epidermal growth factor receptor 
variant III (EGFRvIII), have not demonstrated complete clearance [72]. Moreover, due 
to the relatively low mutational rate of GBM there is a lack sufficient neoantigens 
and new antigenic targets are necessary [69].
The fact that human cytomegalovirus (HCMV) is absent in healthy tissue, but found in 
75-100% of various grade gliomas makes it an attractive target candidate for HCMV-
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specific cytotoxic (CD8+) T cells [73]. Interestingly, recent studies showed that HCMV 
has a higher infection efficiency in GBM SLC compared to other glioma cell lines 
and HCVM infection can even induce a SLC phenotype in GBM tumor cells [74]. As 
GBM is a highly heterogeneous tumor, a single antigenic target is likely insufficient. 
Therefore we hypothesize that the combination of endogenous and HCMV epitopes 
for the activation of tumor specific T cells would represent a viable alternative 
to enhance killing of both ‘regular’ tumor cells and SLC. The potential of patient-
derived HCMV specific T cells to target GBM has been described. A clinical trial 
using HCMV pp65-RNA pulsed DCs in combination with vaccine site pre-conditioning 
showed effective pp65-specific immune responses for several months and highest 
in long-term surviving patients, confirming the potential of HCMV as target for GBM 
treatment [75]. The multivalent glyco-dendrimer vaccine described in chapter 4 of 
this thesis can represent a viable strategy to include the different HCMV antigens 
and induce adaptive immunity against cancers such as GBM.
Epitope inclusion within multivalent antigenic dendrimers
Designing synthetic peptide (anti-tumor) vaccines comes with challenges, including 
chemical parameters such as solubility and stability, and the influence on biological 
activity [76]. The PAMAM-dendrimers used in this thesis (chapter 4 and 5) are often 
used as tool to enhance both aqueous solubility and stability [77]. We observed 
that conjugation of hydrophobic peptide sequences, such as the HLA-A2 specific 
HCMV epitope, appeared to overrule PAMAM-dendrimer core solubility leading to 
aggregates (Chapter 5, Figure S1A). There are ways to avoid this aggregation e.g. 
by addition of combined hydrophobic CD8 (MHC I) and hydrophilic CD4 (MHC II) 
epitopes as we used in chapter 4 with the melanoma specific gp100 construct. Also 
addition of hydrophilic amino acids to the antigenic epitope could rescue solubility 
of the HCMV specific glyco-dendrimers (chapter 5, Figure S1B-C). However, when 
combining epitopes or including other amino acids within the natural peptide 
sequence, it is important to ensure that no unwanted peptide sequences appear 
following intracellular processing. These unwanted sequences may instruct adverse 
immune responses against epitopes present on other tissues than the tumor. 
Furthermore, we should be aware that different peptide sequences may influence 
3D conformation of the glyco-dendrimers [78]. Careful evaluation of CLR targeting 
for enhanced uptake and (cross)-presentation is required when new peptides are 
conjugated to create tumor specific (glyco)-dendrimers. Nevertheless, our glycan-
modified vaccine described in chapter 4 has the potential to be used in a “one-size-




fits-multiple-tumors” format, since the multivalent nature can harbor multiple tumor 
specific or shared epitopes.
Concluding remarks
In summary, this thesis shows that the CLR Langerin and DC-SIGN expressed by human 
skin LC and dermal DC, respectively, are excellent candidates for targeted intradermal 
anti-tumor vaccination strategies. By designing a ‘’tailor-made’’ multivalent glycan-
modified vaccine with the glycan LeY, a dual targeting ability arises to both receptors. 
This ensures endocytosis by multiple human skin DC in situ using one formulation 
of a glycan-modified vaccine. Inclusion of an SLP consisting of both a CD4+ and 
CD8+ gp100 specific antigen resulted in activation of both CD4+ and CD8+ T cells. 
Furthermore, we show that the addition of PRR agonists as adjuvant enhances tumor 
specific CD8+ T cell activation. Importantly, future studies should focus on the use 
of models which combine the complexity of the human skin and adjuvant induced 
immune cell- and antigen trafficking. The intradermal anti-tumor vaccination strategy 
targeting multiple human skin DC subsets that we have generated has potential merit 
for use against multiple tumor types that are eradicated by tumor specific CD4+ and 
CD8+ T cells.
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“Dansen met Dendritische Cellen: richten op humane huid dendritische cellen 
voor anti-tumor immuniteit”
Recentelijk komt het onderwerp vaccineren vaak in het nieuws en vooral ook voorbij 
op sociale media, en helaas niet altijd in een goed daglicht. Maar wat is vaccineren 
nou eigenlijk, wat houdt het werkelijk in en hoe kunnen we het vandaag de dag ook 
gebruiken voor anti-kanker therapie, zoals beschreven in dit proefschrift?
Van oudsher wordt vaccineren gebruikt voor het aanzetten van het immuunsysteem 
om ziekteverwekkers, zoals virussen, af te kunnen weren zonder hier ernstig ziek 
van te worden. Hiertoe worden onderdelen van het virus in het vaccin gestopt 
welke niet zullen leiden tot infectie, maar wel specifiek worden herkent door het 
immuunsysteem om de afweer op te bouwen. In het geval van infectieziekten 
kan dit vooraf, ofwel profylactisch, zodat het immuunsysteem op moment van 
infectie snel kan reageren en voorkomen dat we ziek worden. Voor kanker kunnen 
we enkel profylactisch vaccineren wanneer deze viraal geïnduceerd is, zoals bij 
baarmoederhalskanker, om het verschijnen van dit type kanker te voorkomen.
De meeste tumoren ontstaan echter door een opbouw van mutaties in de cel onder 
invloed van bijvoorbeeld UV-straling, met als gevolg ongeremde groei. Een anti-
kanker vaccin zal alleen werken als het herkenning van deze mutaties door het 
immuunsysteem aanzet. Aangezien het lastig is vooraf te bepalen welke mutaties 
zullen opdoemen, kunnen vaccins tegen dit type kanker enkel achteraf, ofwel 
therapeutisch, gegeven worden. In dit proefschrift beschrijven we de ontwikkeling 
van een therapeutisch anti-kanker vaccin, waarvoor we melanoom ter illustratie 
hebben gebruikt.
Om inzicht te geven hoe een vaccin precies werkt en hoe hier gebruik gemaakt van 
kan worden, is het belangrijk de werking van het immuun systeem te begrijpen. 
In ons lichaam zitten dendritische cellen (DC) die constant de omgeving aftasten. 
Komen ze iets tegen wat er niet hoort te zijn, dan nemen ze dit op om te verwerken 
tot kleine peptiden. Tussen de vele peptiden die gegenereerd worden zitten 
specifieke sequenties, de antigenen, die geladen kunnen worden op zogenaamde 
MHC moleculen. DC migreren vervolgens naar de lymfeklieren waar T cellen het 
peptide gepresenteerd in MHC op het celmembraan van de DC zullen herkennen 




voor activatie. Grofweg kunnen de T cellen opgedeeld worden in twee groepen: de 
(CD4+) helper en de (CD8+) cytotoxische T cellen. Zoals de naam al zegt, zullen helper 
T cellen helpen bij initiëren van gerichte immuun responsen door andere immuun 
cellen aan te sturen, terwijl cytotoxische T cellen zelf direct kunnen doden. Met anti-
kanker vaccinatie willen we dan ook met name de cytotoxische T cellen activeren.
Voor het activeren van de helper of cytotoxische T cellen gebruikt de DC twee 
klassieke routes om de antigenen te presenteren. De eerste is voor componenten die 
van buiten de cel komen (bijvoorbeeld bacteriën) en de tweede voor componenten 
die aanwezig zijn in de cel (bijvoorbeeld virussen). Componenten van buiten de cel 
worden verwerkt tot peptiden die geladen en gepresenteerd worden op MHC type 
II moleculen voor helper T cel activatie, terwijl die van binnen in de cel op MHC 
type I moleculen worden gepresenteerd voor cytotoxische T cel activatie. Echter, de 
peptiden afkomstig van componenten buiten de cel kunnen door de DC ook op MHC 
type I moleculen geladen worden, beter bekend als cross-presentatie. Deze derde 
route van antigeen presentatie is met name belangrijk voor anti-kanker vaccins, 
aangezien het vaccin van buitenaf door de DC opgenomen zal worden.
Naast herkenning van peptide-MHC complexen hebben T cellen nog extra stimulatie 
van de DC nodig, gegeven via co-stimulatoire moleculen. Als deze stimulatie niet 
aanwezig is zullen de T cellen niet geactiveerd worden en in anergie gaan. De DC 
brengt co-stimulatoire moleculen tot expressie na het herkennen van een “gevaar” 
signaal via “patroon herkennende receptoren” (PRR). Er zijn ook PRR die opname 
faciliteren door het binden van suikers, de C-type lectine receptoren (CLR). Daarnaast 
kan opname via CLR cross-presentatie verhogen doordat peptiden beschikbaar 
komen voor belading van MHC type I moleculen. Een anti-kanker vaccin moet dus 
uit twee componenten bestaan: de tumor specifieke antigenen en een gevaar signaal.
Een belangrijk aspect van vaccineren is de plek van toedienen, omdat het vaccin bij 
de DC terecht moet komen om immuniteit op te kunnen bouwen. In onze huid zitten 
meerdere typen DC, namelijk Langerhans cellen (LC) in de epidermis (opperhuid) 
en drie verschillende DC in de dermis (lederhuid). De verschillende DC zijn elk 
gespecialiseerd in het induceren van op maat gemaakte immuun responsen. Dit 
maakt de huid een zeer geschikte plek voor het toedienen van een vaccin.
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In dit proefschrift hebben we de mogelijkheden onderzocht om een anti-kanker 
vaccin te ontwikkelen dat in de huid geïnjecteerd kan worden voor het opwekken 
van anti-kanker immuun responsen. Hiervoor hebben we gebruik gemaakt van het 
melanoom specifieke eiwit gp100, waarvan de peptide (of antigeen) sequenties 
bekend zijn. Deze kunnen we chemisch synthetiseren om aan het eerste benodigde 
component van een vaccin te voldoen. Daarnaast hebben we onderzocht of we 
verhoogde cross-presentatie kunnen induceren door de gesynthetiseerde gp100 
peptiden te koppelen aan suikers welke CLR kunnen binden die aanwezig zijn op de 
verschillende huid DC. Verder hebben we onderzocht of en hoe we met behulp van 
het tweede vaccin component, het gevaar signaal, de cytotoxische T cel activatie 
kunnen verhogen.
In hoofdstuk 2 hebben we laten zien dat peptide opname via de CLR Langerin in 
combinatie met het gevaar signaal Poly I:C resulteert in verhoogde cytotoxische T cel 
activatie. Verder hebben we laten zien dat Langerin efficiënter is voor cytotoxische 
T cel activatie dan een andere CLR welke ook aanwezig is op LC, Dectin-1. Dit komt 
doordat de synthetische peptiden opgenomen via Langerin langer intact blijven 
dan via Dectin-1, wat ervoor zorgt dat ze langer beschikbaar zijn om in de cross-
presentatie route terecht te komen.
In hoofdstuk 3 bestuderen we de route die antigenen nemen na opname via 
DC-SIGN. Ook peptide opname via deze receptor kan cytotoxische T cel activatie 
induceren wat we wederom konden verhogen door een gevaar signaal erbij te geven. 
In dit hoofdstuk laten we zien dat dit specifieke gevaar signaal, LPS, ervoor zorgt dat 
peptiden opgenomen via DC-SIGN vrij komen in het cytosol van de cel en daarmee 
beschikbaar voor cross-presentatie en cytotoxische T cel activatie.
Naar aanleiding van de bevindingen in hoofdstuk 2 en 3, waarin vaccin opname 
via zowel Langerin als DC-SIGN individueel versterkte cytotoxische T cel activatie 
gaven, was onze vraag of een verdere versterking mogelijk was door een vaccin te 
ontwikkelen dat simultaan gericht kan worden aan Langerin en DC-SIGN. Op die 
manier kunnen meerdere huid DC geactiveerd worden voor het instrueren van 
anti-kanker immuun responsen. Hiervoor hebben we gebruik gemaakt van een 
suikerstructuur welke door zowel Langerin als DC-SIGN herkend wordt. Echter 
heeft Langerin voorkeur voor kleine suiker-gecoate peptide-structuren, terwijl 
DC-SIGN beter grote opneemt. Daarom hebben we in hoofdstuk 4 een geraamte 




gebruikt waar meerdere peptiden aan gekoppeld kunnen worden. Dit gaf meerdere 
groottes, multivalente peptide-structuren, waaraan we de suiker Lewis Y (LeY) hebben 
gekoppeld om uit te zoeken welke door beide receptoren herkent en verwerkt wordt 
voor cytotoxische T cel activatie. Daarbij hebben we de gevaar signalen Poly I:C en 
MPLA (een LPS afgeleide) gebruikt, zoals in hoofdstuk 2 en 3. Dit heeft geresulteerd 
in een enkel melanoom specifiek vaccin dat in één keer meerdere humane huid DC 
kan bereiken voor instructie van anti-kanker immuun responsen.
We hebben in hoofdstuk 2, 3 en 4 laten zien dat het activeren van PRR op DC 
met behulp van de gevaar signalen Poly I:C en LPS/MPLA van belang is om betere 
cytotoxische T cel activatie te krijgen. In hoofdstuk 5 hebben we onderzocht of 
het veel gebruikte gevaar signaal ‘MDP’, afkomstig van bacteriën, ook gebruikt kan 
worden voor activatie van humane huid DC en cytotoxische T cellen. MDP wordt 
herkent door een PRR welke zich in het cytosol van de DC bevindt, NOD2, en zal dus 
pas na opname het gevaar signaal kunnen afgeven. Daarom hebben we onze unieke 
multivalente peptide-structuur gebruikt, en hier chemisch MDP aan gekoppeld. We 
laten zien dat dit een efficiënte manier is om MDP in de huid DC te krijgen en hiermee 
verhoogde cytotoxische T cel activatie te genereren.
Het toedienen van intradermale vaccins geschiedt gewoonlijk via injectie, echter, zijn 
er nieuwe technieken in ontwikkeling die dit kunnen vergemakkelijken. Een van die 
technieken is het gebruik van een laser welke kleine gaatjes in de huid maakt, waarna 
het vaccin erop toegediend wordt. Behalve het toegenomen gemak, zijn er ook 
studies die laten zien dat via de laser gevaar signalen afgegeven worden, wat het apart 
toevoegen van gevaar moleculen aan een vaccin overbodig maakt. In hoofdstuk 6 
hebben we gekeken of onze anti-kanker vaccins ook na laser behandeling toegediend 
kunnen worden en of dit een toegevoegde waarde heeft ten opzichte van injecteren 
voor het induceren van anti-kanker immuun responsen. Hiervoor hebben we gebruik 
gemaakt van een humaan huid model, waarin we laten zien dat injecteren beter 
werkt voor het toedienen van onze anti-kanker vaccins door verhoogde opname en 
T cel activatie vergeleken met toediening na laser behandeling.
In conclusie, in dit proefschrift hebben we een anti-kanker vaccin ontwikkeld 
bestaande uit een melanoom specifiek, synthetisch multivalente peptide-structuur 
met daaraan suikers, en een gevaar signaal. Dit heeft geresulteerd in specifieke 
opname door meerdere huid DC via Langerin en DC-SIGN , na intradermale injectie. 
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De gerichte levering naar deze CLRs in combinatie met gevaar signalen heeft 
geresulteerd in verhoogde cytotoxische T cel activatie, welke de capaciteit hebben 
om specifiek kanker cellen te doden en daarmee kanker op te ruimen. Kortom, 
ons synthetische vaccin bied de mogelijkheid voor inclusie van meerdere kanker 
specifieke antigenen en heeft potentie voor klinisch onderzoek om kanker in de 
toekomst te genezen.
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Oktober 2014 begon het grote avontuur. Waar we toen de grap maakten dat 2020 ons 
jaar zou worden, konden we klaarblijkelijk de toekomst voorspellen. Na zinderende 
hitte, watervallen op de trap, pierenbadjes in de gang en de grote migratie overleefd 
te hebben, is nu ook ein-de-lijk mijn thesis af! Wat een bevalling, alhoewel… 
vergeleken daarmee valt het eigenlijk allemaal reuze mee, het duurt alleen wat 
langer. Het tot stand komen van dit “boekje” is uiteraard niet vanzelf gegaan en ook 
zeker niet zonder de hulp van velen.
Allereerst mijn promotor Yvette. Wat vond ik het spannend om te komen solliciteren. 
Bij thuiskomst op mijn nagels zitten bijten terwijl je me ongeveer 10 minuten nadat 
ik naar buiten was gelopen al had gemaild dat ik de positie mocht komen vervullen.. 
kwam ik 3 uur later pas achter. Ik ben heel erg blij dat ik mijn PhD in jou groep en 
onder jou supervisie heb mogen doen. Niet alleen op wetenschappelijk vlak heb 
ik veel van je geleerd, maar door je grote mensen kennis heb ik mezelf ook op 
persoonlijk vlak kunnen ontwikkelen. Je zag dingen voor ik het zelf doorhad, maar 
gaf ook tijd en ruimte om dit zelf te ontdekken en ervan te leren. Heel veel dank voor 
alle tijd en energie die je in me heb gestoken en het vertrouwen dat je me geeft om 
mijn carrière te vervolgen in het onderwijs onder jouw hoede!
Dan natuurlijk mijn co-promotoren. Juan, we met when I was a 1st year master 
student and supervised me during my 2nd year for my master thesis. Then I already 
learned that you have a very creative mind and are a great writer, and was very 
pleased to hear you would be there at my site during my PhD as well. You are always 
up-to-date with the latest technical developments and guided me to use these to up 
the game of my experiments and analysis. I want to thank you for your time and input 
during the course of my PhD. It is special that you are now here as co-promotor, who 
would have thought the first time I walked through your office door.
Tanja, in het begin vond ik jou best intimiderend met je ongelofelijke hoeveelheid 
kennis en directe aanpak. Maar gedurende de vele huid meetings heb ik je ook leren 
kennen als een ontzettend leuk persoon, want er werd naast goed gediscussieerd 
ook zeker veel gelachen. Je input is ontzettend waardevol geweest voor mijn PhD 
en daar wil ik je ontzettend voor bedanken. Het gezellige borrelen in Aken tijdens 
de DC2018 zal me altijd bijblijven.




Ook wil ik hier graag de leescommissie bedanken voor de tijd die ze gestoken hebben 
in het kritisch lezen van mijn thesis en het aanwezig zijn tijdens mijn verdediging.
Nu mijn spetterende, fantastische, niet te missen paranimfen; Lenneke en Eveline.
Lennieee, mijn absolute tegenpool, maar we hadden direct een klik toen ik me 
bij groep Yvette mocht voegen. Met jou heb ik zoveel gedaan dat ik het hier niet 
eens allemaal op kan sommen, zelfs de high-lights wordt een te lange lijst. Ik heb 
altijd enorm veel gehad aan je steun en frisse blik op mijn project. Ik bewonder je 
doorzettingsvermogen, kritische blik en de manier waarop je dingen aanpakt zonder 
aarzeling. We zijn geen directe collega’s meer, maar ik ben heel blij om je nu echt een 
goede vriendin te kunnen noemen. Lang leve de “koffiemomentjes” over de telefoon!
Liliiii, onze gekke, lieve hello-kitty-china girl. Tijdens ons eerste congres in de Efteling 
hebben we gezellig in een stapelbedje gelegen, mijn hello-kitty pyjama broek was 
een directe klik. Maar ons echte grote avontuur was natuurlijk DC2016 in Shanghai!! 
Dumplinggsss, shoppen, zoektocht naar de perfecte zwarte schoen met rode zool, 
rondlopen, manicure/pedicures en owja natuurlijk onze fan-tas-tische presentaties 
op het congres… iets met panda’s en tussen gerenommeerde onderzoekers staan… 
heerlijkheid! Je onverschrokkenheid, openheid, zorgzaamheid en sociale kameleon-
kunde vind ik eeuwig genieten. Gelukkig zullen we elkaar nog gewoon zien, want 
we blijven nog “ff” hangen op de MCBI, FEEST!! En er is een klein mannetje die 
zo’n fantastisch mens als oppas wel kan waarderen (als mama college moet geven 
bijvoorbeeld).
Dan natuurlijk Hakan en Martino, de chemical magicians! Zonder jullie zou dit 
proefschrift er niet eens liggen. Martino, thanks for the synthesis of all those 
peptides! Hakan, niets van wat ik vroeg was te gek voor jou en je input hoe we het 
beste construct konden verkrijgen is onmisbaar geweest. Heel veel dank daarvoor!
De zoete kern: Sophie H, Sjoerd, Sophie D. We zijn allemaal rond dezelfde tijd 
begonnen en ik heb dan ook veel steun en gezelligheid aan jullie gehad. Sophie H, 
jij nam me gelijk onder je vleugels om me wegwijs te maken in het huidmodel en alle 
bijkomende assays. Je hebt een enorm doorzettingsvermogen en ik wil je bedanken 
voor de fijne samenwerking die we hebben gehad. Een samenwerking die voor mij 
ook erg leerzaam is geweest en heeft geresulteerd in een paar mooie hoofdstukken! 
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Sjoerd (Stuaaaart) & Sophie D (Dusosieee), dank voor alle gezellige, hylarische (iets 
met prinsessen inpak papier) en zeker ook wetenschappelijke momenten. Sjoerd, 
ik moest even wennen aan jou onuitputtelijke discussie modus, maar ik kan het 
nu heel erg waarderen. Jou kennis van de literatuur is ongekend en stiekem ook 
heel handig, want je stuurde alles al door voor ik überhaupt aan zoeken toe was 
gekomen, thanks a bunch. Sophie D’tje, ik heb van de zijlijn kunnen zien hoe jij kliniek 
en wetenschap een stukje dichter bij elkaar heb gebracht. Wat een boel positieve 
energie heb jij met je meegebracht en ik ben blij dat ik daar tijdens mijn PhD van 
heb mogen meegenieten.
Mijn O2 roomies Dieke en Ernesto! Diek, voor de grote verhuizing kende ik je 
eigenlijk helemaal niet zo goed en had ik vooral het beeld dat je een pittige tante 
bent die niet schroomt om te zeggen wat ze denkt. Nu is dat zeker ook iets wat ik 
ontzettend aan jou waardeer, je bent altijd eerlijk en zal niet om de hete brij heen 
draaien. Maar ik heb je als roomie ook leren kennen als een ontzettend lief en 
zorgzaam iemand. Ik wil je dan ook enorm bedanken voor alle koffie-momentjes 
en fijne gesprekken die we hebben gehad als roomies en mama’s, en hoop dat we 
contact zullen blijven houden!
Ernie, our morning-misery-mister. You came into the room a bit later, but it was (and 
is ;)) so much fun! You are one of those silent forces with so much knowledge and 
great suggestions. Thanks for being you.
Eetclub & koffiepauze team: Kath, Lau, Do, Leo, Kel, Man, Ri, Pau (het is bijna 
een liedje). Zonder had ik het niet overleefd. Kathathaaa, “neem 3 bananen, 
CHUTTENEEEEY, kieeep, hink-stap-sprong…”. Lachen, gieren, brullen, ik heb ervan 
genoten en geniet er nog steeds van. Graag gedaan en vooral beeedankt. Laura, de 
stille kracht van glycotreat. Helaas ben je een muis affectionado, maar dat neemt niet 
weg dat je ook voor mijn (bijna) muisloze PhD ontzettend waardevol bent geweest. 
Altijd behulpzaam en in voor een afleidingspraatje, dank daarvoor! Do’tje, onze altijd 
positieve brokkenpiloot. Als student hoorde je er al direct helemaal bij en ik ben blij 
dat je ook je PhD in de groep bent komen doen. Het zit je niet allemaal mee, maar 
toch weet jij er alles uit te halen. Samen hebben we heel wat huid assays gedaan en 
ook kort het lab van CCA onveilig gemaakt om door te kunnen blijven stomen tijdens 
de verhuizing. Dank voor je positiviteit, onuitputtelijke creativiteit en gezelligheid. 
Leoni (Lehooo), wij kennen elkaar al sinds de master en ik ben blij dat we ook een 




tijd op de MCBI als collega’s hebben kunnen werken! Helaas moest je ons ook weer 
verlaten, maar we komen elkaar nog wel tegen. Je reactie op mijn zwangerschap 
zal ik nooit vergeten. Dankje voor alle gezelligheid! Kelly (vergeet niet regelmatig 
een dansje te doen!), Mandy, Richard en Paula, vooral richting het einde van mijn 
PhD heb ik jullie vaak lastig kunnen vallen met mijn afleidings-hyperactiviteit, suiker 
toevoer en lekker kunnen koffieleuten. Dank, dank, dank.
Uiteraard wil ik iedereen van groep Yvette (subgroep Joke, Sandra, Juan, Jan) 
bedanken voor behulpzame meetings, gezellige Sinterkerstvieringen en het zijn van 
steun en toeverlaat gedurende een PhD. Joyce, je voegde je bij het skin(ny) ladies 
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studente, dank voor je inzet en vrolijke noot. Lisa, je staat toch maar mooi als auteur 
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heb ingezet tijdens je stage, waar ik je voor wil bedanken.
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Hiervoor wil ik Lianne Meij van de Bergman Clinics bedanken. Ook veel dank aan 
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Uiteraard is een dankje voor de ouders en grote zus ook op zijn plaats. Paps, mams 
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Timo en Abel, de twee belangrijkste mannen in mijn leven (pap, jij ook nog steeds 
hoor). Timo, mijn steun en toeverlaat, ik weet niet wat ik zonder jou zou beginnen. 
Abel, ons mooie, vrolijke, energieke kerelmansie. Kleine topper. Jij maakt elke dag 
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